

FORM PTO 1390  
(REV 10-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

HO-P01899US3

(09906355)

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

097980381  
To be assigned

INTERNATIONAL APPLICATION NO.

PCT/US00/15410

INTERNATIONAL FILING DATES

01 June 2000

PRIORITY DATE CLAIMED

01 June 1999

19 January 2000

TITLE OF  
INVENTIONCOMPOSITIONS & METHODS FOR THE THERAPEUTIC USE OF AN ATONAL-  
ASSOCIATED SEQUENCE FOR DEAFNESS, OSTEOARTHRITIS, AND ABNORMAL  
CELL PROLIFERATION

APPLICANT(S) FOR DO/EO/US Huda Zoghbi et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to promptly begin national examination procedures (35 U.S.C. 371 (f)).
4. ☒ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c)(2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☒ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

**Items 11 to 16 below concern document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 & 3.31 is included.
13. ☐ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: Fee transmittal  
Return postcard  
Copy of Written opinion dated 08/29/01  
Copy of Article 34 Amendments filed 09/28/01  
Copy of Examination Report dated 09/26/01  
Copy of ISR dated 12/04/00

VIA U.S. EXPRESS MAIL #ET575269302US

U.S. APPLICATION NO. (if known) <b>09/980381</b> to be assigned		INTERNATIONAL APPLICATION NO. PCT/US00/15410		ATTORNEY'S DOCKET NUMBER HO-P01899US3 (09906355)	
17. <input checked="" type="checkbox"/> The following fees are submitted:				<b>CALCULATIONS</b> PTO USE ONLY	
<b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1000.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$860.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$710.00 <input checked="" type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$	690.00
Surcharge of \$ 130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$	130.00
<b>CLAIMS</b>	<b>NUMBER FILED</b>	<b>NUMBER EXTRA</b>	<b>RATE</b>		
Total claims	142 -20 =	122	x 18	\$	2196.00
Independent claims	15 -3 =	12	x 84	\$	1008.00
MULTIPLE DEPENDENT CLAIM(s) (if applicable)			x 280	\$	280.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$	4304.00
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
<b>SUBTOTAL =</b>				\$	2152.00
Processing fee of \$ _____ for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +				\$	
<b>TOTAL NATIONAL FEE =</b>				\$	2,152.00
Fee for recording the enclosed assignment (37 CFR 1.21 (h)). Assignment must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31) ( _____ per property). +				\$	
<b>TOTAL FEES ENCLOSED =</b>				\$	2,152.00
				<b>Amount to be Refunded:</b>	\$
				<b>Charged:</b>	\$2,152.00
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>06-2375</u> (order 09906355) in the amount of \$ <u>2,152.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to my Deposit Account No. <u>06-2375</u> . A duplicate copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO: Melissa L. Sistrunk FULBRIGHT & JAWORSKI L.L.P. 1301 McKinney, Suite 5100 Houston, Texas 77010-3095 (713) 651-3735					
				SIGNATURE: <u>Melissa L. Sistrunk</u> NAME: _____ 45,579 REGISTRATION NUMBER DATED: Nov. 30, 2001	

Rec'd PCT/PTC 0 6 MAR 2002

#3

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU098494603US, in an envelope addressed to: Box Sequence, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: Mar. 6, 2002

Signature: *Susan Hunter*  
(Susan Hunter)

Docket No.: HO-P01899US3  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Huda Y. Zoghbi, et al.

Customer No. 26271  
(09906355/OTA99-47/  
LVM 205429)

Application No.: 09/980,381 / PCT/US00/15410

Group Art Unit: N/A

Filed: June 1, 2000

Examiner: Not Yet Assigned

For: COMPOSITIONS AND METHODS FOR THE  
THERAPEUTIC USE OF AN ATONAL-  
ASSOCIATED SEQUENCE FOR DEAFNESS,  
OSTEOARTHRITIS AND ABNORMAL CELL  
PROLIFERATION

**TRANSMITTAL OF INITIAL NUCLEOTIDE  
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

**Box PCT**

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

As required by the Notification of Missing Requirements Under USC 371 in the DO/EO/US, enclosed are the following which are submitted within the two-month response period set to expire on March 9, 2002.

- Initial paper copy of sequence listing; and
- Initial CRF copy of sequence listing;

Applicants respectfully request the entry of the present statement in regard to the enclosed sequence listing in the above-referenced application.

Applicants state the information recorded in the computer readable form copy of the sequence listing is identical to the paper copy of the sequence listing.

No new matter has been added to the substitute Sequence Listing.

Applicants respectfully request the above-referenced patent application be placed upon the files for examination.

Dated: March 6, 2002

Respectfully submitted,

By Melissa L. Sistrunk  
Melissa L. Sistrunk

Registration No.: 45,579  
FULBRIGHT & JAWORSKI L.L.P.  
1301 McKinney, Suite 5100  
Houston, Texas 77010-3095  
(713) 651-3735  
(713) 651-5246 (Fax)  
Agent for Applicant

09980381-030602



VIA U.S. EXPRESS MAIL #EK102657645US

Docket: HO-P01899WO0

IN THE UNITED STATES RECEIVING OFFICE  
UNDER THE PATENT COOPERATION TREATY

In re Application of: Baylor College of Medicine  
Int'l Appln. No.: US00/15410  
Int'l Filing Date: 1 June 2000  
For: COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE OF AN ATONAL-ASSOCIATED  
SEQUENCE FOR DEAFNESS, OSTEOARTHRITIS AND ABNORMAL CELL PROLIFERATION

ARTICLE 34 AMENDMENTS**BOX PCT**

Assistant Commissioner for Patents  
Washington, DC 20231  
Attn.: RO/US

Sir:

For your review and consideration, listed below are Article 34 Amendments regarding this application. Applicants submit that support for the additional claims regarding fusion proteins comprising an *atonal*-associated sequence are found, for example, on page 52, lns 11-18. Support for claims to methods of therapy wherein an *atonal*-associated sequence is administered to a subject in conjunction with another therapeutic nucleic acid sequence may be found, for example, on page 58, lns. 14-20, page 59, ln. 20-page 62, ln. 2 and page 62, lns. 5-13.

Applicants submit herewith an additional page for these added amendments and the renumbered substitute page for the Abstract.

47. A fusion protein comprising an *atonal*-associated amino acid sequence or fragment thereof and a desired amino acid sequence.

48. A nucleic acid sequence encoding the fusion protein of claim 47.

49. A method of delivering an *atonal*-associated amino acid sequence to an animal, wherein the method comprises administering to the animal a nucleic acid sequence encoding an *atonal*-associated amino acid sequence and a nucleic acid sequence encoding an additional therapeutic amino acid sequence.

50. The method of claim 20, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

51. The method of claim 21, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

52. The method of claim 22, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

53. The method of claim 24, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

54. The method of claim 26, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

55. The composition of claim 40, wherein the composition further comprises an additional amino acid sequence or nucleic acid sequence that is not an *atonal*-associated nucleic acid sequence or amino acid sequence.

It is believed that a \$9.00 fee is due in connection with this paper; please charge the fee to our Deposit Account No. 06-2375 order 09906355. If any other fees are required, please charge them to the same account. A duplicate copy of this letter is enclosed for that purpose.

Respectfully submitted,



Melissa L. Sistrunk  
Registration No. 45,579

**Fulbright & Jaworski L.L.P.**  
1301 McKinney, Suite 5100  
Houston, Texas 77010-3095  
(713) 651-3735

Dated: 28 September 2001

47. A fusion protein comprising an *atonal*-associated amino acid sequence or fragment thereof and a desired amino acid sequence.

48. A nucleic acid sequence encoding the fusion protein of claim 47.

49. A method of delivering an *atonal*-associated amino acid sequence to an animal, wherein the method comprises administering to the animal a nucleic acid sequence encoding an *atonal*-associated amino acid sequence and a nucleic acid sequence encoding an additional therapeutic amino acid sequence.

50. The method of claim 20, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

51. The method of claim 21, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

52. The method of claim 22, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

53. The method of claim 24, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

54. The method of claim 26, wherein the method comprises delivering an *atonal*-associated nucleic acid sequence and a second nucleic acid sequence encoding a non-*atonal*-associated therapeutic agent.

55. The composition of claim 40, wherein the composition further comprises an additional amino acid sequence or nucleic acid sequence that is not an *atonal*-associated nucleic acid sequence or amino acid sequence.

## ABSTRACT

Compositions and methods are disclosed for the therapeutic use of an *atonal*-associated nucleic acid or amino acid sequence. Also, an animal heterozygous for an *atonal*-associated gene inactivation is also disclosed having at least one *atonal*-associated nucleic acid sequence replaced by insertion of a heterologous nucleic acid sequence used to detect expression driven by an *atonal*-associated promoter sequence, wherein the inactivation of the *atonal*-associated nucleic acid sequence prevents expression of the *atonal*-associated gene.

**COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE**  
**OF AN *ATONAL*-ASSOCIATED SEQUENCE FOR DEAFNESS,**  
**OSTEOARTHRITIS,**  
**AND ABNORMAL CELL PROLIFERATION**

The work herein was supported by grants from the United States Government.

The United States Government may have certain rights in the invention.

5           This application claims priority to a provisional application Serial No. 60/137,060  
filed June 1, 1999 and to a second provisional application Serial No. 60/176,993 filed  
January 19, 2000.

**FIELD OF THE INVENTION**

10           The present invention relates in general to the field of genetic diagnosis and  
therapy and, more particularly, to the characterization and use of an *atonal*-associated  
nucleic acid or amino acid sequence, or any of its homologs or orthologs, as a therapeutic  
agent for the treatment of deafness, partial hearing loss, vestibular defects due to damage  
or loss inner ear hair cells, osteoarthritis, and abnormal cell proliferation.

15           **BACKGROUND OF THE INVENTION**

          An intricate pattern of interactions within and between cells directs the sequential  
development of neurons from dividing neuroepithelial progenitor cells. Multiple  
extracellular and intracellular signals moderate this process. Among the key intracellular  
20   signals are transcription factors, which induce the expression of a cascade of genes. One

subclass of transcription factors, belonging to the basic helix-loop-helix (bHLH) family of proteins, is expressed early on when the decision to proliferate or differentiate is made. This function is a particularly crucial one as mutations in these genes early in development can wipe out entire neural structures.

5 In *Drosophila*, the gene *atonal* (*ato*), which is homologous to *Math1*, *Math2*, *Hath1* and *Hath2*, encodes a bHLH protein essential for the development of chordotonal organs (sensory organs found in the body wall, joints and antenna that function in proprioception, balance and audition) (Eberl, 1999; McIver, 1985; van Staaden and Römer, 1998). CHOs populate the peripheral nervous system (PNS) in the body wall and  
10 joints (thorax, abdomen, sternum, wings, legs) and antennae (Moulins, 1976), providing the fly with sensory information much as touch and mechanoreceptors do in vertebrates (McIver, 1985; Moulins, 1976). Boyan (Boyan, 1993) proposed that, in the course of evolution, different CHOs became specialized for hearing in different insects. This hypothesis was recently confirmed by van Staaden and Römer (1998). In *Drosophila*,  
15 CHOs in the Johnston organ, located in the second antennal segment, function in near field hearing (Dreller and Kirschner, 1993; Eberl, 1999) and negative geotaxis.

During development *ato* is expressed in a cluster of progenitor cells from which the CHO founder cells are selected (Jarman et al., 1993). It likely functions by regulating the expression of genes necessary for the specification and development of the CHO  
20 lineage; as it encodes a basic helix-loop-helix protein (bHLH) that dimerizes with the Daughterless protein and binds to E-box sequences, thereby activating genes (Jarman et al., 1993). CHO specificity is encoded by the *ato* basic domain, which is required for DNA binding in bHLH proteins (Chien et al., 1996; Davis et al., 1990; Jarman and

Ahmed, 1998; Vaessin et al., 1990). *ato* is both necessary and sufficient for the generation of CHOs in the fly: loss of *ato* function leads to the loss of CHOs, while ectopic *ato* expression causes ectopic CHO formation (Jarman et al., 1993). Adult flies that lack *atonal* function are uncoordinated, do not fly, and are deficient in hearing.

- 5 Overexpression of the fly *atonal* gene can generate new chordotonal neurons, indicating that *atonal* is both essential and sufficient for the development of this neuronal population.

In vertebrates, during myogenesis and neurogenesis, cell fate specification requires basis helix-loop-helix (bHLH) transcription factors. *Math1* (for mouse a*tonal* 10 homolog-1) is such a factor, and is expressed in the hindbrain, dorsal spinal cord, external germinal layer of the cerebellum, gut, joints, ear and Merkel cells of the skin (which function as mechanoreceptors) (Akazawa et al., 1995; Ben-Arie et al., 1996; Ben-Arie et al., 1997). Mice heterozygous for a targeted deletion of *Math1* (*Math1*<sup>+/-</sup>) are viable and appear normal, but *Math1* null mice (*Math1*<sup>-/-</sup>) die shortly after birth and lack 15 cerebellar granule neurons.

*Math1* is one of *ato*'s closest known homologs, with 82% amino acid similarity in the bHLH domain and 100% conservation of the basic domain that determines target recognition specificity (Ben-Arie et al., 1996; Chien et al., 1996). *Math1* is transiently expressed in the CNS starting at embryonic day 9 (E9) in the dorsal portion of the neural 20 tube. *Math1* is also expressed in the rhombic lip of the fourth ventricle of the brain, where cerebellar granule cell precursors are born at E13-15 (Alder et al., 1996). Upon proliferation and differentiation, these progenitor cells migrate to form the external granule layer (EGL) of the cerebellar primordia (Hatten and Heintz, 1995). Proliferating

EGL cells continue to express *Math1* during the first three postnatal weeks, until shortly before they migrate to their final adult destination to generate the internal granule layer (IGL) of the cerebellum (Akazawa et al., 1995; Ben-Arie et al., 1996). Another group of cells, a small population of neuronal precursors in the dorsal spinal cord, expresses *Math1* during E10-E14 (Akazawa et al., 1995; Ben-Arie et al., 1996). These precursor cells also express the LIM homeodomain proteins (LH2A and LH2B), markers of the D1 class of commissural interneurons (Lee et al., 1998). Helms and Johnson (1998) reported that *lacZ* expression under the control of *Math1* regulatory elements reproduced *Math1* expression patterns in the developing cerebellum and spinal cord, and demonstrated that *Math1* is expressed in precursors that give rise to a subpopulation of dorsal commissural interneurons.

To determine the in vivo function of *Math1*, the inventors generated mice (*Math1*<sup>-/-</sup>) lacking the MATH1 protein. This null mutation causes major cerebellar abnormalities: lack of granule cell proliferation and migration from the rhombic lip at E14.5, and absence of the entire EGL at birth (Ben-Arie et al., 1997). It is not clear whether the agenesis of cerebellar granule neurons is due to failure of progenitor specification or the cells' inability to proliferate and/or differentiate. Neonates cannot breathe and die shortly after birth, but there are no gross defects in any cranial nerves or brain stem nuclei that could explain respiratory failure.

The fact that *Math1* is expressed in the inner ear suggests that *Math1* expression is necessary for the development of auditory or balance organs. The inner ear initially forms as a thickening of the ectoderm, termed the otic placode, between rhombomeres 5 and 6 in the hindbrain. The otic placode gives rise to neurons of the VIII<sup>th</sup> cranial



nerve and invaginates to become the otocyst, from which the inner ear will develop. The mature mammalian inner ear comprises one auditory organ, the cochlea, and five vestibular organs: the utricle, the saccule, and three semicircular canals. The sensory epithelia of these organs consist of mechanoreceptive hair cells, supporting cells and nerve endings. Hair cells serve as mechanoreceptors for transducing sound waves and head motion into auditory and positional information. Hair cells and supporting cells both arise from a common progenitor cell and proliferate and differentiate within the sensory epithelia, with peak mitoses between embryonic day 13 and 18 (E13-18) in mice. Although several genes have been implicated in the development of the inner ear, such as *int2* (Mansour et al., 1993; *pax2* (Torres et al., 1996; and *Hmx3* (Wang et al., 1998). None have been shown to be required for the genesis of hair cell specifically.

Damage to hair cells is a common cause of deafness and vestibular dysfunction, which are themselves prevalent diseases. Over 28 million Americans have impaired hearing; vestibular disorders affect about one-quarter of the general population, and half of our elderly. The delicate hair cells are vulnerable to disease, aging, and environmental trauma (i.e., antibiotics, toxins, persistent loud noise). Once these cells are destroyed, they cannot regenerate in mammals. Therefore, a need exists to address the problems of patients with congenital, chronic or acquired degenerative hearing impairment and loss or balance problems, and to provide compositions, methods and reagents for use in treating hearing loss and vestibular function.

In support of the teaching of the present invention, others have demonstrated that *Math1*, upon overexpression, induces significant production of extra hair cells in postnatal rat inner ears (Zheng and Gao, 2000). Briefly, although fate determination is

usually completed by birth for mammalian cochlear hair cells, overexpression of *Math1* in postnatal rat cochlear explant cultures results in additional ear hair cells which derive from columnar epithelial cells located outside the sensory epithelium in the greater epithelial ridge. Furthermore, conversion of postnatal utricular supporting cells into hair cells is facilitated by *Math1* expression. The ability of *Math1* to permit production of hair cells in the ear is strong evidence in support of the claimed invention.

### SUMMARY OF THE INVENTION

In one embodiment of the present invention there is an animal having a heterologous nucleic acid sequence replacing an allele of an *atonal*-associated nucleic acid sequence under conditions wherein said heterologous sequence inactivates said allele. In a preferred embodiment said heterologous sequence is expressed under control of an *atonal*-associated regulatory sequence. In a specific embodiment both *atonal*-associated alleles are replaced. In an additional specific embodiment both *atonal*-associated alleles are replaced with nonidentical heterologous nucleic acid sequences. In an additional embodiment said animal has a detectable condition wherein said condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, imbalance, joint disease, osteoarthritis, abnormal proliferation of neoplastic neuroectodermal cells and formation of medulloblastoma. In another embodiment of the present invention said heterologous nucleic acid sequence is a reporter sequence selected from the group consisting of  $\beta$ -galactosidase, green fluorescent protein (GFP), blue fluorescent protein (BFP), neomycin, kanamycin, luciferase,  $\beta$ -glucuronidase and chloramphenicol transferase (CAT). In

another specific embodiment said reporter sequence regulatable or is expressed in brain tissue, neural tissue, skin tissue, non-ossified cartilage cells, joint chondrocytes, Merkel cells, inner ear sensory epithelia and brain stem nuclei. In additional specific embodiments said *atonal*-associated allele is replaced with an *atonal*-associated nucleic acid sequence under control of a regulatable promoter sequence or a tissue-specific promoter sequence wherein said tissue is selected from the group consisting of brain tissue, neural tissue, skin tissue, non-ossified cartilage cells, joint chondrocytes, Merkel cells, inner ear sensory epithelia and brain stem nuclei. In additional embodiments said animal is a mouse, *Drosophila*, zebrafish, frog, rat, hamster or guinea pig.

10 In another embodiment of the present invention is a method for screening for a compound in an animal, wherein said compound affects expression of an *atonal*-associated nucleic acid sequence comprising delivering said compound to said animal wherein said animal has at least one allele of an *atonal*-associated nucleic acid sequence inactivated by insertion of a heterologous nucleic acid sequence wherein said  
15 heterologous nucleic acid sequence is under control of an *atonal*-associated regulatory sequence, and monitoring for a change in said expression of said *atonal*-associated nucleic acid sequence. In specific embodiments said compound upregulates or downregulates said expression of an *atonal*-associated nucleic acid sequence. In additional embodiments said animal is a mouse or *Drosophila*. In a specific embodiment  
20 the heterologous nucleic acid sequence is a reporter sequence. In an additional specific embodiment the heterologous nucleic acid sequence is selected from the group consisting of  $\beta$ -galactosidase, green fluorescent protein (GFP), blue fluorescent protein (BFP),

neomycin, kanamycin, luciferase,  $\beta$ -glucuronidase and chloramphenicol transferase (CAT).

Another embodiment of the present invention is a compound which affects expression of an *atonal*-associated nucleic acid sequence. In specific embodiments said  
5 compound upregulates or downregulates expression of an *atonal*-associated nucleic acid sequence. In a specific embodiment said compound affects a detectable condition in an animal wherein said condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, an imbalance disorder, joint disease, osteoarthritis, abnormal proliferation of neoplastic neuroectodermal cells and  
10 formation of medulloblastoma.

Another embodiment of the present invention is a method for screening for a compound in an animal, wherein said compound affects a detectable condition in said animal, comprising delivering said compound to said animal wherein at least one allele of an *atonal*-associated nucleic acid sequence in said animal is inactivated by insertion  
15 of a heterologous nucleic acid sequence, wherein said heterologous nucleic acid sequence is under the control of an *atonal*-associated regulatory sequence, and monitoring said animal for a change in the detectable condition. In a specific embodiment said detectable condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, an imbalance disorder, joint disease,  
20 osteoarthritis, abnormal proliferation of neoplastic neuroectodermal cells and formation of medulloblastoma. In another embodiment said delivery of said compound affects expression of said heterologous nucleic acid sequence. In specific embodiments said expression of said heterologous nucleic acid sequence is upregulated or downregulated.

In additional specific embodiments said animal is a mouse, *Drosophila*, zebrafish, frog, rat, hamster or guinea pig.

Another embodiment of the present invention is a compound wherein said compound affects said detectable condition. In specific embodiments said compound affects expression of a heterologous nucleic acid sequence. In additional specific  
5       embodiments said compound upregulates or downregulates expression of a heterologous nucleic acid sequence.

In other embodiments of the present invention are methods of treating an animal, including a human, for cerebellar granule neuron deficiencies, for promoting  
10       mechanoreceptive cell growth, for generating hair cells, for treating hearing impairment or an imbalance disorder, for treating a joint disease, for treating for an abnormal proliferation of cells, and for treating for a disease that is a result of loss of functional *atonal*-associated nucleic acid or amino acid sequence. Said methods include administering a therapeutically effective amount of an *atonal*-associated nucleic acid or  
15       amino acid sequence. In specific embodiments said administration is by a vector selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated vector, a plasmid, or any other nucleic acid based vector, a liposome, a nucleic acid, a peptide, a lipid, a carbohydrate and a combination thereof of said vectors. In a specific embodiment said vector is a non-viral vector or a viral vector. In another specific  
20       embodiment said vector is a cell. In a preferred embodiment said vector is an adenovirus vector comprising a cytomegalovirus IE promoter sequence and a SV40 early polyadenylation signal sequence. In another specific embodiment said cell is a human cell. In an additional specific embodiment said joint disease is osteoarthritis. In a

specific embodiment said *atonal*-associated nucleic acid or amino acid sequence is Hath1 or Math1. In another specific embodiment the cell contains an alteration in an *atonal*-associated nucleic acid or amino acid sequence. In an additional specific embodiment the amino acid sequence has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58. In an additional specific embodiment the nucleic acid sequence encodes a polypeptide which has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58.

In another embodiment of the present invention is a method for treating an animal for an abnormal proliferation of cells comprising altering *atonal*-associated nucleic acid or amino acid sequence levels in a cell. In a specific embodiment said alteration is reduction or said nucleic acid or amino acid sequence contains an alteration.

In another embodiment of the present invention is a composition comprising an *atonal*-associated amino acid sequence or nucleic acid sequence in combination with a delivery vehicle wherein said vehicle delivers a therapeutically effective amount of an *atonal*-associated nucleic acid sequence or amino acid sequence into a cell. In specific embodiments said vehicle is the receptor-binding domain of a bacterial toxin or any fusion molecule or is a protein transduction domain. In a specific embodiment said protein transduction domain is from the HIV TAT peptide. In a specific embodiment said *atonal*-associated amino acid sequence or nucleic acid sequence is Hath1 or Math1.

In another embodiment of the present invention there is a composition to treat an organism for loss of hair cells, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific

embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for loss of hair cells, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for loss of hair cells, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for a cerebellar neuron deficiency, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a cerebellar neuron deficiency, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a cerebellar neuron deficiency, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for hearing impairment, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or

alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for hearing impairment, wherein said organism

5 comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for hearing impairment, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

10 In another embodiment of the present invention there is a composition to treat an organism for imbalance, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic

15 acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for imbalance, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for imbalance, wherein said organism comprises a

20 defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for osteoarthritis, wherein said organism comprises a defect in an *atonal*-



associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for osteoarthritis, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for osteoarthritis, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for a joint disease, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a joint disease, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a joint disease, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for abnormal proliferation of cells, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific  
5 embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for abnormal proliferation of cells, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the  
10 present invention there is a composition to treat an organism for abnormal proliferation of cells, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for cancer, wherein said organism comprises a defect in an *atonal*-associated  
15 nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for cancer, wherein said organism comprises defect in a nucleic acid sequence  
20 which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for cancer, wherein said organism comprises a defect in an amino acid

sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In a specific embodiment said cancer is medulloblastoma.

Other and further objects, features and advantages would be apparent and eventually more readily understood by reading the following specification and by reference to the company drawing forming a part thereof, or any examples of the presently preferred embodiments of the invention are given for the purpose of the disclosure.

#### DESCRIPTION OF THE DRAWINGS

Figure 1A and 1B demonstrate that the inner ear  $\beta$ -Gal staining (blue) of *Math1* heterozygous embryos as described hereinabove. Figure 1A shows the otic vesicle (OV) at E12.5 and Figure 1B the inner ear at E14.5 of *Math1*<sup>+/ $\beta$ -Gal</sup> embryos. Sensory epithelia stained positively in the cochlea (C), saccule (S), utricle (U), and semicircular canal ampullae (SCA). A schematic diagram of the inner ear is depicted alongside the staining for reference, blue indicates location of the sensory epithelia. The original magnifications of the images taken under the microscope were x100 For Figure 1A and x50 for Figure 1B.

Figures 2A through 2F are scanning electron micrographs of E18.5 inner ear sensory epithelia in wild-type and *Math1* <sup>$\beta$ -Gal/ $\beta$ -Gal</sup> mice. Wild-type mice epithelia are shown in Figures 2A, 2C, and 2E and null mouse epithelia in Figures 2B, 2D, and 2F. The organ of Corti of the cochlea are shown and indicated in Figures 2A and 2B. In the

wild-type mouse there are three rows of outer hair cells (1, 2, 3), one row of inner hair cells (I), all with hair bundles (HB). The tectorial membrane (TM), an accessory structure of the cochlea, may be observed at the bottom. Above the sensory epithelium are squamous cells (SQ) with rudimentary kinocilia (RK). In null mice (Figure 2B), there are only squamous cells. Crista ampullaries of a vertical semicircular canal are depicted in Figures 2C and 2D. The null mouse crista is similar to the wild-type in overall shape, including the septum (eminentia) cruciatum (EC), but is smaller. The macula of the utricle is the focus of Figure 2E and 2F. Again, the macula of the null mouse is smaller than the wild-type. Scale bars are as follows: 10  $\mu$ m in Figures 2A and 2B, 50  $\mu$ m in Figures 2C and 2D, and 100  $\mu$ m in Figures 2E and 2F.

Figures 3A through 3F are light micrographs of semi-thin transverse sections of inner ear sensory epithelia in wild-type mice (Figures 3A, 3C, and 3E) and *Math1* <sup>$\beta$ -Gal/ $\beta$ -Gal</sup> (Figures 3B, 3D, and 3F), all mice were observed at E18.5. As observed in the cochlea of wild-type mice, Figure 3A, three outer hair cells (1, 2, 3) and one inner (I) hair cell are present. Conversely, the null mouse cochlea (Figure 3B) has only squamous cells (SQ) in the same region. Hair cells (HC) and supporting cells (SC) are present in the wild-type crista ampullaris (Figure 3C) and utricular macula (Figure 3E), but only supporting cells are present in null mice (Figure 3D and 3F). The crista was cut obliquely, accounting for the multiple layers of hair cells in Figure 3C. The otolithic membrane (OM), an accessory structure of the utricle, is present in both wild-type mice (Figure 3E) and null mice (Figure 3F). Scale bars equal 100  $\mu$ m in (Figures 3A and 3B); 50  $\mu$ m in (Figures 3C and 3D); and 25  $\mu$ m in (Figures 3E and 3F).

Figures 4A and 4B are transmission electron micrographs of E18.5 utricular macula in wild-type and *Math1* <sup>$\beta$ -Gal/ $\beta$ -Gal</sup> mice. Figure 4A shows that the hair cells (HC) and supporting cells (SC) are present in wild-type utricular macula. By contrast, only supporting cells are present in the null mouse (Figure 4B). Hair cells have hair bundles (HB) and supporting cells have microvilli (MV). Hair cells are less electron-dense and have more apical nuclei than supporting cells, but only the latter have secretory granules (SG). Some immature hair cells (IM) are evident in the wild-type, but not in the null mouse. The scale bar in all the figures equals 10 $\mu$ m.

Figures 5A through 5F show the Calretinin staining pattern of inner ear sensory epithelia. Sections through the utricle of E16.5 wild-type (Figures 5A and 5C) and *Math1* <sup>$\beta$ -Gal/ $\beta$ -Gal</sup> (Figure 5B and 5D) littermates were counterstained with propidium iodide (red) for confocal microscopy. Sections were cut through the crista ampullaris of E18.5 wild-type (Figure 5E) and *Math1* <sup>$\beta$ -Gal/ $\beta$ -Gal</sup> (Figure 5F) were counterstained with DAPI (blue) for immunofluorescent microscopy. The crista is cut at an oblique angle, which accounts for the multiple layers of hair cells in (Figure 5E). Immunostaining of Calretinin (green, arrows) is evident in hair cells of wild-type (Figures 5A, 5C, and 5E) but not null mice (Figures 5B, 5D, and 5F). Boxed areas in Figures 5A and 5B indicate the regions magnified in Figures 5C and 5D. Scale bar equals 100  $\mu$ m in (Figure 5A and 5B), 15  $\mu$ m in (Figures 5C and 5D) and an original magnification of x200 in (Figures 5E and 5F).

Figure 6A and 6B show the expression pattern of *Math1* in mouse articular cartilage using the *Math1*<sup>+/ $\beta$ -Gal</sup> heterozygote. Figure 6A shows the staining pattern of a P14 mouse forelimb and demonstrates expression in all joints. Figure 6B is a

magnification (20X) of an elbow joint from the same mouse that demonstrates that *Math1* is expressed exclusively in the non-ossified articular chondrocytes.

Figure 7A through 7C show replacement of *Math1* coding region by *lacZ* gene. Figure 7A, Top, has a map of the *Math1* genomic locus. The coding region is shown as a black box. The sites of the probes used to detect the wild-type and mutant alleles are shown as black bars. The targeting vector is in the middle with the sites for homologous recombination indicated by larger Xs. In the targeted locus shown at the bottom, *lacZ* is translated under the control of *Math1* regulatory elements. Figure 7B demonstrates Southern blot analysis of embryonic stem cells using the 3' external probe. The upper band represents wt allele and the lower band the targeted mutant allele (mut) in targeted clones. Figure 7C demonstrates Southern blot analysis of DNA from the progeny of heterozygous mice demonstrating the presence of the targeted allele and absence of the wild-type allele in *Math1*<sup>b-gal/b-gal</sup> mice (asterisks). The abbreviations are as follows: (A) ApaI; (H) HindIII; (RI) EcoRI; (S) Sall; and (X) XbaI.

Figures 8A through 8H show *Math1/lacZ* expression and cerebellar phenotype in *Math1*<sup>+/b-gal</sup> and *Math1*<sup>b-gal/b-gal</sup> mice. Figure 8A shows *Math1/lacZ* expression in the dorsal neural tube at E9.5 and (Figure 8B) E10.5. Figure 8C indicates a section through the hind brain at E10.5 has *Math1/lacZ* expression in the dorsal portion (arrows). Figure 8D demonstrates that in a spinal cord section from E12.5 embryo, dorsal cells migrate ventrally (arrows). Figure 8E shows at E14.5 expression is observed in the EGL progenitors at the rhombic lip and in migrating cells that will populate the EGL. Figure 8F demonstrates in *Math1*<sup>b-gal/b-gal</sup> mice, *Math1/lacZ* expression is limited to a few cells in the rhombic lip, which is significantly reduced in size. Figure 8G shows that at P0

*Math1/lacZ* is expressed in the EGL. Figure 8H demonstrates that the EGL is absent in the null mice. Original magnification for Figures 8C through 8H was 100x.

Figure 9A through 9G shows expression of *Math1/lacZ* in the inner ear and brain stem and histological analysis of ventral pontine nucleus. X-gal staining of E18.5 *Math1*<sup>+/-gal</sup> utricular crista (Figure 9A) and inner ear sensory epithelia of *Math1*<sup>+/-gal</sup> (Figure 9B) and *Math1*<sup>bgal/bg</sup> (Figure 9C). The *Math1/lacZ* expression in the upper hair cell layer of the sensory epithelia of (Figures 9A and 9B) and the characteristic calyx appearance (arrowhead). In the null mice X-gal staining of epithelial cells is non-specific in the absence of hair cells (Figure 9C). Whole-brain X-gal staining of *Math1*<sup>+/-gal</sup> (Figure 9D) and *Math1*<sup>bgal/bg</sup> (Figure 9E) at E18.5 is demonstrated. There is positive staining of the pontine nucleus (arrowhead) and cerebellum (arrow) in *Math1*<sup>+/-gal</sup> mice, which is lacking or greatly reduced in null mutants in both the cerebellum, and pontine nucleus (inset). Figures 9F and 9G show haematoxylin and eosin staining of sagittal sections through the pons of a wild type and null mutant (Figures 9F and 9G, respectively), showing the loss of the ventral pontine nucleus in null mutants. The original magnifications were as follows: (A) 400x (B & C) 1000x, (D & E) 8x, inset in D & E 100x, (F & G) 10x.

Figures 10A through 10E demonstrate *Math1/lacZ* is expressed in joint chondrocytes. X-gal staining of whole embryos at (Figure 10A) E12.5 and (Figure 10B) E16.5 illustrates that *Math1/lacZ* is expressed in all joints (Figure 10C). Horizontal section through the elbow joint of E18.5 *Math1*<sup>+/-gal</sup> mouse shows that it is expressed in resting chondrocytes (arrow). Figure 10D shows a horizontal section through a humero-radial joint at P10 that has expression in the articular chondrocytes (arrowhead)

and resting chondrocytes (arrow). Figure 10E shows high magnification of a section through a wrist joint indicating *Math1/lacZ* is expressed in articular chondrocytes. The original magnification is was follows: (C) 10x; (D) 20x; and (E) 40x.

Figures 11A through 11L show *Math1/lacZ* expression in Merkel cells. To  
 5 identify the structures stained on the hairy and non-hairy skin, E16.5 littermate embryos were stained as whole mounts, sectioned, and microscopically examined. Shown are sections through the vibrissae (Figure 11A), foot pad at low (Figure 11B) and high magnification of the region marked by an arrow in B (Figure 10C), and hairy skin (Figure 11D). In all sections the localization of the stained cells was as expected from Merkel  
 10 cells. To look for macroscopic defects in null mice, close-up pictures were taken through a stereomicroscope of *Math1*<sup>+/-b-gal</sup> (control, panels E-H) and *Math1*<sup>b-gal/b-gal</sup> (null, panels I-L) littermate mice. Staining in null mice appeared stronger because of a dosage effect in the vibrissae (E, I), limb joints (F, J), and foot pads (G, K). In contrast, the staining intensity of null (J, L) mice was markedly weaker than that of heterozygous (F, H) mice  
 15 in the touch domes associated with the hairy skin. The original magnification is was follows: A x200; B x50; C x400; D x500; E-G-H-I-K-L x32; F-J x16.

Figures 12A through 12E show lack of *lacZ*-stained touch domes in *Tabby* mice. *Tabby/Tabby* females were crossed with *Math1*<sup>+/-b-gal</sup> males, and their progeny were X-gal stained and gender-determined at E16.5. Staining around primary vibrissae in the snout  
 20 was detected in both female embryos heterozygous for the *Tabby* mutation (Figure 12A) and male embryos hemizygous for the mutation (Figure 12B). Secondary vibrissae, which are known to vary in number in the *Tabby* mutants (black arrows), were also stained. The staining of the touch domes was less intense in the *Tabby/X* female (Figure



12D) than *Math1*<sup>+/-b-gal</sup> (wt for *Tabby*) embryos (Figure 12C), since *Tabby* is a semidominant mutation. However, patches of stained touch domes were detected in a female embryo that carried a wild-type allele at the *Tabby* locus (Figure 12A, red arrow, and 12D). In contrast, a hemizygous male completely lacked both staining and touch domes, due to the loss of hair follicles that abolishes the development of Merkel cells (Figures 12B and 12E).

Figures 13 A through 13F demonstrate marker analysis of Merkel cells in wild type and *Math1* null mice. Skin sections from *Math1*<sup>+/+</sup> and *Math1*<sup>b-gal/b-gal</sup> reacted with antibodies against MATH1 (Figures 13A and 13B), cytokeratin 18 (Figures 13C and 13D), and chromogranin A (Figures 13E and 13F). Polyclonal antibodies to MATH1 identify multiple basal nuclei in rare abdominal hair follicles of wild type (Figure 13A) but not mutant mice (Figure 13B). Monoclonal antibodies to cytokeratin 18 and chromogranin A identify Merkel cells in both wild type (Figures 13C and 13E) and mutant (Figures 13D and 13F) mice. The original magnification was 100X.

Figures 14A through 14G show *Math1* rescues the lack of chordotonal neurons in *Drosophila ato* mutant embryos. Figure 14A shows a dorsal view of the thorax of a wild-type fly. Note there are regular array of bristles or macrochaetae. Figure 14B shows a similar view of a transgenic fly in which *Math1* was overexpressed using the UAS/GAL4 system (Brand and Perrimon, 1993). This ectopic expression leads to numerous extra bristles that are external sensory organs (another type of mechano receptor), not CHOs. Ectopic CHOs were produced in many other regions. Figure 14C shows a lateral view of two abdominal clusters containing 6 CHOs in addition to external sensory organs, revealed by a neuronal-specific antibody (Mab 22C10). The 5 lateral

CHOs form a cluster, and the sixth is dorsal to the cluster. Figure 14D shows a similar view of an *ato* mutant embryo showing lack of the CHOs. Figure 14E demonstrates ubiquitous expression of *Math1* induces new CHO neurons in *ato* mutant embryos in the proper location. Figure 14F shows *in situ* hybridization of whole mount third instar brain using the *ato* cDNA as a probe. Note expression in the developing optic lobes ("horse shoe" expression patterns) and two punctate clusters of cells in the middle of the brain lobes (arrow heads). Figure 14G shows *Math1* expression in *Drosophila* induces CHO formation in normal and ectopic locations. The (+) indicates presence of CHOs and (-) indicates their absence. Number of (+) in the first column is used to quantify the relative increase in the number of CHOs observed when *Math1* is expressed.

#### DETAILED DESCRIPTION OF THE INVENTION

It is readily apparent to one skilled in the art that various embodiments and modifications may be made to the invention disclosed in this Application without departing from the scope and spirit of the invention.

The term "abnormal proliferation" as used herein is defined as any proliferation of any type of cell, wherein said cell is not under the constraints of normal cell cycle progression and wherein said proliferation may result in a tumor or any cancerous development.

The term "alteration" as used herein is defined as any type of change or modification to a nucleic acid or amino acid. Said change or modification includes any mutation, deletion, rearrangement, addition to a nucleic acid. This includes posttranscriptional processing such as addition of a 5' cap, intron processing and

polyadenylation. Mutations can be nonsense, missense, frameshift, or could lead to a truncated amino acid or could alter the conformation of the amino acid. The alteration to a nucleic acid may be present in regulatory sequences or may affect trans-acting factors. Also, multiple alterations may be present. Said change or modification also

5 includes any change to an amino acid including methylation, myristilation, acetylation, glycosylation, or a change to signals associated with processing of said amino acid including intracellular or intercellular localization signals and cleaving of extraneous amino acids. Said alteration may also affect degradation or folding of said protein.

The term “*atonal*-associated” as used herein is defined as any nucleic acid

10 sequence or amino acid sequence which is the *Drosophila atonal* nucleic acid sequence or amino acid sequence, or is any sequence which is homologous to or has significant sequence similarity to said nucleic acid or amino acid sequence, respectively. The sequence can be present in any animal including mammals and insects. As used herein, significant sequence similarity means similarity is greater than 25% and can occur in any

15 region of another sequence. Examples of *atonal*-associated include but are not limited to *Math1* (mouse a*tonal* homolog 1), *Cath1* (chicken a*tonal* homolog 1), *Hath1* (human a*tonal* homolog 1), and *Xath1* (Xenopus a*tonal* homolog 1). Furthermore, multiple homologous or similar sequences may exist in an animal.

The term “cerebellar granule neuron deficiencies” as used herein is defined as any

20 deficiency associated with cerebellar granule neurons and can include loss of cerebellar granule neurons, cerebellar granule neuron precursor cells, lack of granule cell proliferation, lack of granule cell migration and lack of cerebellar external granule layer cells.

The term “defect” as used herein is defined as an alteration, mutation, flaw or loss of expression of an *atonal*-associated sequence. A skilled artisan is aware that loss of expression concerns expression levels of an *atonal*-associated sequence which are not significant or detectable by standard means in the art. A skilled artisan is also aware that

5 loss, or absence, of expression levels in an adult organism, such as a human, occurs naturally and leads to impairment of hearing over time. Thus, “defect” as used herein includes the natural reduction or loss of expression of an *atonal*-associated sequence.

The term “delivering” as used herein is defined as bringing to a destination and includes administering, as for a therapeutic purpose.

10 The term “delivery vehicle” as used herein is defined as an entity which is associated with transfer of another entity. Said delivery vehicle is selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated vector, a plasmid, a liposome, a nucleic acid, a peptide, a lipid, a carbohydrate and a combination thereof.

15 The term “detectable condition” as used herein is defined as any state of health or status of an animal, organ or tissue characterized by specific developmental or pathological symptoms. Examples include but are not limited to loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, imbalance, joint disease, osteoarthritis and abnormal proliferation of cells.

20 The term “heterologous” as used herein is defined as nucleic acid sequence which is of or relating to nucleic acid sequence not naturally occurring in a particular locus. In an alternative embodiment, the heterologous nucleic acid sequence naturally occurs in a particular locus, but contains a molecular alteration compared to the naturally occurring

locus. For instance, a wild-type locus of an atonal-associated sequence may be used to replace a defective copy of the same sequence.

The term "imbalance disorder" as used herein is defined as a medical condition wherein an organism has impaired balance. In a specific embodiment the impairment is due to a defect of vestibular origin. In another specific embodiment the disorder is a vestibular disorder of balance perception including but not limited to Meniere disease, vertigo and layrinthitis.

The term "inactivated" as used herein is defined as a state in which expression of a nucleic acid sequence is reduced or completely eliminated. Said inactivation can occur by transfer or insertion of another nucleic acid sequence or by any means standard in the art to affect expression levels of a nucleic acid sequence.

The term "precursors" as used herein is defined as progenitor cells from which other cells derive their origin and/or properties.

The term "regulatable reporter sequence" as used herein is defined as any sequence which directs transcription of another sequence and which itself is under regulatory control by an extrinsic factor or state. Examples of extrinsic factors or states include but are not limited to exposure to chemicals, nucleic acids, proteins, peptides, lipids, carbohydrates, sugars, light, sound, hormones, touch, or tissue-specific milieu. Examples of regulatable reporter sequences include the GAL promoter sequence and the tetracycline promoter/transactivator sequence.

The term "regulatory sequence" as used herein is defined as any sequence which controls either directly or indirectly the transcription of another sequence. Said control

can be either regarding the initiation or cessation of transcription or regarding quantity or tissue distribution of transcription.

The term "reporter sequence" as used herein is defined as any sequence which demonstrates expression by a regulatory sequence. Said reporter sequence can be used as a marker in the form of an RNA or in a protein. Examples of reporter sequences are b-galactosidase, green fluorescent protein (GFP), blue fluorescent protein (BFP), neomycin, kanamycin, luciferase, b-glucuronidase and chloramphenicol transferase (CAT). In a specific aspect of the present invention, the presence and quantity of the reporter sequence product, whether it be a nucleic acid or amino acid, reflects the level of transcription by the promoter sequence which regulates it.

The term "therapeutically effective" as used herein is defined as the amount of a compound required to improve some symptom associated with a disease. For example, in the treatment of hearing impairment, a compound which improves hearing to any degree or arrests any symptom of hearing impairment would be therapeutically effective. In the treatment of a joint disease, a compound which improves the health or movement of a joint to any degree or arrests any symptom of a joint disease would be therapeutically effective. In the treatment of abnormal proliferation of cells, a compound which reduces the proliferation would be therapeutically effective. In the treatment of cancer, a compound which reduces proliferation of the cells, reduces tumor size, reduces metastases, reduces proliferation of blood vessels to said cancer, facilitates an immune response against the cancer would be therapeutically effective, for example. A therapeutically effective amount of a compound is not required to cure a disease but will provide a treatment for a disease.

The term “vector” as used herein is defined as a biological vehicle for delivery of a specific entity. In a specific embodiment the entity is an *atonal*-associated nucleic acid.

5 In one aspect of the present invention there are methods and reagents which include utilization of an *atonal*-associated nucleic acid or amino acid sequence for the therapeutic use of detectable conditions such as loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, an imbalance disorder, joint disease, osteoarthritis and abnormal proliferation cells. Thus, any homolog or ortholog of *atonal*  
10 (from *Drosophila*) including but not limited to *Cath1* (from chicken), *Hath1* (from human), *Math1* (from mice) or *Xath1* (from *Xenopus*) may be used in the present invention. In a preferred embodiment these sequences are directed to treatment of an animal, specifically a human, for the detectable conditions stated above. It is within the scope of the invention to encompass any sequence which is homologous to or has  
15 significant sequence similarity to said nucleic acid or amino acid sequence, respectively. The sequence can be present in any animal including mammals and insects. As used herein, significant sequence similarity means similarity (identity of amino acid residues or nucleic acid bases) is greater than 25% and can occur in any region of the sequence. In another embodiment an *atonal*-associated sequence as used herein has greater than  
20 about 50% sequence similarity, greater than about 70% similarity, or greater than about 80% similarity.

It is within the scope of the present invention that an *atonal*-associated nucleic acid sequence or amino acid sequence is utilized wherein domains important for activity,

such as the basic HLH region, are included in a molecule but further comprise alterations, mutations, deletions or substitutions in regions of the nucleic acid or amino acid sequence which are not part of a domain important for an activity and do not affect its function.

Examples of *atonal*-associated include but are not limited to *Math1* (mouse a*tonal* homolog 1), *Cath1* (chicken a*tonal* homolog 1), *Hath1* (human a*tonal* homolog 1), and *Xath1* (Xenopus a*tonal* homolog 1). Such examples are represented in SEQ ID NO:1 through SEQ ID NO:66, although others very likely exist in related organisms. A skilled artisan is cognizant of means to identify such sequences which have significant similarity, such as searching database collections of nucleic and amino acid sequence located on the World Wide Web, including <http://www.ncbi.nlm.nih.gov/Genbank/GenbankSearch.html>.

The sequences provided herein and the corresponding GenBank Accession numbers are listed parenthetically as follows: SEQ ID NO:1 (NM\_005172); SEQ ID NO:2 (NP\_005163.1); SEQ ID NO:3 (AW413228); SEQ ID NO: 4 (NM\_009719); SEQ ID NO:5 (NP\_033849.1); SEQ ID NO:6 (NM\_009718); SEQ ID NO: 7 (NP\_033848.1) SEQ ID NO:8 (NM\_009717); SEQ ID NO: 9 (NP\_033847.1); SEQ ID NO:10 (NM\_007500); SEQ ID NO: 11(NP\_031526.1); SEQ ID NO:12 (NM\_007501); SEQ ID NO:13 (AW280518); SEQ ID NO:14(AW236965); SEQ ID NO:15(AW163683); SEQ ID NO:16 (AF134869); SEQ ID NO: 17(AAD31451.1); SEQ ID NO:18 (AJ012660); SEQ ID NO:19 (CAA10106.1); SEQ ID NO:20 (AJ012659); SEQ ID NO:21 (CAA10105.1); SEQ ID NO:22 (AF071223); SEQ ID NO:23 (AAC68868.1); SEQ ID NO:24 (U76208); SEQ ID NO:25 (AAC53029.1); SEQ ID NO:26 (U76210); SEQ ID NO:27 (AAC53033.1); SEQ ID NO:28 (U76209); SEQ ID NO:29 (AAC53032.1); SEQ



ID NO:30 (U76207); SEQ ID NO:31 (AAC53028.1); SEQ ID NO:32 (AF036257); SEQ  
 ID NO:33 (AAC15969.1); SEQ ID NO:34 (AF034778); SEQ ID NO:35 (AJ001178);  
 SEQ ID NO:36 (CAA04572.1); SEQ ID NO:37 (Y07621); SEQ ID NO:38  
 (CAA68900.1); SEQ ID NO:39 (AF024536); SEQ ID NO:40 (AAB82272.1); SEQ ID  
 5 NO:41 (D85188); SEQ ID NO:42 (BAA12738.1); SEQ ID NO:43 (D44480); SEQ ID  
 NO:44 (BAA07923.1); SEQ ID NO:45 (D43694); SEQ ID NO:46 (BAA07791.1); SEQ  
 ID NO:47 (D85845); SEQ ID NO:48 (BAA12880.1); SEQ ID NO:49 (U93171); SEQ ID  
 NO:50 (AAB58669.1); SEQ ID NO:51 (U93170); SEQ ID NO:52 (AAB58668.1); SEQ  
 ID NO:53 (U61152); SEQ ID NO:54 (AAB41307.1); SEQ ID NO:55 (U61151); SEQ ID  
 10 NO:56 (AAB41306.1); SEQ ID NO:57 (U61148); SEQ ID NO:58 (AAB41305.1); SEQ  
 ID NO:59 (U61149); SEQ ID NO:60 (AAB41304.1); SEQ ID NO:61 (U61150); SEQ ID  
 NO:62 (AAB41303.1); SEQ ID NO:63 (L36646); SEQ ID NO:64 (AAA21879.1); SEQ  
 ID NO:69 (AA625732).

In an aspect of the invention there is an animal having a heterologous nucleic acid  
 15 sequence replacing an allele of an *atonal*-associated nucleic acid sequence under  
 conditions wherein said heterologous sequence inactivates said allele. In an alternative  
 embodiment a heterologous sequence is delivered to a cell for extrachromosomal  
 propagation. In another alternative embodiment a heterologous sequence is integrated  
 into the chromosome of a cell in a locus other than the locus of an *atonal*-associated  
 20 nucleic acid sequence. In a preferred embodiment said heterologous sequence is  
 expressed under control of an *atonal*-associated regulatory sequence. In a specific  
 embodiment both *atonal*-associated alleles are replaced. In an additional specific  
 embodiment both *atonal*-associated alleles are replaced with nonidentical heterologous

nucleic acid sequences. Methods to generate transgenic animals are well known in the art, and a skilled artisan would refer to such references as Transgenic Animals by Grosveld and Kollias (eds.) or Mouse Genetics and Transgenics : A Practical Approach by Jackson et al. (eds.).

5

In an additional embodiment a transgenic animal of the present invention has a detectable condition wherein said condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, imbalance, joint disease, osteoarthritis and abnormal proliferation of cells. In another embodiment of the present invention a heterologous nucleic acid sequence is a reporter sequence selected from the group consisting of  $\beta$ -galactosidase, green fluorescent protein (GFP), blue fluorescent protein (BFP), neomycin, kanamycin, luciferase,  $\beta$ -glucuronidase and chloramphenicol transferase (CAT). In another specific embodiment, a reporter sequence is regulatable or is expressed in brain tissue, neural tissue, skin tissue, non-ossified cartilage cells, joint chondrocytes, Merkel cells, inner ear epithelial cells and brain stem nuclei. In additional specific embodiments said *atonal*-associated allele is replaced with an *atonal*-associated nucleic acid sequence under control of a regulatable promoter sequence or a tissue-specific promoter sequence wherein said tissue is selected from the group consisting of brain tissue, neural tissue, skin tissue, non-ossified cartilage cells, joint chondrocytes, Merkel cells, inner ear epithelial cells and brain stem nuclei. In additional embodiments a transgenic animal is a mouse, *Drosophila*, frog, zebrafish, rat, guinea pig, or hamster.

In another embodiment of the present invention is a method for screening for a compound in an animal, wherein said compound affects expression of an *atonal*-associated nucleic acid sequence comprising delivering said compound to said animal wherein said animal has at least one allele of an *atonal*-associated nucleic acid sequence  
5 inactivated by insertion of a heterologous nucleic acid sequence wherein said heterologous nucleic acid sequence is under control of an *atonal*-associated regulatory sequence, and monitoring for a change in said expression of said *atonal*-associated nucleic acid sequence. Examples of regulatory sequences may include promoter sequences, enhancers or silencers.

10 In specific embodiments there is a compound which upregulates or downregulates said expression of an *atonal*-associated nucleic acid sequence. The upregulation or downregulation may be by increasing the rate of transcription or decreasing the rate of mRNA decay.

Another embodiment of the present invention is a compound which affects  
15 expression of an *atonal*-associated nucleic acid sequence. In specific embodiments said compound upregulates or downregulates expression of an *atonal*-associated nucleic acid sequence. In a specific embodiment said compound affects a detectable condition in an animal wherein said condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, an imbalance disorder, joint  
20 disease, osteoarthritis, abnormal proliferation of cells and formation of cancer.

Another embodiment of the present invention is a method for screening for a compound in an animal, wherein the compound affects a detectable condition in the animal, comprising delivering the compound to the animal wherein at least one allele of

an *atonal*-associated nucleic acid sequence in said animal is inactivated by insertion of a heterologous nucleic acid sequence, wherein said heterologous nucleic acid sequence is under the control of an *atonal*-associated regulatory sequence, and monitoring said animal for a change in the detectable condition. In a specific embodiment said detectable

5 condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, an imbalance disorder, joint disease, osteoarthritis and abnormal proliferation of cells. In another embodiment said delivery of said compound affects expression of said heterologous nucleic acid sequence. In specific embodiments said expression of said heterologous nucleic acid sequence is

10 upregulated or downregulated. In additional specific embodiments the animal is a mouse, *Drosophila*, frog, zebrafish, rat, hamster and guinea pig.

Another embodiment of the present invention is a compound wherein said compound affects a detectable condition in a transgenic animal of the present invention. In specific embodiments said compound affects expression of a heterologous nucleic acid

15 sequence. In additional specific embodiments said compound upregulates or downregulates expression of a heterologous nucleic acid sequence.

In other embodiments of the present invention are methods of treating an animal, including a human, for cerebellar granule neuron deficiencies, for promoting mechanoreceptive cell growth, for generating hair cells, for treating hearing impairment

20 or imbalance, for treating a joint disease, for treating for an abnormal proliferation of cells, and for treating for a disease that is a result of loss of functional *atonal*-associated nucleic acid or amino acid sequence. Said methods include administering a therapeutically effective amount of an *atonal*-associated nucleic acid or amino acid

sequence. In specific embodiments said administration is by a vector selected from the group consisting of a viral vector (including bacteriophage, animal and plant viruses), a plasmid, cosmid or any other nucleic acid based vector, a liposome, a nucleic acid, a peptide, a lipid, a carbohydrate and a combination thereof of said vectors. In a specific

5 embodiment said viral vector is an adenovirus vector, a retrovirus vector, or an adeno-associated vector, including a lentivirus vector, Herpes virus vector, alpha virus vector, *etc.* Thus, the vector may be viral or non-viral. In a preferred embodiment said vector is an adenovirus vector comprising a cytomegalovirus IE promoter sequence and a SV40 early polyadenylation signal sequence. In another specific embodiment said cell is a

10 human cell. In an additional specific embodiment said joint disease is osteoarthritis. In an additional specific embodiment the cell contains an alteration in an *atonal*-associated amino acid sequence, wherein said amino acid sequence has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58.

In a specific embodiment, the present invention also provides a method of treating

15 an animal in need of treatment for a deficiency in cerebellar granule neurons, a hearing impairment, an imbalance disorder, a joint disease, or in need of promoting mechanoreceptive cell growth, or a disease that is a result of loss of functional *atonal*-associated nucleic acid or amino acid sequences. This method comprises delivering a transcription factor having an amino acid with at least about 70% identity, preferably at

20 least about 80% identity, and more preferably at least about 90% identity to the sequence AANARERRRMHGLNHAFDQLR to a cell in the animal. In some embodiments, the cell in the animal is located in the inner ear of the animal. Preferably, the transcription

factor competes with *atonal* for binding to Daughterless protein (Jarman et al., 1993) or competes for binding with Math-1 to E47 protein (Akazawa et al., 1995).

In an embodiment of the present invention there is provided a method for treating an organism for a disease that is a result of loss of functional *atonal*-associated nucleic acid or amino acid sequence. A skilled artisan is aware that this loss may be due to natural reduction or absence of significant (or to detectable levels) expression which occurs in an adult human.

In another embodiment of the present invention is a method for treating an animal for an abnormal proliferation of cells comprising altering *atonal*-associated nucleic acid or amino acid sequence levels in a cell. In a specific embodiment said alteration is reduction or said nucleic acid or amino acid sequence contains an alteration.

In a preferred embodiment of the present invention there are compositions to treat an organism for various medical conditions, discussed herein, comprising an *atonal*-associated nucleic acid sequence or amino acid sequence in combination with a delivery vehicle, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. A skilled artisan is aware that an adult organism, such as an adult human, naturally does not express *atonal* to significant or detectable levels, but instead expresses *atonal* in an embryonic stage of development (see the Examples). Thus, in a preferred embodiment, compositions to treat an organism as discussed herein, include compositions to treat organisms who do not contain a mutation in an *atonal* nucleic acid or amino acid sequence but who naturally have *atonal* no longer expressed to significant or detectable levels.

In another embodiment of the present invention is a composition comprising an *atonal*-associated amino acid sequence or nucleic acid sequence in combination with a delivery vehicle wherein said vehicle delivers a therapeutically effective amount of an *atonal*-associated nucleic acid sequence or amino acid sequence into a cell. In specific  
5       embodiments said vehicle is the receptor-binding domain of a bacterial toxin or any fusion molecule or is a protein transduction domain. In a specific embodiment said protein transduction domain is from the HIV TAT peptide.

In another embodiment of the present invention there is a composition to treat an organism for loss of hair cells, wherein said organism comprises a defect in an *atonal*-  
10       associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for loss of hair cells, wherein said organism comprises  
15       defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for loss of hair cells, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

20       In another embodiment of the present invention there is a composition to treat an organism for a cerebellar neuron deficiency, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific

embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a cerebellar neuron deficiency, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation  
5 of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a cerebellar neuron deficiency, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an  
10 organism for hearing impairment, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a  
15 composition to treat an organism for hearing impairment, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for hearing impairment, wherein said organism comprises a defect in an amino acid sequence which is associated with  
20 regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for an imbalance disorder, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a



mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for an imbalance disorder, wherein said organism  
5 comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for imbalance, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

10 In another embodiment of the present invention there is a composition to treat an organism for osteoarthritis, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic  
15 acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for osteoarthritis, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for osteoarthritis, wherein said organism  
20 comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for a joint disease, wherein said organism comprises a defect in an *atonal*-

associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a joint disease, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for a joint disease, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for abnormal proliferation of cells, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for abnormal proliferation of cells, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for abnormal proliferation of cells, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence.

In another embodiment of the present invention there is a composition to treat an organism for cancer, wherein said organism comprises a defect in an *atonal*-associated nucleic acid sequence. In a specific embodiment the defect is a mutation or alteration of said *atonal*-associated nucleic acid sequence. In another specific embodiment the defect affects a regulatory sequence of said *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for cancer, wherein said organism comprises defect in a nucleic acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In an additional embodiment of the present invention there is a composition to treat an organism for cancer, wherein said organism comprises a defect in an amino acid sequence which is associated with regulation of an *atonal*-associated nucleic acid sequence. In a specific embodiment said cancer is medulloblastoma.

## NUCLEIC ACID-BASED EXPRESSION SYSTEMS

### 1. Vectors

One of skill in the art would be well equipped to construct a vector through standard recombinant techniques, which are described in Sambrook et al., 1989 and Ausubel et al., 1994, both incorporated herein by reference.

The term "expression vector" refers to a vector containing a nucleic acid sequence coding for at least part of a gene product capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. In other cases, these

sequences are not translated, for example, in the production of antisense molecules or ribozymes. Expression vectors can contain a variety of "control sequences," which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence in a particular host organism. In addition to control  
5 sequences that govern transcription and translation, vectors and expression vectors may contain nucleic acid sequences that serve other functions as well and are described infra.

**a. Promoters and Enhancers**

10 A "promoter" is a control sequence that is a region of a nucleic acid sequence at which initiation and rate of transcription are controlled. It may contain genetic elements at which regulatory proteins and molecules may bind such as RNA polymerase and other transcription factors. A promoter may or may not be used in conjunction with an "enhancer," which refers to a *cis*-acting regulatory sequence involved in the  
15 transcriptional activation of a nucleic acid sequence.

Naturally, it will be important to employ a promoter and/or enhancer that effectively directs the expression of the DNA segment in the cell type, organelle, and organism chosen for expression. Those of skill in the art of molecular biology generally know the use of promoters, enhancers, and cell type combinations for protein expression,  
20 for example, see Sambrook et al. (1989), incorporated herein by reference. The promoters employed can be constitutive, tissue-specific, inducible, and/or useful under the appropriate conditions to direct high level expression of the introduced DNA

segment, such as is advantageous in the large-scale production of recombinant proteins and/or peptides. The promoter can be heterologous or endogenous.

The identity of tissue-specific promoters or elements, as well as assays to characterize their activity, is well known to those of skill in the art. Examples of such regions include the human LIMK2 gene (Nomoto et al. 1999), the somatostatin receptor 2 gene (Kraus et al., 1998), murine epididymal retinoic acid-binding gene (Lareyre et al., 1999), human CD4 (Zhao-Emonet et al., 1998), mouse alpha2 (XI) collagen (Tsumaki, et al., 1998), D1A dopamine receptor gene (Lee, et al., 1997), insulin-like growth factor II (Wu et al., 1997), human platelet endothelial cell adhesion molecule-1 (Almendro et al., 1996).

**b. Initiation Signals and Internal Ribosome Binding Sites**

A specific initiation signal also can be required for efficient translation of coding sequences. These signals include the ATG initiation codon or adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, can be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be "in-frame" with the reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be either natural or synthetic. The efficiency of expression can be enhanced by the inclusion of appropriate transcription enhancer elements.

In certain embodiments of the invention, the use of internal ribosome entry sites (IRES) elements are used to create multigene, or polycistronic, messages. IRES elements

can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message (see U.S. Patent 5,925,565 and 5,935,819, herein incorporated by reference).

**c. Multiple Cloning Sites**

Vectors can include a multiple cloning site (MCS), which is a nucleic acid region that contains multiple restriction enzyme sites, any of which can be used in conjunction with standard recombinant technology to digest the vector. (See Carbonelli et al., 1999, Levenson et al., 1998, and Cocca, 1997, incorporated herein by reference.)

**d. Splicing Sites**

Most transcribed eukaryotic RNA molecules will undergo RNA splicing to remove introns from the primary transcripts. Vectors containing genomic eukaryotic sequences can require donor and/or acceptor splicing sites to ensure proper processing of the transcript for protein expression. (See Chandler et al., 1997, herein incorporated by reference.)

**e. Polyadenylation Signals**

In expression, one will typically include a polyadenylation signal to effect proper polyadenylation of the transcript. Specific embodiments include the SV40

polyadenylation signal and/or the bovine growth hormone polyadenylation signal, convenient and/or known to function well in various target cells.

**f. Origins of Replication**

5 In order to propagate a vector in a host cell, it can contain one or more origins of replication sites (often termed "ori"), which is a specific nucleic acid sequence at which replication is initiated.

**g. Selectable and Screenable Markers**

10 In certain embodiments of the invention, the cells contain nucleic acid construct of the present invention, a cell can be identified *in vitro* or *in vivo* by including a marker in the expression vector. Such markers would confer an identifiable change to the cell permitting easy identification of cells containing the expression vector. Generally, a selectable marker is one that confers a property that allows for selection. A positive  
15 selectable marker is one in which the presence of the marker allows for its selection, while a negative selectable marker is one in which its presence prevents its selection. An example of a positive selectable marker is a drug resistance marker.

Usually the inclusion of a drug selection marker aids in the cloning and  
20 identification of transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selectable markers. In addition to markers conferring a phenotype that allows for the discrimination of transformants based on the implementation of conditions, other types of markers

including screenable markers such as GFP or enhanced GFP, whose basis is colorimetric analysis, are also contemplated. Alternatively, screenable enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) can be utilized. One of skill in the art would also know how to employ immunologic markers, possibly in conjunction with FACS analysis. Further examples of selectable and screenable markers are well known to one of skill in the art.

## 2. Expression Systems

Numerous expression systems exist that comprise at least a part or all of the compositions discussed above. Prokaryote- and/or eukaryote-based systems can be employed for use with the present invention to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and widely available.

The insect cell/baculovirus system can produce a high level of protein expression of a heterologous nucleic acid segment, such as described in U.S. Patent No. 5,871,986, 4,879,236, both herein incorporated by reference, and which can be bought, for example, under the name MAXBAC® 2.0 from INVITROGEN® and BACPACK™ BACULOVIRUS EXPRESSION SYSTEM FROM CLONTECH®. Other examples of expression systems are well known in the art.

## Nucleic Acid Detection

In addition to their use in directing the expression of atonal-associated proteins, polypeptides and/or peptides, the nucleic acid sequences disclosed herein have a variety



of other uses. For example, they have utility as probes or primers or in any of the methods for embodiments involving nucleic acid hybridization, amplification of nucleic acid sequences, detection of nucleic acids, and other assays. A skilled artisan is aware of the following patents regarding details of these methods: U.S. Patent No. 5,840,873;

5 U.S. Patent No. 5,843, 640; U.S. Patent No. 5,843,650; U.S. Patent No. 5,843,651; U.S. Patent No. 5,843,663; U.S. Patent No. 5,846,708; U.S. Patent No. 5,846,709; U.S. Patent No. 5,846,717; U.S. Patent No. 5,846,726; U.S. Patent No. 5,846,729; U.S. Patent No. 5,846,783; U.S. Patent No. 5,849,481; U.S. Patent No. 5,849,483; U.S. Patent No. 5,849,486; U.S. Patent No. 5,849,487; U.S. Patent No. 5,849,497; U.S. Patent No.

10 5,849,546; U.S. Patent No. 5,849,547; U.S. Patent No. 5,851,770; U.S. Patent No. 5,851,772; U.S. Patent No. 5,853,990; U.S. Patent No. 5,853, 993; U.S. Patent No. 5,853,992; U.S. Patent No. 5,856,092; U.S. Patent No. 5,858,652; U.S. Patent No. 5,861,244; U.S. Patent No. 5,863,732; U.S. Patent No. 5,863,753; U.S. Patent No. 5,866,331; U.S. Patent No. 5,866,336; U.S. Patent No. 5,866,337; U.S. Patent No.

15 5,900,481; U.S. Patent No. 5,905,024; U.S. Patent No. 5,910,407; U.S. Patent No. 5,912,124; U.S. Patent No. 5,912,145; U.S. Patent No. 5,912,148; U.S. Patent No. 5,916,776; U.S. Patent No. 5,916,779; U.S. Patent No. 5,919,626; U.S. Patent No. 5,919,630; U.S. Patent No. 5,922, 574; U.S. Patent No. 5,925,517; U.S. Patent No. 5,925,525; U.S. Patent No. 5,928,862; U.S. Patent No. 5,928,869; U.S. Patent No.

20 5,928,870; U.S. Patent No. 5,928,905; U.S. Patent No. 5,928,906; U.S. Patent No. 5,929,227; U.S. Patent No. 5,932,413; U.S. Patent No. 5,932,451; U.S. Patent No. 5,935,791; U.S. Patent No. 5,935,825; U.S. Patent No. 5,939,291; U.S. Patent No. 5,942,391; European Application No. 320 308; European Application No. 329 822; GB

Application No. 2 202 328; PCT Application No. PCT/US87/00880; PCT Application No. PCT/US89/01025; PCT Application WO 88/10315; PCT Application WO 89/06700; and PCT Application WO 90/07641.

## 5 Kits

All the essential materials and/or reagents required for detecting a sequence selected from SEQ ID NO:1 through SEQ ID NO:66 in a sample can be assembled together in a kit. This generally will comprise a probe or primers designed to hybridize specifically to individual nucleic acids of interest in the practice of the present invention, such as the nucleic acid sequences in SEQ ID NO:1 through SEQ ID NO:66. Also included can be enzymes suitable for amplifying nucleic acids, including various polymerases (reverse transcriptase, Taq, etc.), deoxynucleotides and buffers to provide the necessary reaction mixture for amplification. Such kits can also include enzymes and other reagents suitable for detection of specific nucleic acids or amplification products. Such kits generally will comprise, in suitable means, distinct containers for each individual reagent or enzyme as well as for each probe or primer pair.

## *Atonal*-Associated Nucleic Acids

### 20 A. Nucleic Acids and Uses Thereof

The term "nucleic acid" will generally refer to at least one molecule or strand of DNA, RNA or a derivative or mimic thereof, comprising at least one nucleobase, such as, for example, a naturally occurring purine or pyrimidine base found in DNA (e.g.

adenine "A," guanine "G," thymine "T" and cytosine "C") or RNA (e.g. A, G, uracil "U" and C). The term "nucleic acid" encompass the terms "oligonucleotide" and "polynucleotide." The term "oligonucleotide" refers to at least one molecule of between about 3 and about 100 nucleobases in length. The term "polynucleotide" refers to at least one molecule of greater than about 100 nucleobases in length. These definitions generally refer to at least one single-stranded molecule, but in specific embodiments will also encompass at least one additional strand that is partially, substantially or fully complementary to the at least one single-stranded molecule. Thus, a nucleic acid can encompass at least one double-stranded molecule or at least one triple-stranded molecule that comprises one or more complementary strand(s) or "complement(s)" of a particular sequence comprising a strand of the molecule. As used herein, a single stranded nucleic acid can be denoted by the prefix "ss", a double stranded nucleic acid by the prefix "ds", and a triple stranded nucleic acid by the prefix "ts."

Thus, the present invention also encompasses at least one nucleic acid that is complementary to a atonal-associated nucleic acid. In particular embodiments the invention encompasses at least one nucleic acid or nucleic acid segment complementary to the nucleic acid sequences set forth in SEQ ID NO:1 through SEQ ID NO:66, of those which are nucleic acid sequences. Nucleic acid(s) that are "complementary" or "complement(s)" are those that are capable of base-pairing according to the standard Watson-Crick, Hoogsteen or reverse Hoogsteen binding complementarity rules. As used herein, the term "complementary" or "complement(s)" also refers to nucleic acid(s) that are substantially complementary, as can be assessed by the same nucleotide comparison set forth above. The term "substantially complementary" refers to a nucleic acid

comprising at least one sequence of consecutive nucleobases, or semiconsecutive nucleobases if one or more nucleobase moieties are not present in the molecule, are capable of hybridizing to at least one nucleic acid strand or duplex even if less than all nucleobases do not base pair with a counterpart nucleobase.

5           Herein certain embodiments, a "gene" refers to a nucleic acid that is transcribed. As used herein, a "gene segment" is a nucleic acid segment of a gene. In certain aspects, the gene includes regulatory sequences involved in transcription, or message production or composition. In particular embodiments, the gene comprises transcribed sequences that encode for a protein, polypeptide or peptide. In other particular aspects, the gene  
10           comprises an atonal-associated nucleic acid, and/or encodes an atonal-associated polypeptide or peptide coding sequences. In keeping with the terminology described herein, an "isolated gene" can comprise transcribed nucleic acid(s), regulatory sequences, coding sequences, or the like, isolated substantially away from other such sequences, such as other naturally occurring genes, regulatory sequences, polypeptide or peptide  
15           encoding sequences, etc. In this respect, the term "gene" is used for simplicity to refer to a nucleic acid comprising a nucleotide sequence that is transcribed, and the complement thereof. In particular aspects, the transcribed nucleotide sequence comprises at least one functional protein, polypeptide and/or peptide encoding unit. As will be understood by those in the art, this function term "gene" includes both genomic  
20           sequences, RNA or cDNA sequences or smaller engineered nucleic acid segments, including nucleic acid segments of a non-transcribed part of a gene, including but not limited to the non-transcribed promoter or enhancer regions of a gene. Smaller engineered gene nucleic acid segments can express, or can be adapted to express using

nucleic acid manipulation technology, proteins, polypeptides, domains, peptides, fusion proteins, mutants and/or such like.

In certain embodiments, the nucleic acid sequence is a nucleic acid or nucleic acid segment. As used herein, the term "nucleic acid segment", are smaller fragments of a nucleic acid, such as for non-limiting example, those that encode only part of the atonal-associated peptide or polypeptide sequence. Thus, a "nucleic acid segment" can comprise any part of the atonal-associated gene sequence(s), of from about 2 nucleotides to the full length of the atonal-associated peptide or polypeptide encoding region. In certain embodiments, the "nucleic acid segment" encompasses the full length atonal-associated gene(s) sequence. In particular embodiments, the nucleic acid comprises any part of the SEQ ID NO:1 through SEQ ID NO:66, of from about 2 nucleotides to the full length of the sequence disclosed in SEQ ID NO:1 through SEQ ID NO:66.

In certain embodiments, the nucleic acid segment can be a probe or primer. As used herein, a "probe" is a nucleic acid utilized for detection of another nucleic acid and is generally at least about 10 nucleotides in length. As used herein, a "primer" is a nucleic acid utilized for polymerization of another nucleic acid is generally at least about 10 nucleotides in length. A non-limiting example of this would be the creation of nucleic acid segments of various lengths and sequence composition for probes and primers based on the sequences disclosed in SEQ ID NO:1 through SEQ ID NO:66, of those which are nucleic acid sequences.

The nucleic acid(s) of the present invention, regardless of the length of the sequence itself, can be combined with other nucleic acid sequences, including but not

limited to, promoters, enhancers, polyadenylation signals, restriction enzyme sites, multiple cloning sites, coding segments, and the like, to create one or more nucleic acid construct(s). As used herein, a "nucleic acid construct" is a recombinant molecule comprising at least two segments of different nucleic acid sequence. The overall length  
5 can vary considerably between nucleic acid constructs. Thus, a nucleic acid segment of almost any length can be employed, with the total length preferably being limited by the ease of preparation or use in the intended recombinant nucleic acid protocol.

In certain embodiments, the nucleic acid construct is a recombinant vector. As used herein, a "recombinant vector" is a nucleic acid comprising multiple segments of  
10 nucleic acids utilized as a vehicle for a nucleic acid sequence of interest. In certain aspects, the recombinant vector is an expression cassette. As used herein, an expression cassette is a segment of nucleic acid which comprises a gene of interest which can be transferred between different recombinant vectors by means well known in the art.

In particular embodiments, the invention concerns one or more recombinant  
15 vector(s) comprising nucleic acid sequences that encode an atonal-associated protein, polypeptide or peptide that includes within its amino acid sequence a contiguous amino acid sequence in accordance with, or essentially as set forth in, SEQ ID NO:2 through SEQ ID NO:66, of which sequences are amino acid sequences, corresponding to *Homo sapiens* or *Mus musculus* atonal-associated sequence.. In other embodiments, the  
20 invention concerns recombinant vector(s) comprising nucleic acid sequences from other species that encode an atonal-associated protein, polypeptide or peptide that includes within its amino acid sequence a contiguous amino acid sequence in accordance with, or

essentially as set forth in SEQ ID NO:2 through SEQ ID NO:66, of which sequences are amino acid sequences. In particular aspects, the recombinant vectors are DNA vectors.

It will also be understood that amino acid sequences or nucleic acid sequences can include additional residues, such as additional N- or C-terminal amino acids or 5' or 3' sequences, or various combinations thereof, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein, polypeptide or peptide activity where expression of a proteinaceous composition is concerned. The addition of terminal sequences particularly applies to nucleic acid sequences that may, for example, include various non-coding sequences flanking either of the 5' and/or 3' portions of the coding region or can include various internal sequences, i.e., introns, which are known to occur within genes.

It will also be understood that this invention is not limited to the particular nucleic acid or amino acid sequences of SEQ ID NO: through SEQ ID NO:66, of which sequences are amino acids. Recombinant vectors and isolated nucleic acid segments can therefore variously include these coding regions themselves, coding regions bearing selected alterations or modifications in the basic coding region, and they can encode larger polypeptides or peptides that nevertheless include such coding regions or can encode biologically functional equivalent proteins, polypeptide or peptides that have variant amino acids sequences.

The nucleic acids of the present invention encompass biologically functional equivalent atonal-associated proteins, polypeptides, or peptides or atonal-associated proteins, polypeptides or polypeptides. Such sequences can arise as a consequence of

codon redundancy or functional equivalency that are known to occur naturally within nucleic acid sequences or the proteins, polypeptides or peptides thus encoded. Alternatively, functionally equivalent proteins, polypeptides or peptides can be created via the application of recombinant DNA technology, in which changes in the protein, polypeptide or peptide structure can be engineered, based on considerations of the properties of the amino acids being exchanged. Changes designed by man can be introduced, for example, through the application of site-directed mutagenesis techniques as discussed herein below, e.g., to introduce improvements or alterations to the antigenicity of the protein, polypeptide or peptide, or to test mutants in order to examine atonal-associated protein, polypeptide or peptide activity at the molecular level.

Fusion proteins, polypeptides or peptides can be prepared, e.g., where the atonal associated coding regions are aligned within the same expression unit with other proteins, polypeptides or peptides having desired functions. Non-limiting examples of such desired functions of expression sequences include purification or immunodetection purposes for the added expression sequences, e.g., proteinaceous compositions that can be purified by affinity chromatography or the enzyme labeling of coding regions, respectively EP 266,032, or via deoxynucleoside H-phosphonate intermediates as described by Froehler et al., Nucl. Acids Res., 14:5399-5407, 1986,

As used herein an "organism" can be a prokaryote, eukaryote, virus and the like.

As used herein the term "sequence" encompasses both the terms "nucleic acid" and "proteancecous" or "proteanaceous composition." As used herein, the term "proteinaceous composition" encompasses the terms "protein", "polypeptide" and "peptide." As used herein "artificial sequence" refers to a sequence of a nucleic acid not



derived from sequence naturally occurring at a genetic locus, as well as the sequence of any proteins, polypeptides or peptides encoded by such a nucleic acid. A "synthetic sequence", refers to a nucleic acid or proteinaceous composition produced by chemical synthesis *in vitro*, rather than enzymatic production *in vitro* (i.e. an "enzymatically produced" sequence) or biological production *in vivo* (i.e. a "biologically produced" sequence).

### Cancer Therapies

10           Given the present invention is directed to methods and compositions for the treatment of abnormal cell proliferation, a discussion of therapies of cancer, which is the state of abnormal cell proliferation, is warranted.

A wide variety of cancer therapies, such as radiotherapy, surgery, chemotherapy and gene therapy, are known to one of skill in the art, can be used regarding the methods  
15           and compositions of the present invention.

### Radiotherapeutic agents

Radiotherapeutic agents and factors include radiation and waves that induce DNA damage for example, g-irradiation, X-rays, UV-irradiation, microwaves, electronic  
20           emissions, radioisotopes, and the like. Therapy can be achieved by irradiating the localized tumor site with the above described forms of radiations.

Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 weeks), to single doses of 2000 to 6000 roentgens.

Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.

### **Surgery**

5           Surgical treatment for removal of the cancerous growth is generally a standard procedure for the treatment of tumors and cancers. This attempts to remove the entire cancerous growth. However, surgery is generally combined with chemotherapy and/or radiotherapy to ensure the destruction of any remaining neoplastic or malignant cells. Thus, surgery can be used in the context of the present invention.

10

### **Chemotherapeutic Agents**

These can be, for example, agents that directly cross-link DNA, agents that intercalate into DNA, or agents that lead to chromosomal and mitotic aberrations by affecting nucleic acid synthesis.

15           Agents that directly cross-link nucleic acids, specifically DNA, are envisaged and are shown herein, to eventuate DNA damage leading to a synergistic antineoplastic combination. Agents such as cisplatin, and other DNA alkylating agents can be used.

Agents that damage DNA also include compounds that interfere with DNA replication, mitosis, and chromosomal segregation. Examples of these compounds  
20   include adriamycin (also known as doxorubicin), VP-16 (also known as etoposide), verapamil, podophyllotoxin, and the like. Widely used in clinical setting for the treatment of neoplasms these compounds are administered through bolus injections

intravenously at doses ranging from 25-75 mg/m<sup>2</sup> at 21 day intervals for adriamycin, to 35-100 mg/m<sup>2</sup> for etoposide intravenously or orally.

Cancer therapies also include a variety of combination therapies with both chemical and other types of treatments. Chemotherapeutics include, for example, cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, raloxifene, estrogen receptor binding agents, taxol, gemcitabine, navelbine, farnesyl-protein transferase inhibitors, transplatinum, 5-fluorouracil, vincristin, vinblastin and methotrexate, or any analog or derivative variant of the foregoing.

## Genes

### Gene Therapy Administration

For gene therapy, a skilled artisan would be cognizant that the vector to be utilized must contain the gene of interest or a suitable fragment thereof operatively linked to a promoter. For antisense gene therapy, the antisense sequence of the gene of interest or a suitable fragment thereof would be operatively linked to a promoter. One skilled in the art recognizes that in certain instances other sequences such as a 3' UTR regulatory sequences are useful in expressing the gene of interest. Where appropriate, the gene therapy vectors can be formulated into preparations in solid, semisolid, liquid or gaseous forms in the ways known in the art for their respective route of administration. Means known in the art can be utilized to prevent release and absorption of the composition until it reaches the target organ or to ensure timed-release of the composition. A

pharmaceutically acceptable form should be employed which does not ineffectuate the compositions of the present invention. In pharmaceutical dosage forms, the compositions can be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds. A sufficient amount of vector containing the therapeutic nucleic acid sequence must be administered to provide a pharmacologically effective dose of the gene product.

One skilled in the art recognizes that different methods of delivery can be utilized to administer a vector into a cell. Examples include: (1) methods utilizing physical means, such as electroporation (electricity), a gene gun (physical force) or applying large volumes of a liquid (pressure); and (2) methods wherein said vector is complexed to another entity, such as a liposome, viral vector or transporter molecule.

Accordingly, the present invention provides a method of transferring a therapeutic gene to a host, which comprises administering the vector of the present invention, preferably as part of a composition, using any of the aforementioned routes of administration or alternative routes known to those skilled in the art and appropriate for a particular application. Effective gene transfer of a vector to a host cell in accordance with the present invention to a host cell can be monitored in terms of a therapeutic effect (e.g. alleviation of some symptom associated with the particular disease being treated) or, further, by evidence of the transferred gene or expression of the gene within the host (e.g., using the polymerase chain reaction in conjunction with sequencing, Northern or Southern hybridizations, or transcription assays to detect the nucleic acid in host cells, or using immunoblot analysis, antibody-mediated detection, mRNA or protein half-life

studies, or particularized assays to detect protein or polypeptide encoded by the transferred nucleic acid, or impacted in level or function due to such transfer).

These methods described herein are by no means all-inclusive, and further methods to suit the specific application will be apparent to the ordinary skilled artisan.

- 5 Moreover, the effective amount of the compositions can be further approximated through analogy to compounds known to exert the desired effect.

Furthermore, the actual dose and schedule can vary depending on whether the compositions are administered in combination with other pharmaceutical compositions, or depending on interindividual differences in pharmacokinetics, drug disposition, and metabolism. Similarly, amounts can vary in *in vitro* applications depending on the particular cell line utilized (e.g., based on the number of vector receptors present on the cell surface, or the ability of the particular vector employed for gene transfer to replicate in that cell line). Furthermore, the amount of vector to be added per cell will likely vary with the length and stability of the therapeutic gene inserted in the vector, as well as also the nature of the sequence, and is particularly a parameter which needs to be determined empirically, and can be altered due to factors not inherent to the methods of the present invention (for instance, the cost associated with synthesis). One skilled in the art can easily make any necessary adjustments in accordance with the exigencies of the particular situation.

- 20 It is possible that cells containing the therapeutic gene can also contain a suicide gene (i.e., a gene which encodes a product that can be used to destroy the cell, such as herpes simplex virus thymidine kinase). In many gene therapy situations, it is desirable to be able to express a gene for therapeutic purposes in a host cell but also to have the

capacity to destroy the host cell once the therapy is completed, becomes uncontrollable, or does not lead to a predictable or desirable result. Thus, expression of the therapeutic gene in a host cell can be driven by a promoter although the product of said suicide gene remains harmless in the absence of a prodrug. Once the therapy is complete or no longer  
5 desired or needed, administration of a prodrug causes the suicide gene product to become lethal to the cell. Examples of suicide gene/prodrug combinations which can be used are Herpes Simplex Virus-thymidine kinase (HSV-tk) and ganciclovir, acyclovir or FIAU; oxidoreductase and cycloheximide; cytosine deaminase and 5-fluorocytosine; thymidine kinase thymidilate kinase (Tdk::Tmk) and AZT; and deoxycytidine kinase and cytosine  
10 arabinoside.

The method of cell therapy can be employed by methods known in the art wherein a cultured cell containing a copy of a nucleic acid sequence or amino acid sequence of *Math1* is introduced.

In yet another embodiment, the secondary treatment is a secondary gene therapy  
15 in which a second therapeutic polynucleotide is administered before, after, or at the same time a first therapeutic polynucleotide encoding all or part of an atonal-associated polypeptide. Delivery of a vector encoding either a full length or partial atonal-associated polypeptide in conjunction with a second vector encoding another gene product will have a combined anti-hyperproliferative effect on target tissues. Alternatively, a  
20 single vector encoding both genes can be used.

### **Immunotherapy**

- Immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells. The immune effector can be, for example, an antibody specific for some marker on the surface of a tumor cell. The antibody alone can serve as an effector of therapy or it can recruit other cells to actually effect cell killing.
- 5 The antibody also can be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent. Alternatively, the effector can be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target. Various effector cells include cytotoxic T cells and NK cells.
- 10 Immunotherapy, thus, could be used as part of a combined therapy, in conjunction with Ad-mda7 gene therapy. The general approach for combined therapy is discussed below. Generally, the tumor cell must bear some marker that is amenable to targeting, i.e., is not present on the majority of other cells. Many tumor markers exist and any of these can be suitable for targeting in the context of the present invention. Common
- 15 tumor markers include carcinoembryonic antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, erb B and p155.

### Combination Treatments

- 20 It can be desirable in utilizing the present invention to combine the compositions with other agents effective in the treatment of hyperproliferative disease, such as anti-cancer agents. An "anti-cancer" agent is capable of negatively affecting cancer in a subject, for example, by killing cancer cells, inducing apoptosis in cancer cells,

reducing the growth rate of cancer cells, reducing the incidence or number of metastases, reducing tumor size, inhibiting tumor growth, reducing the blood supply to a tumor or cancer cells, promoting an immune response against cancer cells or a tumor, preventing or inhibiting the progression of cancer, or increasing the lifespan of a subject with cancer.

- 5 More generally, these other compositions would be provided in a combined amount effective to kill or inhibit proliferation of the cell. This process can involve contacting the cells with the expression construct and the agent(s) or multiple factor(s) at the same time. This can be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting the cell with two distinct
- 10 compositions or formulations, at the same time, wherein one composition includes the expression construct and the other includes the second agent(s).

Tumor cell resistance to chemotherapy and radiotherapy agents represents a major problem in clinical oncology. One goal of current cancer research is to find ways to

15 improve the efficacy of chemo- and radiotherapy by combining it with gene therapy. For example, the herpes simplex-thymidine kinase (HS-tK) gene, when delivered to brain tumors by a retroviral vector system, successfully induced susceptibility to the antiviral agent ganciclovir (Culver, et al., 1992). In the context of the present invention, it is contemplated that mda-7 gene therapy could be used similarly in conjunction with

20 chemotherapeutic, radiotherapeutic, or immunotherapeutic intervention, in addition to other pro-apoptotic or cell cycle regulating agents.

Alternatively, the gene therapy can precede or follow the other agent treatment by intervals ranging from minutes to weeks. In embodiments where the other agent and



expression construct are applied separately to the cell, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the agent and expression construct would still be able to exert an advantageously combined effect on the cell. In such instances, it is contemplated that one can contact the

5 cell with both modalities within about 12-24 h of each other and, more preferably, within about 6-12 h of each other. In some situations, it can be desirable to extend the time period for treatment significantly, however, where several d (2, 3, 4, 5, 6 or 7) to several wk (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.

10 Various combinations can be employed, gene therapy is "A" and the secondary agent, such as radio- or chemotherapy, is "B":

A/B/A B/A/B B/B/A A/A/B A/B/B B/A/A A/B/B/B B/A/B/B

15 B/B/B/A B/B/A/B A/A/B/B A/B/A/B A/B/B/A B/B/A/A

B/A/B/A B/A/A/B A/A/A/B B/A/A/A A/B/A/A A/A/B/A

Administration of the therapeutic expression constructs of the present invention to a

20 patient will follow general protocols for the administration of chemotherapeutics, taking into account the toxicity, if any, of the vector. It is expected that the treatment cycles would be repeated as necessary. It also is contemplated that various standard therapies,

as well as surgical intervention, can be applied in combination with the described hyperproliferative cell therapy.

### **Inhibitors of Cellular Proliferation**

5           The tumor suppressor oncogenes function to inhibit excessive cellular proliferation. The inactivation of these genes destroys their inhibitory activity, resulting in unregulated proliferation. The tumor suppressors p53, p16 and C-CAM are specific embodiments utilized in the present invention. Other genes that can be employed according to the present invention include Rb, APC, DCC, NF-1, NF-2, WT-1, MEN-I,  
10 MEN-II, zac1, p73, VHL, MMAC1 / PTEN, DBCCR-1, FCC, rsk-3, p27, p27/p16 fusions, p21/p27 fusions, anti-thrombotic genes (e.g., COX-1, TFPI), PGS, Dp, E2F, ras, myc, neu, raf, erb, fms, trk, ret, gsp, hst, abl, E1A, p300, genes involved in angiogenesis (e.g., VEGF, FGF, thrombospondin, BAI-1, GDAIF, or their receptors) and MCC.

### **15 Regulators of Programmed Cell Death**

Apoptosis, or programmed cell death, is an essential process for normal embryonic development, maintaining homeostasis in adult tissues, and suppressing carcinogenesis (Kerr et al., 1972). The Bcl-2 family of proteins and ICE-like proteases have been demonstrated to be important regulators and effectors of apoptosis in other  
20 systems. The Bcl-2 protein, discovered in association with follicular lymphoma, plays a prominent role in controlling apoptosis and enhancing cell survival in response to diverse apoptotic stimuli (Bakhshi et al., 1985; Cleary and Sklar, 1985; Cleary et al., 1986; Tsujimoto et al., 1985; Tsujimoto and Croce, 1986). The evolutionarily conserved

Bcl-2 protein now is recognized to be a member of a family of related proteins, which can be categorized as death agonists or death antagonists. Different family members have been shown to either possess similar functions to Bcl-2 (e.g., BclXL, BclW, BclS, Mcl-1, A1, Bfl-1) or counteract Bcl-2 function and promote cell death (e.g., Bax, Bak, Bik, Bim, Bid, Bad, Harakiri).

### Other agents

It is contemplated that other agents can be used in combination with the present invention to improve the therapeutic efficacy of treatment. These additional agents include immunomodulatory agents, agents that affect the upregulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adhesion, or agents that increase the sensitivity of the hyperproliferative cells to apoptotic inducers.

### Dosage and Formulation

The nucleic acid sequences and amino acid sequences (active ingredients) of this invention can be formulated and administered to treat a variety of disease states by any means that produces contact of the active ingredient with the agent's site of action in the body of an animal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic active ingredients or in a combination of therapeutic active ingredients. They can be

administered alone, or with a pharmaceutically acceptable carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage administered will be a therapeutically effective amount of active ingredient and will, of course, vary depending upon known factors such as the pharmacodynamic characteristics of the particular active ingredient and its mode and route of administration; age, sex, health and weight of the recipient; nature and extent of symptoms; kind of concurrent treatment, frequency of treatment and the effect desired.

The active ingredient can be administered orally in solid dosage forms such as capsules, tablets and powders, or in liquid dosage forms such as elixirs, syrups, emulsions and suspensions. The active ingredient can also be formulated for administration parenterally by injection, rapid infusion, nasopharyngeal absorption or dermoabsorption. The agent can be administered intramuscularly, intravenously, or as a suppository. In addition, parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. Suitable pharmaceutical carriers are described in *Remington's Pharmaceutical Sciences*, a standard reference text in this field.

Additionally, standard pharmaceutical methods can be employed to control the duration of action. These are well known in the art and include control release preparations and can include appropriate macromolecules, for example polymers, polyesters, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methyl cellulose, carboxymethyl cellulose or protamine sulfate. The concentration of macromolecules as well as the methods of incorporation can be adjusted in order to control release. Additionally, the agent can be incorporated into particles of polymeric materials such as polyesters, polyamino acids, hydrogels, poly (lactic acid) or

ethylenevinylacetate copolymers. In addition to being incorporated, these agents can also be used to trap the compound in microcapsules.

Useful pharmaceutical dosage forms for administration of the compounds of this invention can be illustrated as follows.

5           Capsules: Capsules are prepared by filling standard two-piece hard gelatin capsules each with a therapeutically effective amount of powdered active ingredient, 175 milligrams of lactose, 24 milligrams of talc and 6 milligrams magnesium stearate.

Soft Gelatin Capsules: A mixture of active ingredient in soybean oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin  
10 capsules containing a therapeutically effective amount of the active ingredient. The capsules are then washed and dried.

Tablets: Tablets are prepared by conventional procedures so that the dosage unit is a therapeutically effective amount of active ingredient. 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline  
15 cellulose, 11 milligrams of cornstarch and 98.8 milligrams of lactose. Appropriate coatings can be applied to increase palatability or to delay absorption.

Injectable: A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredients in 10% by volume propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized.

20           Suspension: An aqueous suspension is prepared for oral administration so that each 5 millimeters contain a therapeutically effective amount of finely divided active ingredient, 200 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution U.S.P. and 0.025 millimeters of vanillin.

Accordingly, the pharmaceutical composition of the present invention can be delivered via various routes and to various sites in an animal body to achieve a particular effect (see, e.g., Rosenfeld et al. (1991), supra; Rosenfeld et al., Clin. Res., 39(2), 311A (1991a); Jaffe et al., supra; Berkner, supra). One skilled in the art will recognize that

5 although more than one route can be used for administration, a particular route can provide a more immediate and more effective reaction than another route. Local or systemic delivery can be accomplished by administration comprising application or instillation of the formulation into body cavities, inhalation or insufflation of an aerosol, or by parenteral introduction, comprising intramuscular, intravenous, peritoneal,

10 subcutaneous, intradermal, as well as topical administration.

The composition of the present invention can be provided in unit dosage form wherein each dosage unit, e.g., a teaspoonful, tablet, solution, or suppository, contains a predetermined amount of the composition, alone or in appropriate combination with other active agents. The term "unit dosage form" as used herein refers to physically

15 discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of the compositions of the present invention, alone or in combination with other active agents, calculated in an amount sufficient to produce the desired effect, in association with a pharmaceutically acceptable diluent, carrier, or vehicle, where appropriate. The specifications for the unit dosage forms of the present

20 invention depend on the particular effect to be achieved and the particular pharmacodynamics associated with the pharmaceutical composition in the particular host.

These methods described herein are by no means all-inclusive, and further methods to suit the specific application will be apparent to the ordinary skilled artisan.

Moreover, the effective amount of the compositions can be further approximated through analogy to compounds known to exert the desired effect.

5           The following examples are offered by way of example, and are not intended to limit the scope of the invention in any manner.

### **EXAMPLE 1**

#### **Mouse *atonal* homolog 1 (*Math1*)**

10           It has been found that the present methods for the treatment of the hearing impaired have failed to address the problem directly, that is, the regeneration of auditory hair cell populations. The present invention in a preferred embodiment is directed to a member of the bHLH family, the *Math1* gene or an another *atonal*-associated nucleic acid sequence, and its requirement for generation of cerebellar granule neurons and inner  
15 ear hair cells. This discovery has wide ramifications not only for understanding neurodevelopment but also for therapies for a variety of prevalent disorders, as described below.

          The mouse *atonal* homolog 1 (*Math1*) is expressed in the precursors of the cerebellar granule neurons; a few cells in the dorsal portion of the developing spinal cord;  
20 the inner ear; Merkel cells (touch receptors on the skins); and joints. Overexpressing *Math1* in an otherwise differentiated cell can induce the formation or differentiation into a progenitor or mature inner ear hair cell-like cell.

*Math1* expression in the precursors of the cerebellar granule neurons suggests it is required for function in the cerebellum and brain. The cerebellum is essential for fine motor coordination and posture, and its dysfunction disrupts balance, speech and limb movements. Cerebellar development typically begins at about embryonic day 9.5 (E9.5) when a small group of cells in the hindbrain proliferates and migrates rostrally to form the external granule layer, brain stem, and pontine neurons. This population of neuronal progenitors, which continues to express *Math1*, further proliferates and migrates internally to form the cerebellar granule neurons that are the predominant neuronal population in the cerebellum and brain. Mice that do not express *Math1* completely lack cerebellar granule neurons and their precursors. *Math1* is thus essential for the generation of these neurons and endows the very sparse population of neurons at E9.5 with the ability to proliferate into billions and then differentiate (Ben-Arie et al., 1997). Both these functions are of great medical significance. To understand normal proliferation provides necessary insight into abnormal proliferation, as observed in cancer. Cerebellar tumors of the primitive neuroectodermal type (e.g., medulloblastoma) are the most common solid malignancy in children. *Math1* expressing cells contribute significantly to these tumors.

*Math1* is expressed in the non-ossified joint cartilage (see Figure 6) that typically degenerates in osteoarthritis. This is the most prevalent form of arthritis, with 90% of people over 40 showing some degree of osteoarthritis in one or more joints. Given the properties of *Math1* in cellular generation and proliferation, its artificial expression in affected joints can allow regeneration of the cells that constitute non-ossified cartilage.



Disclosed herein are compositions and methods for the use of the *Math1* gene, its human homolog (*Hath1*) or any of its homologs, orthologs, chimeric fusion proteins or derivatives of any suitable *atonal*-associated nucleic acid sequence or any another *atonal*-associated nucleic acid sequence. To learn about the functions of *Math1* in mammals,

5 the *Math1* gene was deleted from a mouse using a strategy that permitted detection of cells that express *Math1*. Disclosed are the creation and characterization of mice that can be used to screen for compounds which could be utilized to decrease or augment *Math1* expression in inner ear hair cells and other cells in which *Math1* expression is associated.

10 Methods are also disclosed for the study, characterization and treatment of neoplastic proliferation of neuroectodermal origin since *Math1* expression is essential for the generation and proliferation of cerebellar granule neurons. Also, it has been discovered that *Math1* plays a role in the development of cells that produce non-ossified joint cartilage, which are associated with the development of osteoarthritis. These

15 discoveries have led to a method of screening for compounds that can be helpful for the treatment of inner ear hair cell loss and other diseases that occur due to the functional loss of *Math1*, such as osteoarthritis.

More particularly, the present invention provides an animal heterozygous for *Math1* gene inactivation or an another *atonal*-associated nucleic acid sequence, wherein

20 at least one *Math1* allele or another *atonal*-associated nucleic acid sequence has been replaced by insertion of a heterologous nucleic acid sequence, wherein the inactivation of the *Math1* or *atonal*-associated sequence prevents expression of the *Math1* or *atonal*-associated allele. The mouse can be further used to generate mice homozygous for

*Math1* or another *atonal*-associated sequence gene inactivation and can further include a second heterologous nucleic acid sequence, wherein at least one of the heterologous genes is used to detect expression driven by the *Math1* or *atonal*-associated sequence regulatory elements. The complete or partial inactivation of the functional *Math1* or

5 *atonal*-associated sequence can be detected in, e.g., proprioceptive cells, granule neurons and their progenitor cells, or non-ossified cartilage cells.

Examples of heterologous nucleic acid sequences are reporter sequences such as b-galactosidase, green fluorescent protein (GFP), blue fluorescent protein (BFP), neomycin, kanamycin, luciferase, b-glucuronidase and chloramphenicol transferase

10 (CAT). The *Math1* or *atonal*-associated sequence can also be replaced under the control of regulatable promoter sequences or can be a tissue-specific promoter sequences. Said promoter sequences can be partial or can contain the entire promoter.

The present invention can also be used as, or as part of, a method for screening for a compound, wherein the administration of the compound affects a developmental

15 and/or pathological condition wherein said condition is a result of reduction in expression of the *Math1* or *atonal*-associated sequence, the method including, administering the compound to a transgenic mouse that is homozygous for *Math1* or *atonal*-associated sequence inactivation, wherein at least one *Math1* or *atonal*-associated allele is inactivated by insertion of a heterologous nucleic acid sequence, wherein the inactivation

20 of the *Math1* or *atonal*-associated sequence prevents expression of the *Math1* or *atonal*-associated gene, and monitoring the mouse for a change in the developmental and/or pathological condition. The types of pathological conditions that can be examined include, but are not limited to loss of hair cells, loss of cerebellar granule neurons or their

precursors, lack of granule cell proliferation or migration, lack of cerebellar external granule layer cells, hearing impairment, an imbalance disorder, joint disease, osteoarthritis, abnormal proliferation of neoplastic neuroectodermal cells and formation of medulloblastoma. As used herein, the screen provides for a compound that by  
5 upregulating expression of a heterologous nucleic acid sequence is a positive effector and for a compound that by downregulating expression of a heterologous nucleic acid sequence is a negative effector.

Yet another embodiment of the present invention is a method of promoting mechanoreceptive cell growth, that includes contacting a cell with a *Math1* or *atonal*-  
10 associated protein or gene in an amount effective to cause said cell to express an inner ear hair cell marker. An example of a hair cell marker for use with the method is calretinin. The cell can be contacted with a vector that expresses a *Math1* or *atonal*-associated nucleic acid sequence or amino acid sequence. *Math1* or *atonal*-associated nucleic acid sequence-expressing recombinant vectors can include an adenoviral vector,  
15 a retroviral vector, an adeno-associated vector, a plasmid, a liposome, a protein, a lipid, a carbohydrate and a combination thereof of said vectors. *Math1* or *atonal*-associated sequence can be under the control of, e.g., a cytomegalovirus IE promoter sequence or the cytomegalovirus IE promoter sequence and a SV40 early polyadenylation signal sequence, or any other combination of appropriate promoter sequences, enhancer  
20 sequence, and polyadenylation.

Furthermore, a method is disclosed for treating hearing impairment or an imbalance disorder that includes administering to an animal, including a human, with hearing loss or an imbalance disorder a therapeutically effective amount of a *Math1* or

*atonal*-associated amino acid sequence or nucleic acid sequence. The hearing or balance impairment can be complete or partial and can affect either one ear or both ears. In a preferred embodiment, there is a substantial impairment of hearing. Hearing and an imbalance disorder can be affected separately or concomitantly in an animal to be treated, and said hearing and/or an imbalance disorder could be as a result of trauma, disease, age-related condition, or could be due to loss of hair cells for any reason.

The present invention is also directed to a composition that includes a *Math1* or *atonal*-associated protein or gene in combination with a delivery vehicle, wherein the delivery vehicle causes a therapeutically effective amount of *Math1* or *atonal*-associated sequence to be delivered into a cell. The delivery vehicle can be further defined as a vector that comprises a *Math1* or *atonal*-associated amino acid sequence or nucleic acid sequence in an animal cell. The vector can be a retroviral or an adenoviral vector or any other nucleic acid based vector which can even be dispersed in a pharmacologically acceptable formulation, and used for intralesional administration. The composition can even be a partially or fully purified protein that is delivered using a liposome, a protein, a lipid or a carbohydrate that promotes the entry of a *Math1* or *atonal*-associated protein into a cell. Examples of proteins that can be used as delivery vehicles include the receptor-binding domains (the non-catalytic regions) of bacterial toxins, such as, e.g., Exotoxin A, cholera toxin and Ricin toxin or protein transduction domains, such as from the HIV TAT protein (Schwarze et al., 1999) (see Example 22). The composition for delivering *Math1* can be a fusion protein.

A skilled artisan is aware that methods to treat animals as disclosed in the invention can be either *in utero* or after birth. Treatment can be given to an embryo and can occur either *ex vivo* or *in vivo*.

5

## **EXAMPLE 2**

### **Animal Model for Organogenesis**

An effective animal model for deficiency in a gene that controls organogenesis will most often have both alleles stably inactivated so that, throughout embryogenesis, one or more tissues cannot revert to a functional wild-type allele. One method of generating animals with an altered genotype is gene targeting (Mansour et al., 1993), in which homologous recombination of newly introduced DNA sequence (i.e., the targeting sequence or construct) and a specific targeted DNA sequence residing in the chromosome results in the insertion of a portion of the newly introduced DNA sequence into the targeted chromosomal DNA sequence. This method is capable of generating animals of any desired genotype, and is especially useful for gene disruption (i.e., to "knock out") at a specific chromosomal gene sequence by inserting a selectable marker into the gene or completely replacing the gene with another nucleotide sequence.

To knock out a genomic sequence, a cloned fragment must be available and intron-exon boundaries within the fragment defined (Mansour et al., 1993). Typically, the targeting construct contains a selectable marker such as Neo (neomycin resistance, see Mansour et al., 1993) flanked by sequences homologous to the chromosomal target DNA, and beyond one of these flanking sequences the herpes simplex virus thymidine kinase gene (HSV-TK, see generally, McKnight et al., 1980). The targeting construct is

introduced, e.g., by electroporation, into embryo-derived stem (ES) cells where homologous recombination results in an insertion of the Neomycin resistance marker (Neo), but not the HSV-TK gene, into the targeted chromosomal DNA sequence. The altered ES cells are neomycin resistant and HSV-TK<sup>-</sup> and so are able to grow in the presence of both G418 and gancyclovir antibiotics. Random insertions contain the HSV-TK gene and are thus sensitive to gancyclovir (Mansour, et al.). Positive ES clones are then microinjected into blastocysts to generate germ-line chimeric mice, which are then bred to obtain progeny that are homozygous for the knock out gene. Such general methods of generating knock out animals have been demonstrated using mice. Genes in other animals such as rats, guinea pigs, gerbils, hamsters, and rabbits, can also be used as long as sufficient DNA sequence data are available to make an appropriate targeting construct to knock out the gene of interest.

Although *ato* and *Math1* share a high degree of sequence conservation, there was an apparent discrepancy between their expression patterns and the consequences of their loss of function. Whereas *ato* is expressed primarily in the PNS of the fly and its absence causes loss of almost all CHOs (Jarman et al., 1993), *Math1* is expressed in the CNS and its loss leads to absence of cerebellar granule neurons, the largest neuronal population in the CNS (Ben-Arie et al., 1997). To better understand the functional relations between *ato* and *Math1*, the present invention describes generation of a second *Math1* null allele in mice (*Math1*<sup>b-gal/b-gal</sup>) by replacement of the *Math1* coding region with a b-galactosidase gene (*lacZ*) and performing a subsequent search for CNS expression of *ato* in the fruit fly. The Examples describe a functional link between *ato* and *Math1*: *ato* is expressed

in the fly brain, and *lacZ* expression under the control of *Math1* regulatory elements (*Math1/lacZ*) not only replicated the known expression pattern in the CNS (i.e., the neural tube, spinal cord and cerebellum), but appeared in many other cells of the murine PNS. Overexpression of *Math1* in *Drosophila* caused ectopic CHO formation, providing  
5 further evidence that *ato* and *Math1* are functionally conserved.

The connections and consistency of the relationship between *atonal* in *Drosophila* and *Math1* in the mouse suggests that their use as model systems in the art is justified. A family of homologues have been cloned and analyzed in the mouse including MATH1,2,3,4A, 4B, 4C and 5 (Azakawa et al., 1995; Bartholoma and Nave, 1994; Ben-  
10 Arie et al., 1997; Ben-Arie et al., 1996, Fode et al., 1998; Ma et al., 1998; McCormick et al., 1996; Shimizu et al., 1995; Takebayashi et al., 1997). A *Xenopus atonal* homolog, *Xath1* has been ectopically expressed in *Drosophila* and shown to behave similarly to *ato* (Kim et al., 1997). Furthermore, the ability of *Math1* to induce ectopic CHO formation and to restore CHOs to *ato* mutant embryos (see Example 13) is strong evidence that  
15 *Math1*, and particularly its basic domain, encodes lineage identity information not unlike that encoded by *ato* and that mammalian cells expressing *Math1* are functionally similar and perhaps evolutionarily related to *Drosophila* cells that require *ato*. Thus, the similarities between *atonal* in *Drosophila*, *Xath1* in *Xenopus* and *Math1* in the mouse indicate that these animals are comparable animal model systems. Furthermore, the  
20 widespread use of mice in particular as a model system for humans also suggests that it similarly would allow utilization of the invention in humans.

With advances in molecular genetics now standard in the art, sequences from humans and other species can be used interchangeably in a variety of organisms. For

example, the rat inducible *hsp70* gene was used to produce transgenic mice that overexpressed inducible *hsp70*, allowing organs from transgenic mice to be protected from ischemic injury (Marber et al. *J. clin. Invest.* 95:1446-1456 (1995)) due to the increase in rat *hsp70*. Sequences in other animals have been interchanged including

5 between humans and rodents to develop rodent models to study human disease, i.e. neurodegenerative diseases. One such example is the expression of the human *SCA1* gene, which encodes ataxin-1, in mice (Burrigh, E. N. et al. *Cell* 82:937-948 (1995)). Transgenic mice were generated expressing the human *SCA1* gene with either a normal or an expanded CAG tract. The data illustrated that the expanded CAG repeats were

10 expressed in sufficient amounts in the Purkinje cells to produce degeneration and ataxia. This example illustrates that a mouse model can be established to study spinocerebellar ataxia type 1, which is an autosomal dominant inherited neurologic disorder. In addition to developing mouse models, *Drosophila* is a hallmark model system in the field. Warrick et al. (1999) produced transgenic flies which co-expressed human *hsp70* and a

15 human mutant polyglutamine (*MJDtr-Q78*). Expression of the human mutant polyglutamine *MJDtr-Q78* alone in the flies resulted in the formation of large aggregates in neurons. However, co-expression with human *hsp 70* resulted in suppressed aggregation. These examples illustrate that interchangeability of genes is routine in the field of molecular genetics and model systems provide powerful tools to characterize

20 gene function.

### **EXAMPLE 3**

#### **Generation of Transgenic *Math1* Mice**



To detect subtle *Math1* expression patterns not identified by RNA *in situ* hybridization, and thus further illuminate this gene's role during embryonic development, *Math1* null alleles (*Math1* <sup>$\beta$ -Gal/ $\beta$ -Gal</sup>) were generated by replacing the *Math1* coding region with  $\beta$ -galactosidase ( $\beta$ -Gal).

- 5           The targeting construct, containing a *lacZ* cassette and a *PGK-neo* cassette (Fig. 7A), was used to replace the *Math1* coding region. To delete the entire coding region of *Math1*, a targeting construct was generated that contained the 5' and 3' genomic flanking fragments as described previously (Ben-Arie et al., 1997) flanking a pSAbgal/PGK-neo cassette (Friedrich and Soriano, 1991). The construct is designed so that *lacZ* expression  
10 is driven by endogenous *Math1* control elements, while an independent PGK promoter drives the expression of the selectable marker *neo*.

- The construct was electroporated into ES cells and selection for *neo* was achieved with G418. Fourteen out of 76 (18%) clones underwent homologous recombination. Genotyping of ES cells, yolk sac and tail DNA was performed using Southern analysis  
15 of *EcoR* I digested DNA and probes previously described (Ben-Arie et al., 1997). The targeting construct was electroporated into embryonic stem (ES) cells; 14/76 (18%) clones exhibited correct homologous recombination at the *Math1* locus (Fig. 7B).

- Three ES cell lines carrying the *Math1*<sup>+/ $\beta$ -gal</sup> allele were injected into host blastocysts to generate chimeric mice. *Math1*<sup>+/ $\beta$ -gal</sup> mice were identified and intercrossed  
20 to generate homozygotes (Fig. 7C). The *Math1* deletion was confirmed by Southern analysis using both flanking and internal probes (Fig. 7A).

*Math1* <sup>$\beta$ -Gal/ $\beta$ -Gal</sup> mice show all the phenotypic features reported in the *Math1*<sup>-/-</sup> mice (Ben-Arie et al., 1997; 2000).

**EXAMPLE 4****X-gal staining, histological and immunohistochemical analyses**

Embryos were staged by vaginal plug, with the morning of the plug designated E0.5. Embryos were dissected out of the uterus, separated from extraembryonic membranes, and placed in cold phosphate buffered saline (PBS). The embryos were then fixed in 4% paraformaldehyde (PFA) in PBS for 30 minutes, and washed in cold PBS. Yolk sacs or tails were collected before fixation for DNA extraction and genotyping. Equilibration to improve the penetrability of the staining reagents was performed in 0.02% NP40, 0.01% sodium deoxycholate in PBS for 10 minutes at room temperature.

Whole mount staining with X-gal (Bonnerot and Nicolas, 1993) was performed for 16-24 hours at 30°C while shaking in the same equilibration buffer, which also contained 5mM potassium ferricyanide, 5mM potassium ferrocyanide, and 40 mg/ml X-gal (dissolved in DMSO). When the desired intensity of staining was achieved, usually within 18 hours, embryos were washed in PBS, postfixed for 30 minutes in buffered formalin, serially dehydrated in 25, 50, and 70% ethanol, and stored at 4°C.

For histological analysis embryos were further dehydrated in 80, 90, and 100% ethanol, treated in HistoClear (National Diagnostics), and embedded in Paraplast (Oxford Labware). Seven to 20  $\mu$ m sections were cut using in a microtome (Microme). Counterstaining was performed using nuclear fast red (Vector Laboratories).

Immunohistochemistry was performed as detailed previously (Ben-Arie et al., 1997). Antibodies: Anti-cytokeratin 18 (DAKO) 1:20; Anti-human Chromogranin A (DAKO) 1:100; Anti-MATH1 (see below) 1:200.

**EXAMPLE 5****Expression Patterns in Transgenic *Math1* Mice**

As expected,  $\beta$ -Gal expression in the cerebellum and dorsal spinal cord is identical to that of *Math1*, and interestingly,  $\beta$ -Gal is also expressed throughout the otic vesicle epithelia at E12.5 and in the sensory epithelia of the utricle, saccule, semicircular canals, and cochlea at E14.5 and E15.5 (Figures 1A and 1B). Utricles were obtained from C57BL/129SVEV mice.

Gross morphological analysis of the inner ear of *Math1* <sup>$\beta$ -Gal/ $\beta$ -Gal</sup> mice at E18.5, one day before full gestation, revealed no obvious defects in overall structure and size compared with wild type (wt) littermates. The branches of the VIII<sup>th</sup> cranial nerve were present and reached the epithelia, but degenerated due to absence of the hair cells.

The sensory epithelia were examined in detail. The utricles and cochleas of wild-type, *Math1*<sup>+/ $\beta$ -Gal</sup>, and *Math1* <sup>$\beta$ -Gal/ $\beta$ -Gal</sup> mice were excised to allow viewing of the sensory epithelia with Nomarski optics. Hair bundles were present in both organs of wild-type and heterozygotes, but were completely absent in *Math1* null litter-mates. Scanning electron microscopy (SEM) of the cochlea and vestibular organs confirmed the absence of hair bundles in null mice (Figures 2A through 2F). To determine whether lack of hair bundles reflects the absence of hair cells, cross-sections of the sensory epithelia of all inner ear organs using both light and transmission electron microscopy (LM and TEM, respectively) were examined (Figures 3A through 3F). LM and TEM were carried out as described previously (Lysakowski and Goldberg, 1997). Tissue preparation for SEM consisted of osmication (1% OsO<sub>4</sub> in cacodylate buffer), dehydration, critical-point drying, sputter-coating with gold, and examination in a JEOL 35S electron microscope.

Light microscopy revealed that sensory epithelia in null mice are considerably thinner, lack the normal stratification of cell nuclei and stain uniformly, all of which are consistent with the absence of hair cells. TEM clearly distinguishes between hair cells and supporting cells in normal utricles: hair cells have hair bundles, less electron-dense cytoplasm, more apical nuclei, and no secretory granules (Figures 4A and 4B). The sensory epithelia of the null mutants lack hair cells entirely but do have supporting cells with normal appearance (Rüsch, et al., 1998), including electron-dense cytoplasm, basal nuclei, and secretory granules. However heterozygous *Math1*<sup>+/-Gal</sup> mice retain hair cells.

## EXAMPLE 6

### Expression of a Hair Cell Specific Marker in Transgenic *Math1* Mice

Lack of hair cells at E18.5 can be due to (1) lack of sensory cell progenitors, (2) the inability of progenitors to differentiate into hair cells, or (3) the inability of hair cells to maintain the differential states, as has been observed in the absence of the POU domain transcription factor *Brn3c*. The first possibility is unlikely because progenitors give rise to both hair cells and supporting cells. To evaluate the remaining possibilities, the expression of the hair cell specific marker, calretinin and myosin VI were examined. Calretinin is a member of the calcium binding family of proteins and is expressed in differentiating hair cells (prior to hair bundle formation) and mature inner ear and auditory hair cells, but not in supporting cells. Calretinin expression in *Math1*<sup>β-Gal/β-Gal</sup> and wild-type mice was studied by immunofluorescence on coronal sections of E15.5, E16.5 and E18.5 embryos (Figures 5A through 5F).

For immunofluorescence, embryos were fixed for 1.5 hours in 4% paraformaldehyde/PBS at 4°C, sunk through 15% sucrose/PBS for 5 hours then 30% sucrose/PBS overnight, and snap frozen in a 2-methylbutane dry ice bath. 14 µm sections were cut on a cryostat and mounted onto gelatin-coated slides. Sections were

5 fixed onto slides by dipping for 10 minutes in Streck tissue fixative (Streck laboratories) and air drying. Sections were blocked in 30% normal goat serum and 0.3% triton X-100 in PBS for 1 hr at room temperature (RT). Rabbit anti-calretinin polyclonal antibody (Chemicon laboratories) was diluted 1:200 in blocking solution and incubated overnight on sections at 4°C. Sections were washed 3 times (20 minutes each) in Phosphate-

10 Buffered Saline (PBS) at RT. The secondary antibody anti-rabbit antibody, Alexa 488 (Molecular Probes), was diluted 1:400 in blocking solution and used to detect calretinin. Sections were covered and incubated at RT for 2 hours before washing and mounting in Vectashield containing DAPI (Vector). For confocal microscopy, sections were treated with 25 µg/ml RNase before counterstaining with 50 µg/ml of propidium iodide and

15 mounted in Vectashield without DAPI. Stained sections were viewed under a Bio-Rad 1024 confocal microscope.

Calretinin-positive cells are clearly visible in the sensory epithelia of the semicircular canals and utricles of wild-type mice, but *Math1*<sup>β-Gal/β-Gal</sup> embryos lack calretinin expression at all three states. Using the mouse model disclosed herein the

20 present inventors demonstrate that hair cells never develop within the sensory epithelia of *Math1*<sup>β-Gal/β-Gal</sup> mice. The presence of the tectorial and otolithic membranes (secreted in part by the supporting cells), together with the TEM results, suggests that the

remaining cells in the sensory epithelia of the *Math1* <sup>$\beta$ -Gal/ $\beta$ -Gal</sup> mice are functional supporting cells.

### EXAMPLE 7

#### 5      ***Math1/lacZ* expression mimics *Math1* expression in the developing CNS**

The developing cerebellum at E14.5 and postnatal day 0 (P0) in *Math1*<sup>+/ $\beta$ -gal</sup> and *Math1* <sup>$\beta$ -gal/ $\beta$ -gal</sup> mice were analyzed by RNA *in situ* hybridization analysis.

The analysis showed that the expression pattern of the *lacZ* gene faithfully reproduced the *Math1* expression pattern observed by RNA *in situ* hybridization analysis shown previously (Akazawa et al., 1995; Ben-Arie et al., 1996) (Fig. 2A, B, E, G). Moreover, the cerebellar phenotype in *Math1* <sup>$\beta$ -gal/ $\beta$ -gal</sup> mice (Fig. 8F and 8H) was identical to that observed in *Math1* null mice (Ben-Arie et al., 1997). At E14.5, the precursors of the EGL are present in the rhombic lip from which they migrate over the cerebellar anlage to populate the EGL (Fig. 8E). Mutant mice displayed far fewer of these cells than heterozygous mice (Fig. 8F). At P0, the neurons of the external granule layer (EGL) were completely lacking (Fig. 8H).

*Math1/lacZ* expression in the developing hind brain and spinal cord similarly reproduced the expression pattern of *Math1* (Fig. 8 C, 8D). The only notable difference between the expression patterns established by *in situ* hybridization and *lacZ* staining is that  $\beta$ -galactosidase expression persists in differentiating or migrating cells of the spinal cord because of the stability of the  $\beta$ -GAL protein (Fig. 8D). In summary, the neural tissue expression pattern and cerebellar phenotype associated with the replacement of the *Math1* coding region by *lacZ* is consistent with previously published data on *Math1*

expression (Akazawa et al., 1995; Ben-Arie et al., 1997; Ben-Arie et al., 1996; Helms and Johnson, 1998), demonstrating that the endogenous control elements were not disrupted by insertion of the *lacZ* gene. Moreover, many previously undetected clusters of *lacZ*-expressing cells became apparent upon X-gal staining of whole embryos and sections in *Math1*<sup>+/-gal</sup> mice (see below). It is likely that limitations in the spatial resolution of RNA *in situ* hybridization techniques used to detect the transcript in earlier studies prevented these sites of expression from being discerned (Akazawa et al., 1995; Ben-Arie et al., 1996). Alternatively, the stability of the *lacZ* gene product and the increased sensitivity due to signal amplification allowed us to identify sites of relatively low expression levels.

### **EXAMPLE 8**

#### ***Math1/lacZ* is expressed in inner ear sensory epithelia**

The sensory organs of the inner ear were among the newly identified sites of *Math1/lacZ* expression, demonstrated utilizing the methods described in Example 2. Expression in the otic vesicle was first detected at E12.5 and continued until E18.5 throughout much of the sensory epithelia (Bermingham et al., 1999) (Figure 9A, 9B). Null mutants displayed *Math1/lacZ* expression in the inner ear throughout embryogenesis (Fig. 9C). *Math1* null mutants lack hair cells in all of the sensory organs (Bermingham et al., 1999), but maintain supporting cells, the other sensory epithelia-derived cells (Fig. 9C). These supporting cells seem to be functional, based on their morphology and the presence of overlying membranes secreted in part by these cells. Although the expression of *Math1* in inner ear sensory epithelia was not demonstrated by RNA *in situ*

hybridization analysis, the complete lack of inner ear hair cells in the null mutants leaves little doubt about the authenticity of the *Math1/lacZ* expression pattern.

*Math1* is clearly essential for hair cell development in the inner ear. Its expression pattern and *in vivo* function are akin to those of *Math1*'s proneural homolog, *atonal (ato)* (A. P. Jarman, Y. Grau, L. Y. Jan, Y. N. Jan, *Cell* 73, 1307-21 (1994)). *ato* is expressed in a ring of epithelial cells within the antennal disc of *Drosophila*. Some of these epithelial cells will subsequently develop into mechanoreceptors in the Johnston organ, which is necessary for hearing and negative geotaxis. It is interesting to note that mechanoreceptor progenitor cells are absent in *ato* mutants, whereas only the mechanoreceptors, and not their progenitors, are absent in *Math1* null mice.

Based on the observations made herein, the present inventors have recognized that *Math1* is required for the specification of inner ear hair cells. In a sense, *Math1* acts as a "pro-hair cell gene" in the developing sensory epithelia. In conjunction with two recent studies, the present inventors have recognized that the results provided herein provide evidence supporting a lateral inhibition model for the determination of hair cells and supporting cells (Haddon et al., 1998; Adam, et al., 1998), in which the interplay of *Delta*, *Notch*, and *Serrate1* results in the selection of individual hair cells from clusters of competent cells. Such a model entails that the sensory epithelia express a "pro-hair cell gene" whose function is essential for hair cell fate specification.

The ectopic expression of *ato* in the fruitfly and its homolog *Xath1* in *Xenopus* (Kim et al., 1997) can recruit epithelial cells into specific neuronal fates, and the expression of *Math1* in inner ear epithelia strongly suggests loss of a functional *Math1* gene is likely to be a common cause of deafness and vestibular dysfunction.



**EXAMPLE 9*****Math1/lacZ* is expressed in brain stem nuclei**

In the brainstem *Math1/lacZ* staining appeared from E18.5 to P7 in the ventral pons in the regions corresponding to the pontine nuclei (Fig. 9D and inset). This finding is consistent with the hypothesis of Akazawa and colleagues that *Math1*-positive cells in the developing hind brain are precursors to the bulbopontine neurons (Akazawa et al., 1995). No such staining appeared in the null mutants (Fig. 9E and inset). These data raise the possibility that the absence of *lacZ* staining in pontine nuclei can be due to failure of their precursors to migrate, proliferate, and/or differentiate. Ventral pontine nuclei were examined upon haematoxylin and eosin staining of sections and were found to be missing in the brain stem of null mice (Fig. 9F, G). Furthermore, the failure of null mouse newborns to breathe can be due to absence of these brainstem neurons.

**EXAMPLE 10*****Math1/lacZ* is expressed in chondrocytes**

*Math1*<sup>+/-b-Gal</sup> heterozygotes displayed expression of *Math1* in articular cartilage (Figures 6A and 6B). Figure 6A demonstrates expression in all joints of a forelimb. Upon closer examination of an elbow joint, *Math1* is noted to be expressed exclusively in the non-ossified articular chondrocytes.

Expression of *Math1/lacZ* was detected in the developing proximal joints, such as those of the hip and shoulder, as early as E12.5 (Fig 10A). X-gal positive staining was detected at subsequent developmental stages in a progressive proximal-distal pattern that paralleled the normal development of joints (Figure 10B). In the joints, *Math1/lacZ*

expression immediately follows mesenchymal condensation, which begins at E11.5. Condensed mesenchyme cells differentiate into chondrocytes (Bi et al., 1999; Horton et al., 1993; Karsenty, 1998).

Chondrocytes differentiate in three major phases during bone formation: resting, proliferating and hypertrophic. The resting chondrocytes that populate the articular cartilage are referred to as articular chondrocytes (Buckwalter and Mankin, 1998; Poole, 1997). Prior to birth, resting chondrocytes constitute the entire chondrocyte population in joints. To establish which cells expressed *Math1/lacZ*, sections from E18.5 and P7 *Math1<sup>+/-b-gal</sup>* mice were stained with X-gal. *Math1/lacZ* is expressed in the resting chondrocytes of all joints analyzed at E18.5; resting chondrocytes in the elbow joint are shown in Figure 10C, and Fig. 10D shows the resting, proliferating, and articular chondrocytes of a P7 mouse.

The joints of E18.5 embryos were examined with anti-MATH1 antibody prepared by the following methods. An *EcoR* I-*Hind* III fragment encoding the N-terminal 156 amino acids of the *Math1* open reading frame (*Math1D*) was cloned into the pET 28a+ expression vector (Novagen). *Math1D* fragment was expressed as a His tag fusion protein. Soluble MATH1D protein was purified according to His-tag kit specifications (Novagen) and 2mg of protein were used to immunize Chickens (Cocalico Biologicals Inc.).

Expression was found in resting chondrocytes, whereas no expression was observed in null embryos. It should be noted that not all articular cartilage cells express *Math1/lacZ* (Fig. 10E). *Math1/lacZ* expression in *Math1* null mutants is similar to that

in heterozygous mice at E18.5, suggesting that *Math1* is not required for resting chondrocyte development.

### **EXAMPLE 11**

#### **5                    *Math1/lacZ* is expressed in Merkel cells**

By E14.5 *Math1/lacZ*-positive cells were apparent around the vibrissae and in the skin of much of the body (Fig. 10B). In the trunk, the stained cells were arranged in a striped pattern defined by the epidermal ridges. This staining was apparent only in the hairy, not the glabrous, skin. All the primary (mystical) vibrissae, including the lateral  
10 nasal, maxillary and four large hairs, were positive for *Math1/lacZ*. Staining was also detected in the secondary vibrissae, including the labial, submental, rhinal, and isolated orbital vibrissae (supra-, infra- and post-orbital) (Yamakado and Yohro, 1979). By E15.5 staining appeared in clusters of cells in the foot pads (Fig. 10B).

To identify the *Math1/lacZ*-positive cells in the vibrissae, footpad, and hairy skin,  
15 we examined histological sections from *Math1<sup>+/b-gal</sup>* mice (Fig. 11A-D). Sections through the vibrissae showed that the stained cells are localized to the more apical half of the hair shaft, but are not in the hair itself. Cross sections through the foot pad illustrated staining of cluster of cells in the epidermal layer (Fig. 11 B,C). As shown in Fig. 11D, sections through the truncal skin identified clusters of *Math1/lacZ*-stained cells. The stained cells  
20 were arranged in a horseshoe-shaped pattern centered within an elevated button-like structure in the hairy skin. These button-like structures were identified as touch domes or Haarscheiben (Pinkus, 1905), which are characterized by a thickened epidermis and an elevated dermal papilla with a capillary network. Touch domes are associated with

large guard hairs dispersed between other hair types in the coat. The spatial distribution of *Math1/lacZ*-stained cells, the timing of their appearance at E14.5, and their localization within the mystacial pads of the vibrissae and the touch domes in the hairy skin suggest that these cells correspond to Merkel cells, specialized cells in the epidermis that form slow-adapting type I mechanoreceptor complexes with neurites (Munger, 1991).

The results of comparative analysis of the *Math1/lacZ* expression pattern in heterozygous and homozygous E16.5 animals are shown in Figure 11E-L. *Math1<sup>b-gal/b-gal</sup>* embryos displayed a staining pattern similar to that of *Math1<sup>+b-gal</sup>* littermates in the vibrissae and footpads (Fig. 11E-G, I-K). In contrast, staining in the touch domes of the hairy skin was barely detectable in *Math1<sup>b-gal/b-gal</sup>* embryos (Fig. 11H,L). The reduction of staining in null animals was also obvious at E18.5.

To further define *Math1/lacZ*-positive cells in the skin, *Math1<sup>+b-gal</sup>* mice were mated to *Tabby* mice. *Tabby* (*Ta*) is a spontaneous X-linked mutation displaying a similar phenotype in hemizygous males and homozygous females (Ferguson et al., 1997). *Tabby* mutants lack hair follicles (tylotrich), a subset of Merkel cells that are associated with touch domes in the hairy skin of the trunk (Vielkind et al., 1995), and some of the five secondary vibrissae on the head (Gruneberg, 1971). Hence, in a cross of *Ta/Ta* females with a heterozygous *Math1<sup>+b-gal</sup>* male, 50% of the male progeny are *Ta/Y: Math1<sup>+b-gal</sup>*, allowing us to assess whether the *Math1/lacZ*-positive cells correspond to Merkel cells.

*Ta/Ta* females were time-mated with *Math1*<sup>+/-gal</sup> males, and embryos were harvested at E16.5. Each pup's gender was determined by PCR on tail DNA, using primers (forward 5'-TGAAGCTTTTGGCTTTGAG-3'; SEQ ID NO:67, and reverse 5'-CCGCTGCCAAATTCTTTGG-3'; SEQ ID NO:68) that yielded a 320 bp product from chromosome X, and a 300 bp product from chromosome Y (Liu et al., 1999). Amplification conditions were: 92°C/1 min, 55°C/1 min, 72°C/1 min for 32 cycles, with an initial denaturation step of 94°C/7 min and last extension step of 72°C/7 min. Amplification products were separated on 2% agarose gels. X-gal-stained embryos were scored independently by 2 individuals, and only then were results matched with the determined gender.

Both *Tabby* females and males carrying the *Math1*<sup>+/-gal</sup> allele displayed X-gal staining in the vibrissae and foot pads (Fig. 12A,B). The effect of the *Tabby* mutation on the number of secondary vibrissae was quite clear: hemizygous males completely lacked *Math1/lacZ*-positive cells in the secondary vibrissae (typically lacking in *Ta* mutants) and on the trunk (Fig. 12E). Females that are heterozygous for *Tabby* showed patchy staining in the touch domes (although less than wt), as should be anticipated in female carriers of a mutation in a gene that undergoes random X chromosome inactivation (Fig. 12C,D). The localization and distribution of the positive cells, as well as their absence in selected vibrissae and the trunk of *Tabby* males, strongly indicate that *Math1* is expressed in the Merkel cells associated with guard follicles in the touch domes of the hairy skin.

To ascertain whether *Math1/lacZ* staining pattern reflects normal *Math1* expression pattern, immunohistochemical analysis of MATH1 was performed on sections

from abdominal skin (see Example 2). As seen in Fig. 13A and B, MATH1-positive cells were detected around the hair follicles of *Math1*<sup>+/+</sup> but not *Math1*<sup>b-gal/b-gal</sup> mice. Antibodies against two Merkel cells markers were chosen for further analysis: anti-cytokeratin18, expressed in simple epithelia, and chromogranin, localized to secretory granules of neuroendocrine, endocrine, and neuronal tissues. Both cytokeratin 18 (Fig. 13C,D) and chromogranin A (Fig. 13E,F) confirmed the identity of the *Math1/lacZ*-positive cells as Merkel cells, but did not reveal staining abnormalities in *Math1*<sup>b-gal/b-gal</sup> mice. Thus, *Math1* does not seem to be essential for the genesis of the neuroendocrine Merkel cells, in contrast to pure neuronal cell types like cerebellar EGL and pontine nuclei. Because *Math1* null mutants die at birth, we can not assess whether the entire cluster of Merkel cells is formed or the functional integrity of Merkel cells in these mutants is affected.

## **EXAMPLE 12**

### ***Math1* partially rescues Chinese Hamster**

#### **Ovary Cells in flies deleted for *ato***

This Example demonstrates that *atonal*-associated genes can induce the development of CNS cells in animals deficient in a native atonal-associated gene or gene product. This Example also demonstrates that *atonal*-associated genes can therapeutically function in species in which they are not natively expressed.

Given the remarkable similarity in expression patterns of *ato* and *Math1*, and their identical basic domains, *Math1* was tested to see if it would mimic the effects of *ato* overexpression by producing ectopic chordotonal organs as described by the following methods. Wild-type, also known as *yw* flies, were transformed with a *UAS-Math1*

construct as described (Brand and Perrimon, 1993). To overexpress *Math1* in wild type flies, *yw; UAS-Math1* flies were mated to *HS-Gal4* flies. The progeny were heat shocked as previously described (Jarman et al., 1993). To rescue the loss of chordotonal organs in *ato* mutant flies, *w; UAS-Math1/UAS-Math1; ato1/TM6* flies were crossed to *w; HS-Gal4/CyO; ato1/TM6* flies. Embryos were collected for 3 hr., aged for 3 hr., heat shocked for 30 min. at 37°C and allowed to develop for the next 12-15 hr. Embryos were fixed in 4% formaldehyde in PBS with 50% heptane. Embryos were washed with 100% ethanol, transferred to PBT and stained with mAb 22C10 as previously described (Kania et al., 1995) to detect PNS neurons. Chordotonal neurons were identified by their distinct morphology and position.

Expressing *Math1* during pupal development by heat shock using the UAS-Gal4 system (Brand and Perrimon, 1993) resulted in supernumerary external sense organs on the notum (Fig. 14A,B) and the wing blade, as reported for *ato* (Jarman et al., 1993) and the *Achaete-Scute complex (AS-C)* genes (Brand and Perrimon, 1993; Rodriguez et al., 1990). *Math1* expression in flies, like *ato*, produced ectopic chordotonal organs (Fig. 8G), although with less efficiency. Overexpression of the *AS-C* genes does not, however, result in ectopic chordotonal organs (Jarman et al., 1993). *Math1* thus has a similar functional specificity to *ato*.

Since several *ato* enhancers are *ato*-dependent (Sun et al., 1998), they can be activated by *Math1*, which would then lead to ectopic CHO specification. To determine whether *Math1* can substitute for *ato* function in the fly, and to rule out the possibility that production of CHOs by *Math1* is due to *ato* activation, *Math1* was expressed in *ato* mutant embryos. The mutants lack all chordotonal neurons (Fig. 14C), but

overexpressing *Math1* partially rescues the loss of these neurons (Fig. 14D) in a manner similar to *ato* (Chien et al., 1996).

### **EXAMPLE 13**

#### **5                    Significance of *atonal* and *Math1* in the CNS and PNS**

Over the past few years significant progress has been made towards unraveling the roles of bHLH proteins in vertebrate neurogenesis. Neural vertebrate bHLH-encoding genes were isolated and characterized because *Drosophila* homologues such as *ato* or the

10 *AS-C* genes had been previously shown to be required for neurogenesis (Anderson, 1995; Guillemot, 1995; Lee, 1997; Takebayashi et al., 1997). Indeed, several genes were shown to be proneural because their absence caused a failure of neuroblast or sensory organ precursor (SOP) specification, whereas their overexpression lead to the recruitment of supernumerary neuronal precursors (Ghysen and Dambly-Chaudiere, 1989). With the

15 exception of *neurogenin (Ngn) 1* and *2* (Fode et al., 1998; Ma et al., 1998), it remains uncertain which of the vertebrate homologues play roles similar to their *Drosophila* counterparts, and what precise role different bHLH proteins play in neural development. In *Drosophila*, *ato* is required for the development of a specific subset of sense organs, the chordotonal organs (Jarman et al., 1993). CHOs are internal mechanosensors of the

20 PNS (McIver, 1985). Thus, *ato* and the CHOs provide an excellent system in which to ascertain not only the molecular and developmental relationship between invertebrate and vertebrate neurogenesis vis-à-vis the function of the proneural genes, but also the evolutionary conservation of sensory organ function and specification. Seven *ato*



homologues have been cloned and analyzed in the mouse: *Mouse Atonal Homologues* (*MATH*) 1, 2, 3, 4A (also known as *Ngn2*), 4B (*Ngn3*), 4C (*Ngn1*), and 5 (Akazawa et al., 1995; Bartholomä and Nave, 1994; Ben-Arie et al., 1997, 1996; Fode et al., 1998; Ma et al., 1998; McCormick et al., 1996; Shimizu et al., 1995; Takebayashi et al., 1997). Most

5 are expressed during neurogenesis in both the CNS and PNS. These homologues vary in the degree of their sequence conservation, and can be divided into three groups. The most distantly related group, the neurogenins, includes *Ngn 1, 2* and 3. These gene products share, on average, 53% identity in the bHLH domain with ATO. They are expressed largely in mitotic CNS and sensory ganglia progenitor cells. Recent work suggests that

10 these genes can play a role in neuroblast determination, and can therefore be true proneural genes (Fode et al., 1998; Ma et al., 1998). The second group includes MATH2 and MATH3, which share 57% identity in the bHLH domain with ATO. These proteins have been postulated to function in postmitotic neural cells (Bartholomä and Nave, 1994; Shimizu et al., 1995). *Math2* expression is confined to the CNS, while *Math3* is

15 expressed in both the CNS and the trigeminal and dorsal root ganglia. The third group includes MATH1 and MATH5, which share 67% and 71% identity with the bHLH domain of ATO, respectively. It is noteworthy that both genes encode a basic domain identical to that of ATO. Interestingly, the basic domain of ATO was shown to be sufficient, in the context of another proneural protein (SCUTE), to substitute for the loss

20 of *ato* function (Chien et al., 1996). *Math1* was initially shown to be expressed in the precursors of the cerebellar EGL and in the dorsal spinal cord (Ben-Arie et al., 1997, 1996). *Math5* is expressed in the dividing progenitors in the developing retina and in the vagal ganglion (Brown et al., 1998). With the exception of *Math5* expression in the

neural retina, these observations pose a paradox: none of the vertebrate homologs appeared to be expressed in peripheral organs or tissues similar to those where *ato* is expressed. Jarman et al. (1993) reported that *ato* is expressed in the CNS. In the examples described herein it is shown that, in addition to the inner proliferation center of the optic lobe, *ato* is expressed in a small anteriomedial patch of cells in each brain lobe (Fig. 8F). Because it remains unclear, however, precisely what role *ato* plays in *Drosophila* CNS development, it has been difficult to argue that *ato* and its vertebrate homologues display functional conservation. Our experiments reveal sites of previously uncharacterized *Math1* expression. As expected, we found that *Math1/lacZ* expression in the CNS corresponds to that of *Math1*, but we also found that *Math1* is expressed in the skin, the joints, and the inner ear, in striking parallel to *ato* expression in the fly. Moreover, the expression in the ear (sensory epithelium) and the skin (Merkel cells) is restricted to sensory structures whose function is to convert mechanical stimuli into neuronal electrochemical signals. It is important to point out that in *Drosophila*, *ato* appears to play two roles simultaneously. It is required not only to select the precursors of the CHOs (proneural role), but also to specify these precursors as CHO precursors (lineage identity role) (Jarman and Ahmed, 1998; Jarman et al., 1993). The specificity of *Math1* expression in the periphery makes it tempting to speculate that it, too, can endow specific cells with very specific lineage identities to distinguish them functionally from other sensory structures. The ability of *Math1* to induce ectopic CHO formation and to restore CHOs to *ato* mutant embryos supports the notion that *Math1*, and particularly its basic domain, encodes lineage identity information not unlike that encoded by *ato*. This suggests that the mammalian cells expressing *Math1*, at least in the ear and the skin, are

functionally similar and perhaps evolutionarily related to *Drosophila* cells that require *ato*. Furthermore, *Math5* expression in the neural retina suggests that the functions of *atonal* in the fly are carried out by two genes in the mouse: the development of some mechanoreceptors is under the control of *Math1* and retinal development is possibly

5 under the control of *Math5*. It is interesting to note that in the fully sequenced nematode *C.elegans*, only one homolog of *atonal*, *lin-32*, was identified (Zhao and Emmons, 1995). Mutants with the u282 allele of *lin-32* are touch-insensitive, which strengthens the argument for evolutionary conservation of *atonal* function in mechanoreception. The pattern of *Math1/lacZ* expression in the pontine nuclei suggested this region should be

10 carefully evaluated in null mutants. Although no defects in the pons of *Math1* null mice (Ben-Arie et al., 1997) were originally detected, closer analysis revealed the lack of pontine nuclei at this site. These neurons derive from the rhombic lip (Altman and Bayer, 1996) as do the EGL neurons, which are also lacking in *Math1* null mice. While it is possible to draw parallels between *Math1* and *ato* expression in the skin and ear, it is not

15 clear that such is the case for the joints. *ato* expression in the fly joints is required for the formation of leg CHOs. In contrast, *Math1* is expressed in resting and articular chondrocytes that do not have any described neural function, and for which no parallels exist in the fly. It can be that *Math1* expression in cartilage indicates a novel role for a mechanosensory gene, or it can simply reflect similarities in the molecular events

20 underlying the development of the various *Math1*-expressing cell types. Alternatively, CHOs can also function as joint structural elements in the fly, or articular cartilage can have a mechanoreceptive or transductive capacity yet to be described. There is no evidence at this point to support one or another of these possibilities. Analyzing the

functions of *ato* and *Math1* will enhance our understanding of neural development and the evolutionary conservation of sensory function. The sites and specificity of *Math1* expression can make it suitable as a tool of gene therapy or gene activation approaches to illnesses such as hearing loss and osteoarthritis that are due to age-related or  
5 environmental damage.

#### **EXAMPLE 14**

##### ***Atonal*-Associated Nucleic Acid Delivery using Adenovirus**

10 Human adenoviruses are double-stranded DNA tumor viruses with genome sizes of approximate 36 kb. As a model system for eukaryotic gene expression, adenoviruses have been widely studied and well characterized, which makes them an attractive system for development of adenovirus as a gene transfer system. This group of viruses is easy to grow and manipulate and they exhibit a broad host range *in vitro* and *in vivo*. In  
15 lytically infected cells, adenoviruses are capable of shutting off host protein synthesis, directing cellular machineries to synthesize large quantities of viral proteins, and producing copious amounts of virus.

The E1 region of the genome includes E1A and E1B, which encode proteins responsible for transcription regulation of the viral genome, as well as a few cellular  
20 genes. E2 expression, including E2A and E2B, allows synthesis of viral replicative functions, *e.g.* DNA-binding protein, DNA polymerase, and a terminal protein that primes replication. E3 gene products prevent cytolysis by cytotoxic T cells and tumor necrosis factor and appear to be important for viral propagation. Functions associated

with the E4 proteins include DNA replication, late gene expression, and host cell shutoff. The late gene products include most of the virion capsid proteins, and these are expressed only after most of the processing of a single primary transcript from the major late promoter has occurred. The major late promoter (MLP) exhibits high efficiency during  
5 the late phase of the infection.

As only a small portion of the viral genome appears to be required in *cis*, adenovirus-derived vectors offer excellent potential for the substitution of large DNA fragments when used in connection with cell lines such as 293 cells. Ad5-transformed human embryonic kidney cell lines have been developed to provide the essential viral  
10 proteins *in trans*. The inventors thus reasoned that the characteristics of adenoviruses rendered them good candidates for use in targeting *Math1* deficient cells *in vivo*. In another embodiment these constructs include a *Hath1* or any *atonal*-associated nucleic acid sequence.

Particular advantages of an adenovirus system for delivering foreign proteins to  
15 a cell include: (i) the ability to substitute relatively large pieces of viral DNA by foreign DNA; (ii) the structural stability of recombinant adenoviruses; (iii) the safety of adenoviral administration to humans; (iv) lack of any known association of adenoviral infection with cancer or malignancies; (v) the ability to obtain high titers of the recombinant virus; and (vi) the high infectivity of Adenovirus.

20 One advantage of adenovirus vectors over retroviruses is a higher level of gene expression. Additionally, adenovirus replication is independent of host gene replication, unlike retroviral sequences. Because adenovirus transforming genes in the E1 region can

be readily deleted and still provide efficient expression vectors, oncogenic risk from adenovirus vectors is thought to be negligible.

In general, adenovirus gene transfer systems are based upon recombinant, engineered adenovirus that is rendered replication-incompetent by deletion of a portion of its genome, such as E1, and yet still retains its competency for infection. Relatively large foreign proteins can be expressed when additional deletions are made in the adenovirus genome. For example, adenoviruses deleted in both E1 and E3 regions are capable of carrying up to 10 Kb of foreign DNA and can be grown to high titers in 293. Surprisingly, persistent expression of transgenes following adenoviral infection is possible. Use of the adenovirus gene transfer system can be more useful for the delivery of *Math1* to cells in nascent or damaged cartilage in joints. In particular, the *Math1* adenovirus can be used to deliver *Math1*, and confer *Math1* gene expression in, non-ossified joint cartilage that has been damaged as a consequence of osteoarthritis.

### EXAMPLE 15

#### *Math1*-Adenovirus Constructs

Recombinant virions for the controlled expression of *Math1* can be constructed to exploit the advantages of adenoviral vectors, such as high titer, broad target range, efficient transduction, and non-integration in target cells for the transformation of cells into hair cells. In one embodiment these constructs include a *Hath1* or any *atonal*-associated nucleic acid sequence. In one embodiment of the invention, a replication-defective, helper-independent adenovirus is created that expresses wild type *Math1*

sequences under the control of the human cytomegalovirus promoter or the metallothionine promoter.

Control functions on expression vectors are often provided from viruses when expression is desired in mammalian cells. For example, commonly used promoters are derived from polyoma, adenovirus 2 and simian virus 40 (SV40). The early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication. Smaller or larger SV40 fragments can also be used provided there is included the approximately 250 bp sequence extending from the *HindIII* site toward the *BglII* site located in the viral origin of replication. Further, it is also possible, and often desirable, to use promoter or control sequences normally associated with the *Math1* gene sequence, namely the *Math1* promoter, provided such control sequences are compatible with the host cell systems or the target cell. One such target cell is located in the inner ear of a human patient in need of inner ear hair cells.

An origin of replication can be provided by construction of the vector to include an exogenous origin, such as can be derived from SV40 or other viral (e.g., polyoma, adeno, VSV, BPV) source, or can be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.

20

#### **EXAMPLE 16**

##### ***Atonal-Associated Nucleic Acid Delivery using Retrovirus***

Another approach for gene delivery capitalizes on the natural ability of viruses to enter cells, bringing their own genetic material with them. Retroviruses have promise as gene delivery vectors due to their ability to integrate their genes into the host genome, transferring a large amount of foreign genetic material, infecting a broad spectrum of species and cell types and because they are easily packaged in special cell-lines. Retroviruses can be particularly useful for the delivery of *Math1* into inner ear hair cells that have reduced expression of *Math1*, or that are in need of over-expression of *Math1*.

10

### EXAMPLE 17

#### ***Math1* Retroviral Constructs**

The *Math1* open reading frame (ORF) was excised from pBluescript by an *EcoR* I-*Xba*I digest. The fragment was gel purified, and blunt ended using Klenow DNA polymerase. The retroviral vector pLNCX (purchased from CLONTECH) was linearized with *Hpa*I, and ligated with the *Math1* ORF fragment. The ligation was transformed into transformation competent *E. coli* cells. The resulting antibiotic resistant colonies were assayed for the presence of the correct construct.

The cloning, reproduction and propagation retroviral expression vectors is well known to those of skill in the art. One example of a retroviral gene transfer and expression system that has been used to express *Math1* is the CLONTECH pLNCX, pLXSN and LAPSN expression vectors. For propagation of these vectors PT67 and EcoPack packaging cell lines can be used. For more information on mammalian cell culture, the following general references can be used: *Culture of Animal Cells*, Third



Edition, edition by R. I. Freshney (Wiley-Liss, 1993); and *Current Protocols in Molecular Biology*, ed. By F. M. Ausubel, *et al.*, (Greene Publishing Associates and Wiley & Sons, 1994), relevant portions incorporated herein by reference.

In another embodiment these constructs could be constructed with a *Hath1* or any  
5 *atonal*-associated nucleic acid sequence.

### **EXAMPLE 18**

#### **Maintenance of Packaging Cell Lines**

The maintenance of packaging cell lines, such as the 293 and PT67 packaging cell  
lines, is described briefly. A vial of frozen cells is transferred from liquid N<sub>2</sub> to a 37°C  
10 water bath until just thawed. In order avoid osmotic shock to the cells, and to maximize  
cell survival, 1 ml of (Dulbecco's Modified Eagle Medium) DMEM is added to the tube  
and the mixture is transferred to a 15-ml tube. Another 5 ml of DMEM is added and the  
cells are mixed. After repeating these steps the final volume in the tube should be about  
12 ml. Next, the cells are centrifuged at 500 x g for 10 min. Finally, the supernatant is  
15 removed and the cells are resuspended in maintenance media as described in the next  
step. Generally, the cells are maintained in DMEM (high glucose: 4.5 g/L) containing  
10% Fetal Bovine Serum (FBS), and 4 mM L-glutamine. If desired or necessary, 100  
U/ml penicillin/100 µg/ml streptomycin can be added. It is recommended that are plated  
at 3-5 x 10<sup>5</sup> per 100-mm plate and split every 2 to 3 days, when they reach 70-80%  
20 confluency (confluence is 3-4 x 10<sup>6</sup> per 100-mm plate). The PT67 cell line, for example,  
has a very short doubling time (<16h) and should be split before they become confluent.  
The doubling time for EcoPack-293 cells is 24-36 h.

Cells are split by removing the medium and washing the cells once with PBS. After treatment with 1-2 ml of trypsin-EDTA solution for 0.5-1 min, 5 to 10 ml of media and serum is added to stop trypsinization. The cells are dispersed gently, but thoroughly, by pipetting and are resuspended. Alternatively, a predetermined portion of the cells is replated in a 100-mm plate in 10 ml of medium, followed by rotation or shaking of the plate to distribute the cells evenly. A ratio of up to 1:20 for the PT67 or EcoPack-293 cells is common.

Generally, the percentage of PT67 or EcoPack-293 cells capable of packaging retroviral vectors decreases slowly with continued passage of the cell line. Therefore, packaging cells should be reselected after 2 months of growth in culture. Alternatively, new high-titer cells can be purchased from, e.g., CLONTECH, or low passage number stocks can be frozen, stored and thawed to increase the viral yield.

## **EXAMPLE 19**

### **Methods Utilizing a Retroviral Vector**

The following protocol is used to transfect the retroviral vector for virus production, infection of target cells, and selection of stable clones. Other methods and vectors can also be used with the present invention to express *Math1*, such as those described in *Retroviruses*, ed. by J. M. Coffin & H. E. Varmus (1996, Cold Spring Harbor Laboratory Press, NY) and *Current Protocols in Molecular Biology*, ed. by F. M. Ausubel *et al.* (1994, Greene Publishing Associates and Wiley & Sons), incorporated herein by reference.

Briefly, the transfection of the retroviral vector into PT67 cells was as follows. *Math1* was cloned into pLNX as described hereinabove. The packaging cells were plated to a density of  $5-7 \times 10^5$  cells per 100-mm plate 12-24 hours before transfection. 1-2 hours before transfection, the medium replace with fresh medium. 25  $\mu$ M chloroquine can be added just prior to transfection. Chloroquine increases transfection efficiency 2-3 fold. A 25 mM stock solution of chloroquine can be made in distilled water and filter sterilized.

To each 100-mm plate 10-15  $\mu$ g of plasmid DNA using the desired method is transfected using, e.g., standard calcium-phosphate procedures (CalPhos Mammalian Transfection Kit, #K2050-1). The final volume of transfection mixture should not exceed 1 ml. The transfection solution is added to the medium and the plate is rotated to ensure even distribution. About 8 hours after transfection, a glycerol shock treatment can be performed to increase the uptake of DNA. After 10 to 24 hours post-transfection the medium was removed and the cells were washed twice with PBS, before adding 5 ml DMEM containing 10% FBS. The culture was incubated for an additional 12-48 hours to allow increase in virus titer. The virus titer reaches a maximum ~ 48 hours post-transfection and is generally at least 30% of maximum between 24 and 72 hours post-transfection.

Alternatively, a stable virus-producing cell lines can also be selected. To obtain stable virus-producing cell lines, the transfected packaging cells are plated in a selection medium 2-3 days post-transfection. For G418 selection of neomycin resistance, the cells are selected in the presence of G418 (0.5 mg/ml "active") for one week. Vectors carrying other selectable markers such as Puro, Bleo, or Hyg, can be used to obtain stable virus

producing cell populations as well. Cell populations producing virions that produce titers of  $10^5$ - $10^6$  recombinant virus particles per ml are common. Generally,  $10^5$ - $10^6$  recombinant virus particles per ml is suitable for most purposes. For some studies, higher titer clones can be required. In this case, after antibiotic selection, individual clones are selected using, e.g., clone cylinders or limiting dilution, prior to propagation.

Viral titer can be determined in a variety of ways, one such method is described hereinbelow. The viral titer produced by transiently transfected or stable virus-producing packaging cell lines is determined as follows, NIH/3T3 cells are plated one day prior to beginning the titer procedure. Cells are plated in 6-well plates at a density of  $5 \times 10^4$ - $1 \times 10^5$  cells per well and 4 ml of media are added per well. Virus-containing medium is collected from packaging cells, and polybrene is added to a final concentration of 4  $\mu$ g/ml. The medium is filter-sterilized through a 0.45- $\mu$ m filter. Polybrene is a polycation that reduces the charge repulsion between the virus and the cellular membrane. The filter should be cellulose acetate or polysulfonic (low protein binding) but not nitrocellulose. Nitrocellulose binds proteins in the retroviral membrane, and consequently destroys the virus. Serial dilutions are prepared as follows: six 10-fold serial dilutions are usually sufficient. To dilute the virus use fresh medium containing 4  $\mu$ g/ml of polybrene. Next, NIH/3T3 target cells are infected by adding virus-containing medium to the wells. After 48 hours, the NIH/3T3 cells are stained. The titer of virus corresponds to the number of colonies present at the highest dilution that contains colonies, multiplied by the dilution factor. For example, the presence of four colonies in the  $10^5$  dilution would represent a viral titer of  $4 \times 10^5$ .

For the infection of cells, the following procedure was followed. The target cells were plated 12-18 hours before infection at a cell density of  $3-5 \times 10^5$  per 100-mm plate. For the infection of cells that can be used for a biological assay, control cells can be treated with an insert-free virus produced under identical conditions. Half-maximal infection generally occurs after 5-6 hours of exposure of cells to virus, with maximal infection occurring after approximately 24 hours of exposure. The actual reverse transcription and integration of the retrovirus takes place within 24-36 hours of infection, depending on cell growth kinetics. Expression can be observed at 24 hours, and reaches a maximum at approximately 48 hours. Alternatively, infections can be conducted sequentially, about 12 hours apart. Sequential infection generally increases the efficiency of infection and also increases viral copy number. A minimum of 12 hours between each infection is recommended in order to ensure that cellular receptors will be unoccupied by viral envelope.

## EXAMPLE 20

### **Screening Assays**

Finally, the present invention also provides candidate substance screening methods that are based upon whole cell assays, *in vivo* analysis and transformed or immortal cell lines in which a reporter gene is employed to confer on its recombinant hosts a readily detectable phenotype that emerges only under conditions where *Math1* would be expressed, is under-expressed or is over-expressed. Generally, reporter genes encode a polypeptide not otherwise produced by the host cell that is detectable by analysis, e.g., by chromogenic, fluorometric, radioisotopic or spectrophotometric

analysis. In the present invention the *Math1* gene has been replaced with  $\beta$ -galactosidase in a mouse.

An example of a screening assay of the present invention is presented herein. *Math1* expressing cells are grown in microtiter wells, followed by addition of serial molar proportions of the small molecule candidate to a series of wells, and determination of the signal level after an incubation period that is sufficient to demonstrate, e.g., calretinin expression in controls incubated solely with the vehicle used to resuspend or dissolve the compound. The wells containing varying proportions of candidate are then evaluated for signal activation. Candidates that demonstrate dose related enhancement of reporter gene transcription or expression are then selected for further evaluation as clinical therapeutic agents. The stimulation of transcription can be observed in the absence of expressed *Math1*, in which case the candidate compound might be a positive stimulator of hair cell differentiation. Alternatively, the candidate compound might only give a stimulation in the presence of low levels of *Math1*, which would suggest that it functions to stabilize the formation of *Math1* dimers or the interaction of *Math1* with one or more transcriptional factors. Candidate compounds of either class might be useful therapeutic agents that would stimulate production of inner ear hair cells and thereby address the need of patients with hearing loss or balance control impairments.

20

### EXAMPLE 21

#### **Transfection of Cells with *Math1* Retroviral Vectors**

The present invention provides recombinant host cells transformed or transfected with a polynucleotide that encodes *Math1*, as well as transgenic cells derived from those

transformed or transfected cells. In another embodiment these constructs could be constructed with a *Hath1* or any *atonal*-associated nucleic acid sequence. A recombinant host cell of the present invention is transfected with a polynucleotide containing a functional *Math1* nucleic acid sequence or a chimeric *Math1* gene. Methods of transforming or transfecting cells with exogenous polynucleotides, such as DNA molecules, are well known in the art and include techniques such as calcium-phosphate- or DEAE-dextran-mediated transfection, protoplast fusion, electroporation, liposome mediated transfection, direct microinjection and adenovirus infection.

*Math1* expression using recombinant constructs can be used to target the delivery of *Math1* to cells in need thereof. Different promoter-vector combinations can be chosen by a person skilled in these arts to drive *Math1* expression in different cell types. In some cases, the desired outcome cannot be protein, but RNA, and recombinant vectors would include those with inserts present in either forward or reverse orientations. In addition, some vectors, for instance retroviruses or artificial recombination systems, can be designed to incorporate sequences within a cellular or viral genome in order to achieve constitutive or inducible expression of protein or RNA.

Many of the vectors and hosts are available commercially and have specific features that facilitate expression or subsequent purification. For instance DNA sequences to be expressed as proteins often appear as fusion with unrelated sequences that encode polyhistidine tags, or HA, FLAG, myc and other epitope tags for immunochemical purification and detection, or phosphorylation sites, or protease recognition sites, or additional protein domains such as glutathione S-transferase (GST), maltose binding protein (MBP) (New England Biolabs), and so forth that facilitate

purification. Vectors can also be designed that contain elements for polyadenylation, splicing, and termination, such that incorporation of naturally occurring genomic DNA sequences that contain introns and exons can be produced and processed, or such that unrelated introns and other regulatory signals require RNA processing prior to production of mature, translatable RNAs. Proteins produced in the systems described above are subject to a variety of post-translational modifications, such as glycosylation, phosphorylation, nonspecific or specific proteolysis or processing.

## **EXAMPLE 22**

### **Delivery of Math1 as an Amino Acid Sequence**

A peptide (11 amino acids) derived from HIV has been recently described that when fused to full length proteins and injected into mice allow a rapid dispersal to the nucleus of all cells of the body (Schwarze et al., 1999). Schwarze et al. made fusion proteins to Tat ranging in size from 15 to 120 kDa. They documented a rapid uptake of the fusion proteins to the nuclei of cells throughout the animal, and the functional activity of said proteins was retained.

In an embodiment of the present invention there are constructs containing the *Tat* or *Tat-HA* nucleic acid sequence operatively linked to a *Math1* nucleic acid sequence. In another embodiment these constructs include a *Hath1* or any atonal-associated nucleic acid sequence. The vectors are expressed in bacterial cultures and the fusion protein is purified. This purified Tat-Math1 protein or Tat-Hath1 protein is injected into animal to determine the efficiency of the Tat delivery system into the inner ear, skin, cerebellum, brain stem, spinal cord and joints. Analysis is carried out to determine the potential of



the Tat-Math1/Tat-Hath1 protein in hair cell and neuronal regeneration. This is a viable therapeutic approach either in its own right or in association with other methods or genes.

It should be understood that the methods to screen for compounds which affect *Math1* expression disclosed herein are useful notwithstanding that effective candidates cannot be found, since it is of practical utility to know what upstream effector is necessary for *Math1* transcription.

## REFERENCES

All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

## PUBLICATIONS

- 15 Akazawa, C., Ishibashi, M., Shimizu, C., Nakanishi, S., and Kageyama, R. (1995). A mammalian helix-loop-helix factor structurally related to the product of *Drosophila* proneural gene *atonal* is a positive transcriptional regulator expressed in the developing nervous system. *J Biol Chem* 270, 8730-8.
- 20 Alder, J., Cho, N., and Hatten, M. (1996). Embryonic precursor cells from the rhombic lip are specified to a cerebellar granule neuron identity. *Neuron* 17, 389-399.

Altman, J., and Bayer, S. A. (1996). Development of the Cerebellar System: In Relation to its Evolution, Sturcture, and Functions. Boca Raton, Florida: CRC Press.

Anderson, D. J. (1995). Neural development. Spinning skin into neurons. Curr Biol 5,  
5 1235-8.

Bartholomä, A., and Nave, K. A. (1994). NEX-1: a novel brain-specific helix-loop-helix protein with autoregulation and sustained expression in mature cortical neurons. Mech Dev 48, 217-28.

10 Ben-Arie, N., Hassan, B.A., Birmingham, N.A., Malicki, D.M., Armstrong, D., Matzuk, M., Bellen, H.J., and Zoghbi, H.Y. (2000). Functional conservation of *atonal* and *Math1* in the CNS and PNS. Development 127: 1039-1048.

15 Ben-Arie, N., Bellen, H. J., Armstrong, D. L., McCall, A. E., Gordadze, P. R., Guo, Q., Matzuk, M. M., and Zoghbi, H. Y. (1997). *Math1* is essential for genesis of cerebellar granule neurons. Nature 390, 169-172.

Ben-Arie, N., McCall, A. E., Berkman, S., Eichele, G., Bellen, H. J., and Zoghbi, H. Y.  
20 (1996). Evolutionary conservation of sequence and expression of the bHLH protein Atonal suggests a conserved role in neurogenesis. Human Molecular Genetics 5, 1207-1216.

Bermingham, N. A., Hassan, B. A., Price, S. D., Vollrath, M. A., Ben-Arie, N., Eatock, R. A., Bellen, H. J., Lysakowski, A., and Zoghbi, H. Y. (1999). *Math1*: An essential gene for the generation of inner ear hair cells. *Science* 284, 1837-41.

- 5 Bi, W., Deng, J. M., Zhang, Z., Behringer, R. R., and de Crombrughe, B. (1999). Sox9 is required for cartilage formation. *Nat Genet* 22, 85-9.

Bonnerot, C., and Nicolas, J. F. (1993). Application of LacZ gene fusions to postimplantation development. *Methods Enzymol* 225, 451-69.

10

Boyan, G. S. (1993). Another look at insect audition: the tympanic receptors as an evolutionary specialization of the chordotonal system. *J Insect Physiol* 39, 187-200.

- Brand, A. H., and Perrimon, N. (1993). Targeted gene expression as a means of altering  
15 cell fates and generating dominant phenotypes. *Development* 118, 401-15.

Brown, N. L., Kanekar, S., Vetter, M. L., Tucker, P. K., Gemza, D. L., and Glaser, T. (1998). *Math5* encodes a murine basic helix-loop-helix transcription factor expressed during early stages of retinal neurogenesis. *Development* 125, 4821-4833.

20

Buckwalter, J. A., and Mankin, H. J. (1998). Articular cartilage: tissue design and chondrocyte-matrix interactions. *Instr Course Lect* 47, 477-86.

- Chien, C. T., Hsiao, C. D., Jan, L. Y., and Jan, Y. N. (1996). Neuronal type information encoded in the basic-helix-loop-helix domain of proneural genes. *Proc Natl Acad Sci U S A* 93, 13239-44.
- 5 Davis, R. L., Cheng, P. F., Lassar, A. B., and Weintraub, H. (1990). The MyoD DNA binding domain contains a recognition code for muscle-specific gene activation. *Cell* 60, 733-46.
- Dreller, C., and Kirschner, W. H. (1993). Hearing in honeybees: localization of the  
10 auditory sense organ. *J. Comp Physio A* 173, 275-279.
- Eberl, D. F. (1999). Feeling the vibes: chordotonal mechanisms in insect hearing. *Curr Opin Neurobiol* 9, 389-393.
- 15 Ferguson, B. M., Brockdorff, N., Formstone, E., Ngyuen, T., Kronmiller, J. E., and Zonana, J. (1997). Cloning of Tabby, the murine homolog of the human EDA gene: evidence for a membrane-associated protein with a short collagenous domain. *Hum Mol Genet* 6, 1589-94.
- 20 Fode, C., Gradwohl, G., Morin, X., Dierich, A., LeMeur, M., Goridis, C., and Guillemot, F. (1998). The bHLH protein NEUROGENIN 2 is a determination factor for epibranchial placode-derived sensory neurons. *Neuron* 20, 483-94.

Friedrich, G., and Soriano, P. (1991). Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. *Genes Dev* 5, 1513-23.

Ghyssen, A., and Dambly-Chaudiere, C. (1989). Genesis of the *Drosophila* peripheral nervous system. *Trends Genet* 5, 251-5.

Gruneberg, H. (1971). The tabby syndrome in the mouse. *Proc R Soc Lond B Biol Sci* 179, 139-156.

Guillemot, F. (1995). Analysis of the role of basic-helix-loop-helix transcription factors in the development of neural lineages in the mouse. *Biol Cell* 84, 227-241.

Hatten, M. E., and Heintz, N. (1995). Mechanisms of neural patterning and specification in the developing cerebellum. *Ann Rev Neurosci* 18, 385-408.

Helms, A. W., and Johnson, J. E. (1998). Progenitors of dorsal commissural interneurons are defined by MATH1 expression. *Development* 125, 919-28.

Horton, W. A., Machado, M. A., Ellard, J., Campbell, D., Putnam, E. A., Aulthouse, A. L., Sun, X., and Sandell, L. J. (1993). An experimental model of human chondrocyte differentiation. *Prog Clin Biol Res* 383B, 533-40.

Jarman, A. P., and Ahmed, I. (1998). The specificity of proneural genes in determining *Drosophila* sense organ identity. *Mech Dev* 76, 117-25.

Jarman, A. P., Grau, Y., Jan, L. Y., and Jan, Y. N. (1993). *atonal* is a proneural gene that  
5 directs chordotonal organ formation in the *Drosophila* peripheral nervous system. *Cell*  
73, 1307-21.

Kania, A., Salzberg, A., Bhat, M., D'Evelyn, D., He, Y., Kiss, I., and Bellen, H. J. (1995).  
P-element mutations affecting embryonic peripheral nervous system development in  
10 *Drosophila melanogaster*. *Genetics* 139, 1663-1678.

Karsenty, G. (1998). Genetics of skeletogenesis. *Dev Genet* 22, 301-13.

Lee, J. E. (1997). Basic helix-loop-helix genes in neural development. *Curr. Opin.*  
15 *Neurobiol* 7, 13-20.

Lee, K. J., Mendelsohn, M., and Jessell, T. M. (1998). Neuronal patterning by BMPs: a  
requirement for GDF7 in the generation of a discrete class of commissural interneurons  
in the mouse spinal cord. *Genes Dev* 12, 3394-407.

20

Liu, X. Y., Dangel, A. W., Kelley, R. I., Zhao, W., Denny, P., Botcherby, M., Cattanach,  
B., Peters, J., Hunsicker, P. R., Mallon, A. M., Strivens, M. A., Bate, R., Miller, W.,  
Rhodes, M., Brown, S. D., and Herman, G. E. (1999). The gene mutated in bare patches

and striated mice encodes a novel 3beta-hydroxysteroid dehydrogenase. *Nat Genet* 22, 182-7.

Ma, Q., Chen, Z., del Barco Barrantes, I., de la Pompa, J. L., and Anderson, D. J. (1998).

5 neurogenin1 is essential for the determination of neuronal precursors for proximal cranial sensory ganglia. *Neuron* 20, 469-82.

McCormick, M. B., Tamimi, R. M., Snider, L., Asakura, A., Bergstrom, D., and Tapscott, S. J. (1996). *NeuroD2* and *neuroD3*: distinct expression patterns and transcriptional

10 activation potentials within the *neuroD* gene family. *Mol Cell Biol* 16, 5792-800.

McIver, S. B. (1985). Mechanoreception. In *Comprehensive Insect Physiology, Biochemistry, and Pharmacology* (G. A. Kerkut and L. I. Gilbert, Eds.), pp. 71-132. Oxford: Pergamon Press.

15

Moulins, M. (1976). Ultrastructure of chordotonal organs. In *Structure and Function of Proprioceptors in the Invertebrates* (P. J. Mill, Ed.), pp. 387-426. London: Chapman and Hall.

20 Munger, B. L. (1991). The Biology of Merkel Cells. In *Physiology, Biochemistry, and Molecular Biology of the Skin*, second edition (L. A. Goldsmith, Ed.), pp. 836-856. Oxford, UK: Oxford University Press.

Pinkus, F. (1905). Über Hautsinnesorgane neben dem menschlichen Haar (Haarscheiben) und ihre vergleichend-anatomische Bedeutung. Arch mikr Anat 65, 121-179.

Poole, C. A. (1997). Articular cartilage chondrons: form, function and failure. J Anat  
5 191, 1-13.

Rodriguez, I., Hernandez, R., Modolell, J., and Ruiz-Gomez, M. (1990). Competence to develop sensory organs is temporally and spatially regulated in Drosophila epidermal primordia. Embo J 9, 3583-92.

10

Sambrook, Fritsch, Maniatis, In: Molecular Cloning: A Laboratory Manual, Vol. 1, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, Ch. 7, 7.19-17.29, 1989.

Schwarze, S.R., Ho, A., Vocero-Akbani, A. and Dowdy, S.F. (1999). In vivo protein  
15 transduction: delivery of a biologically active protein in the mouse. Science 285, 1569-72.

Shimizu, C., Akazawa, C., Nakanishi, S., and Kageyama, R. (1995). MATH-2, a mammalian helix-loop-helix factor structurally related to the product of Drosophila proneural gene atonal, is specifically expressed in the nervous system. Eur J Biochem  
20 229, 239-48.



- Sun, Y., Jan, L. Y., and Jan, Y. N. (1998). Transcriptional regulation of atonal during development of the *Drosophila* peripheral nervous system. *Development* 125, 3731-40.
- Takebayashi, K., Takahashi, S., Yokota, C., Tsuda, H., Nakanishi, S., Asashima, M., and  
5 Kageyama, R. (1997). Conversion of ectoderm into a neural fate by ATH-3, a vertebrate basic helix-loop-helix gene homologous to *Drosophila* proneural gene atonal. *Embo J* 16, 384-95.
- Tautz, D., and Pfeifle, C. (1989). A nonradioactive in situ hybridization method for the  
10 localization of specific RNAs in *Drosophila* embryos reveals translation control of the segmentation gene hunchback. *Chromosoma* 98, 81-85.
- Vaessin, H., Caudy, M., Bier, E., Jan, L. Y., and Jan, Y. N. (1990). Role of helix-loop-helix proteins in *Drosophila* neurogenesis. *Cold Spring Harb Symp Quant*  
15 *Biol* 55, 239-45.
- van Staaden, M. J., and Römer, H. (1998). Evolutionary transition from stretch to hearing organs in ancient grasshoppers. *Nature* 384, 773-776.
- 20 Vielkind, U., Sebzda, M. K., Gibson, I. R., and Hardy, M. H. (1995). Dynamics of Merkel cell patterns in developing hair follicles in the dorsal skin of mice, demonstrated by a monoclonal antibody to mouse keratin 18. *Acta Anat* 152, 93-109.

Yamakado, M., and Yohro, T. (1979). Subdivision of mouse vibrissae on an embryological basis, with descriptions of variations in the number and arrangement of sinus hairs and cortical barrels in BALB/c (nu/+; nude, nu/nu) and hairless (hr/hr) strains. *Am J Anat* 155, 153-173.

5

Zhao, C., and Emmons, S. W. (1995). A transcription factor controlling development of peripheral sense organs in *C. elegans*. *Nature* 373, 74-78.

### PATENTS

- 10 U.S. Patent No. 5,840,873, issued Nov. 24, 1998
- U.S. Patent No. 5,843, 640, issued Dec. 1, 1998
- U.S. Patent No. 5,843,650, issued Dec. 1. 1998
- U.S. Patent No. 5,843,651, issued Dec. 1, 1998
- U.S. Patent No. 5,843,663, issued Dec. 1, 1998
- 15 U.S. Patent No. 5,846,708, issued Dec. 8, 1998
- U.S. Patent No. 5,846,709, issued Dec. 8, 1998
- U.S. Patent No. 5,846,717, issued Dec. 8, 1998
- U.S. Patent No.5,846,726, issued Dec. 8, 1998
- U.S. Patent No. 5,846,729, issued Dec. 8, 1998
- 20 U.S. Patent No. 5,846,783, issued Dec. 8, 1998
- U.S. Patent No. 5,849,481, issued Dec. 15, 1998
- U.S. Patent No. 5,849,483, issued Dec. 15, 1998
- U.S. Patent No. 5,849,486, issued Dec. 15, 1998

- U.S. Patent No. 5,849,487, issued Dec. 15, 1998
- U.S. Patent No. 5,849,497, issued Dec. 15, 1998
- U.S. Patent No. 5,849,546, issued Dec. 15, 1998
- U.S. Patent No. 5,849,547, issued Dec. 15, 1998
- 5 U.S. Patent No. 5,851,770, issued Dec. 22, 1998
- U.S. Patent No. 5,851,772, issued Dec. 22, 1988
- U.S. Patent No. 5,853,990, issued Dec. 29, 1998
- U.S. Patent No. 5,853,993, issued Dec. 29, 1998
- U.S. Patent No. 5,853,992, issued Dec. 29, 1998
- 10 U.S. Patent No. 5,856,092, issued Jan. 5, 1999
- U.S. Patent No. 5,858,652, issued Jan. 12, 1999
- U.S. Patent No. 5,861,244, issued Jan. 19, 1999
- U.S. Patent No. 5,863,732, issued Jan. 26, 1999
- U.S. Patent No. 5,863,753, issued Jan. 26, 1999
- 15 U.S. Patent No. 5,866,331, issued Feb. 2, 1999
- U.S. Patent No. 5,866,336, issued Feb. 2, 1999
- U.S. Patent No. 5,866,337, issued Feb. 2, 1999
- U.S. Patent No. 5,900,481, issued May 4, 1999
- U.S. Patent No. 5,905,024, issued May 18, 1999
- 20 U.S. Patent No. 5,910,407, issued June 8, 1999
- U.S. Patent No. 5,912,124, issued June 15, 1999
- U.S. Patent No. 5,912,145, issued June 15, 1999
- U.S. Patent No. 5,912,148, issued June 15, 1999

- U.S. Patent No. 5,916,776, issued June 29, 1999
- U.S. Patent No. 5,916,779, issued June 29, 1999
- U.S. Patent No. 5,919,626, issued July 6, 1999
- U.S. Patent No. 5,919,630, issued July 6, 1999
- 5 U.S. Patent No. 5,922, 574, issued July 13, 1999
- U.S. Patent No. 5,925,517, issued July 20, 1999
- U.S. Patent No. 5,925,525, issued Jul. 20, 1999
- U.S. Patent No. 5,928,862, issued July 27, 1999
- U.S. Patent No. 5,928,869, issued July 27, 1999
- 10 U.S. Patent No. 5,928,870, issued, Jul. 27, 1999
- U.S. Patent No. 5,928,905, issued July 27, 1999
- U.S. Patent No. 5,928,906, issued July 27, 1999
- U.S. Patent No. 5,929,227, issued July 27, 1999
- U.S. Patent No. 5,932,413, issued Aug. 3, 1999
- 15 U.S. Patent No. 5,932,451, issued Aug. 3, 1999
- U.S. Patent No. 5,935,791, issued Aug. 10, 1999
- U.S. Patent No. 5,935,825, issued Aug. 10, 1999
- U.S. Patent No. 5,939,291, issued Aug. 17, 1999
- U.S. Patent No. 5,942,391, issued Aug. 24, 1999
- 20 European Application No. 320 308
- European Application No. 329 822
- GB Application No. 2 202 328
- PCT Application No. PCT/US87/00880

PCT Application No. PCT/US89/01025

PCT Application WO 88/10315

PCT Application WO 89/06700

PCT Application WO 90/07641

5

One skilled in the art readily appreciates that the present invention is well adapted to carry out the objectives and obtain the ends and advantages mentioned as well as those inherent therein. Sequences, mutations, complexes, methods, treatments, pharmaceutical compositions, procedures and techniques described herein are presently representative of the preferred embodiments and are intended to be exemplary and are not intended as limitations of the scope. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention or defined by the scope of the pending claims.

15

What is claimed is:

1. An animal having a heterologous nucleic acid sequence replacing an allele of an *atonal*-associated nucleic acid sequence under conditions wherein said heterologous sequence inactivates said allele.  
5
2. The animal of claim 1 wherein said heterologous nucleic acid sequence is expressed under the control of an *atonal*-associated regulatory sequence.
3. The animal of claim 1 wherein both *atonal*-associated alleles are replaced.
4. The animal of claim 3 wherein said heterologous nucleic acid sequences are nonidentical.  
10
5. The animal of claim 3 wherein said animal has a detectable condition.
6. The animal of claim 5 wherein said detectable condition is selected from the group consisting of loss of hair cells, cerebellar granule neuron deficiencies, hearing impairment, an imbalance disorder, joint disease, osteoarthritis and abnormal proliferation of cells.  
15
7. The animal of claim 1 or 3 wherein said heterologous nucleic acid sequence is a reporter sequence.
8. The animal of claim 1 or 3, wherein said *atonal*-associated allele is replaced with an *atonal*-associated nucleic acid sequence under the control of regulatable promoter sequence.  
20
9. The animal of claim 1 or 3, wherein said *atonal*-associated allele is replaced with an *atonal*-associated nucleic acid sequence under the control of a tissue-specific promoter sequence.

10. The animal of claim 1 or 3 wherein said animal is selected from the group consisting of a mouse, *Drosophila*, zebrafish, frog, rat, hamster and guinea pig.
11. A method for screening for a compound in an animal wherein said compound affects expression of an *atonal*-associated nucleic acid sequence comprising:
- 5 delivering said compound to said animal, wherein said animal has at least one allele of an *atonal*-associated nucleic acid sequence inactivated by insertion of a heterologous nucleic acid sequence, wherein said heterologous nucleic acid sequence is under control of an *atonal*-associated regulatory sequence; and
- 10 monitoring for a change in said expression of said *atonal*-associated nucleic acid sequence.
12. The method of claim 11 wherein said compound affects expression of an *atonal*-associated nucleic acid sequence.
13. The method of claim 11 wherein said compound affects a detectable condition in
- 15 an animal.
14. The method of claim 11, wherein said heterologous nucleic acid sequence is a reporter sequence.
15. A method for screening for a compound in an animal, wherein said compound affects a detectable condition in said animal, comprising:
- 20 delivering said compound to said animal wherein at least one allele of an *atonal*-associated nucleic acid sequence in said animal is inactivated by insertion of a heterologous nucleic acid sequence, wherein said heterologous nucleic acid sequence is under the control of an *atonal*-associated regulatory sequence, and

monitoring said animal for a change in the detectable condition.

16. The method of claim 11 or 15 wherein said compound affects said detectable condition.
17. The method of claim 15 wherein said compound affects expression of said heterologous nucleic acid sequence.
18. A method of treating an animal with a deficiency in cerebellar granule neurons or their precursors comprising delivery of a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.
19. A method of promoting mechanoreceptive cell growth in an animal, comprising delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.
20. A method of generating hair cells comprising delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.
21. A method of treating an animal for hearing impairment, comprising delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.
22. A method of treating an animal for an imbalance disorder, comprising delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.



23. A method of treating an animal for a joint disease comprising delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.
24. A method of treating an animal for an abnormal proliferation of cells comprising  
5 delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.
25. A method of treating an animal for an abnormal proliferation of cells comprising altering *atonal*-associated nucleic acid sequence or amino acid sequence levels in a cell.
- 10 26. A method of treating an animal for a disease that is a result of loss of functional *atonal*-associated nucleic acid or amino acid sequence comprising delivering a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence to a cell of said animal.
27. The method of claim 18, 19, 20, 21, 22, 23, 24, 25 or 26, wherein said amino acid  
15 sequence or nucleic acid sequence is delivered by a delivery vehicle.
28. The method of claim 18, 19, 20, 21, 22, 23, 24, 25 or 26, wherein said amino acid sequence or nucleic acid sequence is delivered by a delivery vehicle, and wherein said delivery vehicle is selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated viral vector, a plasmid, a  
20 liposome, a nucleic acid, a peptide, a lipid, a carbohydrate and a combination thereof.
29. The method of claim 18, 19, 20, 21, 22, 23, 24, 25 or 26, wherein said amino acid sequence or nucleic acid sequence is delivered by a delivery vehicle, wherein said

delivery vehicle is selected from the group consisting of a viral vector or a non-viral vector.

30. The method of claim 18, 19, 20, 21, 22, 23, 24, 25 or 26, wherein said amino acid sequence or nucleic acid sequence is delivered by a delivery vehicle, and wherein  
5 said delivery vehicle is a cell.
31. The method of claim 18, 19, 20, 21, 22, 23, 24, 25 or 26, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Math1.
32. The method of claim 18, 19, 20, 21, 22, 23, 24, 25 or 26, wherein said *atonal*-associated amino acid sequence or nucleic acid sequence is Hath1.
- 10 33. The method of claim 18, 19, 20, 21, 22, 23, 24, 25 or 26, wherein said cell contains an alteration in an *atonal*-associated nucleic acid sequence or amino acid sequence.
34. The method of claim 18, 19, 20, 21, 22, 23, 24, 25 or 26, wherein said amino acid sequence has at least about 80% identity to about 20 contiguous amino acid  
15 residues of SEQ ID NO:58 (Hath1).
35. The method of claim 18, 19, 20, 21, 22, 23, 24, 25 or 26, wherein said nucleic acid sequence encodes a polypeptide which has at least about 80% identity to about 20 contiguous amino acid residues of SEQ ID NO:58 (Hath1).
36. The method of claim 18, 19, 20, 21, 22, 23, 24, 25 or 26, wherein said cell is a  
20 human cell.
37. The method of claim 20 or 21, wherein said delivery comprises injecting into an inner ear a therapeutically effective amount of an *atonal*-associated amino acid sequence or nucleic acid sequence.

38. The method of claim 23 wherein said joint disease is osteoarthritis.
39. The method of claim 24 or 25, wherein said cell is a cancer cell.
40. A composition comprising an *atonal*-associated amino acid sequence or nucleic acid sequence in combination with a delivery vehicle, wherein said delivery vehicle results in delivery of a therapeutically effective amount of *atonal*-associated nucleic acid sequence or amino acid sequence into a cell.
41. The composition of claim 40, wherein said delivery vehicle comprises a vector that expresses an *atonal*-associated nucleic acid sequence or amino acid sequence in an animal cell.
42. The composition of claim 41, wherein said vector is selected from the group consisting of an adenoviral vector, a retroviral vector, an adeno-associated vector, a plasmid, a liposome, a protein, a lipid, a carbohydrate and a combination thereof of said vehicles.
43. The composition of claim 41, wherein said vector is selected from the group consisting of a viral vector or a non-viral vector.
44. The composition of claim 40, wherein said delivery vehicle is the receptor-binding domain of a bacterial toxin.
45. The composition of claim 40, wherein said *atonal*-associated nucleic acid sequence is operatively linked to nucleic acid sequence encoding a receptor-binding domain of a bacterial toxin.
46. The composition of claim 40 wherein said *atonal*-associated nucleic acid sequence is operatively linked to nucleic acid sequence encoding a protein transduction domain.




Figure 1




Figure 2

3/14




Figure 3

4/14




Figure 4

5/14




Figure 5

09980381.030602



6/14



Figure 6A



Figure 6B

09980381 TBE08660

09/980381

7/14





Figure 7

8/14




Figure 8

9/14




Figure 9

10/14




Figure 10



11/14




Figure 11

12/14




Figure 12

2030ED TBE 08660






Figure 13



14/14



G	Wing Hinge	Third Wing Vein	Scutellum
Wild Type	++	-	-
<i>hs-Gal4/UAS-Math1</i>	+++	+	+

Figure 14

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization**  
International Bureau



**(43) International Publication Date**  
**7 December 2000 (07.12.2000)**

(10) International Publication Number  
**WO 00/73764 A2**

PCT

- (51) **International Patent Classification<sup>7</sup>:** **G01N**
- (21) **International Application Number:** PCT/US00/15410
- (22) **International Filing Date:** 1 June 2000 (01.06.2000)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
60/137,060 1 June 1999 (01.06.1999) US  
60/176,993 19 January 2000 (19.01.2000) US
- (71) **Applicant (for all designated States except US):** **BAYLOR COLLEGE OF MEDICINE [US/US];** One Baylor Plaza, Houston, TX 77030 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **ZOGHBI, Huda, Y. [US/US];** 6618 Sewanee, Houston, TX 77005 (US). **BELLEN, Hugo [US/US];** 3411 Mt. Vernon, Houston, TX 77006 (US). **BIRMINGHAM, Nessim [US/US];** 5445 Braesvalley #708, Houston, TX 77096 (US). **HASSAN, Bassem [US/US];** 1422 Richmond Avenue #3053, Houston, TX 77006 (US). **BEN-ARIE, Nissim [IL/IL];**
- Department of Cell and Animal Biology, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Givat-Ram, 91904 Jerusalem (IL).
- (74) **Agent:** **PAUL, Thomas, D.;** Fulbright & Jaworski, Suite 5100, 1301 McKinney, Houston, TX 77010 (US).
- (81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— Without international search report and to be republished upon receipt of that report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**Published:**

— Without international search report and to be republished upon receipt of that report.

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**(54) Title:** COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE OF AN *ATONAL*-ASSOCIATED SEQUENCE FOR DEAFNESS, OSTEOARTHRITIS, AND ABNORMAL CELL PROLIFERATION

(57) **Abstract:** Compositions and methods are disclosed for the therapeutic use of an *atonal*-associated nucleic acid or amino acid sequence. Also, an animal heterozygous for an *atonal*-associated gene inactivation is also disclosed having at least one *atonal*-associated nucleic acid sequence replaced by insertion of a heterologous nucleic acid sequence used to detect expression driven by an *atonal*-associated promoter sequence, wherein the inactivation of the *atonal*-associated nucleic acid sequence prevents expression of the *atonal*-associated nucleic acid.

**WO 00/73764 A2**

[illegible]

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION</b> <b>(37 CFR 1.63)</b>  <input type="checkbox"/> Declaration Submitted with Initial Filing      OR <input checked="" type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)	Attorney Docket Number	HO-P01899US3	
	First Named Inventor	Huda Y. Zoghbi	
	<b>COMPLETE IF KNOWN</b>		
	Application Number	09/980,381 / PCT/US00/15410	
	Filing Date	Nov. 30, 2001 / June 1, 2000	
	Art Unit	N/A	
Examiner Name	Not Yet Assigned		

**As the below named inventor, I hereby declare that:**

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original and first inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE OF AN ATONAL-ASSOCIATED SEQUENCE FOR DEAFNESS, OSTEOARTHRITIS AND ABNORMAL CELL PROLIFERATION

(Title of the invention)

the specification of which

☐ is attached hereto  
 OR

☒ was filed on 11/30/2001 as United States Application Number
09/980,381

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365 (a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
US00/15410	PC	06/01/2000	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

**Declaration for Utility or Design Patent Application**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No.

EU098494603US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.Dated: Mar. 6, 2002 Signature: Susan Hunter (Susan Hunter)

Please type a plus sign (+) inside this box → ☐

PTC/BB/02A (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION		ADDITIONAL INVENTOR(S) Supplemental Sheet Page 1 of 1	
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))	Nessan	Family Name or Surname	Birmingham
Inventor's Signature		Date	
Residence: City	State	Country	USA
Mailing Address:		Citizenship	
City	State	ZIP	Country
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))	Bassem	Family Name or Surname	Hassan
Inventor's Signature		Date	
Residence: City	State	Country	USA
Mailing Address:		Citizenship	
City	State	ZIP	Country
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))	Nissim	Family Name or Surname	Ben-ari
Inventor's Signature		Date	
Residence: City	State	Country	Israel
Mailing Address:		Citizenship	
City	State	ZIP	Country
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))	Nissim	Family Name or Surname	Ben-ari
Inventor's Signature		Date	
Residence: City	State	Country	Israel
Mailing Address:		Citizenship	
City	State	ZIP	Country

20020214 0911AM P3

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION — Utility or Design Patent Application**


Direct all correspondence to:		<input checked="" type="checkbox"/> Customer Number or Bar Code Label	26,271	OR <input type="checkbox"/> Correspondence address below
Name <b>Melissa L. Sistrunk Fulbright &amp; Jaworski LLP</b>				
Address <b>1301 McKinney, Suite 5100</b>				
City	<b>Houston</b>	State	<b>Texas</b>	ZIP <b>77010-3095</b>
Country	<b>USA</b>	Telephone	<b>713.651.3735</b>	Fax <b>713.651.5246</b>
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.				
NAME OF SOLE OR FIRST INVENTOR:			<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Huda Y.		Family Name or Surname <b>Zoghbi</b>
Inventor's Signature <i>[Signature]</i>		Date <b>2/8/2002</b>		
Residence: City	<b>Houston</b>	State	<b>TX</b>	Country <b>USA</b>
Mailing Address:		<b>6618 Sewanee</b>		
City	<b>Houston</b>	State	<b>TX</b>	Country <b>USA</b>
NAME OF SECOND INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor		
Given Name (first and middle [if any])		Hugo		Family Name or Surname <b>Bellen</b>
Inventor's Signature <i>[Signature]</i>		Date <b>2/11/2002</b>		
Residence: City	<b>Houston</b>	State	<b>TX</b>	Country <b>USA</b>
Mailing Address:		<b>3411 Mt. Vernon</b>		
City	<b>Houston</b>	State	<b>TX</b>	Country <b>USA</b>
<input checked="" type="checkbox"/> Additional inventors are being named on the <u>1</u> supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto				

Received: 3/ 4/2002 4:15PM; ->BCOM; #934; Page 3  
03/04/02 MON 17:33 FAX 617 859 9292 ATLAS VENTURE

003

Please type a plus sign (+) inside this box ☒

PTO/SB/02A (11-00)  
Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION		ADDITIONAL INVENTOR(S) Supplemental Sheet Page 1 of 1	
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))	Nessan	Family Name or Surname	Birmingham
Inventor's Signature			
Residence: City	LONDON	State	
		Country	USA
		Citizenship	IRISH
Mailing Address:	55 GROSVENOR ST. ATLAS VENTURE MAYFAIR		
City	LONDON	State	
		ZIP	
		Country	USA
			ENGLAND
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))	Bassem	Family Name or Surname	Hassan
Inventor's Signature			
Residence: City		Country	USA
		Citizenship	USA
Mailing Address:			
City		State	
		ZIP	
		Country	USA
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))	Nissim	Family Name or Surname	Ben-arie
Inventor's Signature			
Residence: City	Mevasseret Zion	Country	Israel
		Citizenship	Israel
Mailing Address:	46 Hachoshen Blvd. Mevasseret Zion, 90805 ISRAEL		
City	Mevasseret Zion	State	
		ZIP	90805
		Country	Israel

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (11-00)

Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>DECLARATION</b>	<b>ADDITIONAL INVENTOR(S)</b> Supplemental Sheet Page 1 of 1
--------------------	--

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any)) <u>Nessan</u>		Family Name or Surname <u>Bermingham</u>	
Inventor's Signature		Date	
Residence: City	State	Country <u>USA</u>	Citizenship <u>USA</u>
Mailing Address:			
City	State	ZIP	Country <u>USA</u>
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any)) <u>Bassem</u>		Family Name or Surname <u>Hassan</u>	
Inventor's Signature <u>Bassem</u>		Date <u>02/06/02</u>	
Residence: City	State	Country <u>USA</u>	Citizenship <u>USA</u>
Mailing Address:			
City	State	ZIP	Country <u>USA</u>
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any)) <u>Nissim</u>		Family Name or Surname <u>Ben-arie</u>	
Inventor's Signature		Date	
Residence: City <u>Mevasseret Zion</u>	State	Country <u>Israel</u>	Citizenship <u>Israel</u>
Mailing Address: <u>46 Hachoshen Blvd.</u> <u>Mevasseret Zion, 90805 ISRAEL</u>			
City <u>Mevasseret Zion</u>	State	ZIP <u>90805</u>	Country <u>Israel</u>

SEQUENCE LISTING

<110> Zoghbi, Huda  
Ben-Arie, Nissim  
Bellen, Hugo  
Birmingham, Nessim  
Hassan, Bassem

<120> COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE OF AN ATONAL-  
ASSOCIATED SEQUENCE FOR DEAFNESS, OSTEOARTHRITIS, AND ABNORMAL CELL  
PROLIFERATION

<130> HO-P01899US3/09906355/OTA 99-47

<140> US 09/980,381

<141> 2001-11-30

<150> US 60/137,060

<151> 1999-06-01

<150> US 60/176,993

<151> 2000-01-19

<150> PCT/US00/15410

<151> 2000-06-01

<160> 69

<170> PatentIn version 3.0

<210> 1

<211> 1065

<212> DNA

<213> HUMAN

<400> 1

atgtcccgcc tgcgtcatgc agaagagtgg gctgaagtga aggagttggg agaccaccat	60
cgccagcccc agccgcatca tctcccgcaa ccgcgcgcgc cgccgcagcc acctgcaact	120
ttgcaggcga gagagcatcc cgtctacccg cctgagctgt ccctcctgga cagcaccgac	180
ccacgcgcct ggctggctcc cactttgcag ggcatctgca cggcacgcgc cgcccagtat	240
ttgctacatt ccccgagct ggggtgectca gagggcgcgtg cgccccggga cgaggtggac	300
ggccgggggg agctggtaag gaggagcagc ggcggtgcc a gcagcagcaa gagccccggg	360
ccggtgaaaag tgcgggaaca gctgtgcaag ctgaaaggcg ggggtggtgt agacgagctg	420
ggctgcagcc gccaacgggc cccttcagc aaacaggtga atggggtgca gaagcagaga	480
cggctagcag ccaacgccag ggagcggcgc aggatgcatg ggctgaacca cgccttcgac	540
cagctgcgca atgttatccc gtcgttcaac aacgacaaga agctgtccaa atatgagacc	600
ctgcagatgg cccaaatcta catcaacgcc ttgtccgagc tgctacaaac gccacggga	660
ggggaacagc caccgcgcgc tccagcctcc tgcaaaagcg accaccacca ccttcgcacc	720
gcggcctcct atgaaggggg cgcgggcaac gcgaccgcag ctgggggtca gcaggcttcc	780

RECEIVED 06 MAR 1992





Pro Pro Pro Pro Ala Ser Cys Lys Ser Asp His His His Leu Arg Thr  
225 230 235 240

Ala Ala Ser Tyr Glu Gly Gly Ala Gly Asn Ala Thr Ala Ala Gly Ala  
245 250 255

Gln Gln Ala Ser Gly Gly Ser Gln Arg Pro Thr Pro Pro Gly Ser Cys  
260 265 270

Arg Thr Arg Phe Ser Ala Pro Ala Ser Ala Gly Gly Tyr Ser Val Gln  
275 280 285

Leu Asp Ala Leu His Phe Ser Thr Phe Glu Asp Ser Ala Leu Thr Ala  
290 295 300

Met Met Ala Gln Lys Asn Leu Ser Pro Ser Leu Pro Gly Ser Ile Leu  
305 310 315 320

Gln Pro Val Gln Glu Glu Asn Ser Lys Thr Ser Pro Arg Ser His Arg  
325 330 335

Ser Asp Gly Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu  
340 345 350

Ala Ser

<210> 3  
<211> 420  
<212> DNA  
<213> MOUSE

<400> 3  
tcgtccacag cgctccgcgc aagcccgcgg cgcggaggac accgtgctcg gttccgggct 60  
gcggggacat tcccggaac acaccggagc agcagctgcg ccgcgacaca tctggagcgg 120  
cgtaggatgt tcgtcaaata tgagactctg gagttgaagg aggaagagga ggtactgatg 180  
ctgctgggct cggcttcccc ggctcggcg accctgacct cgatgtctc cagcgcggac 240  
gaggaggagg acgaggagct gcgcgggccc ggctccgcgc gtgggcagcg tggagcggaa 300  
gccgggcagg ggggtgcagg cagtcggcg tcgggtgctt ggggttgccg gacagggcgg 360  
ctgctatgca ctgtgcacga gtgctagcgt gtgccgtcgc gctcacgggc cgtctgcaga 420

<210> 4  
<211> 645  
<212> DNA  
<213> MOUSE

<400> 4  
atggcgctc atcccttga tgcgtcacc atccaagtgt cccagagac acaacaacct 60  
tttcccgag cctcggacca cgaagtgtc agttccaatt ccacccacc tagccccact 120  
ctcatacctt gggactgtc cgaagcagaa gtgggtgact gccgaggac ctgcaggaag 180  
ctccgcgccc gacgcggagg gcgcaacagg cccaagagcg agttggcact cagcaaacag 240

209060" TAE08560

cgaagaagcc ggcgcaagaa ggccaatgat cgggagcgca atcgcatgca caacctcaac 300  
tcggcgctgg atgcgctgog cgggtgtcctg cccaccttcc cggatgacgc caaacttaca 360  
aagatcgaga ccctgcgctt cgcccacaac tacatctggg cactgactca gacgctgcgc 420  
atagcggacc acagcttcta tggcccggag cccctgtgac cctgtggaga gctggggagc 480  
cccgagggtg gctccaacgg ggactggggc tctatctact cccagctctc ccaagcgggt 540  
aacctgagcc ccacggcctc attggaggaa ttccctggcc tgcagggtgcc cagctcccca 600  
tcctatctgc tcccgggagc actggtgttc tcagacttct tgtga 645

<210> 5  
<211> 214  
<212> PRT  
<213> MOUSE

<400> 5

Met	Ala	Pro	His	Pro	Leu	Asp	Ala	Leu	Thr	Ile	Gln	Val	Ser	Pro	Glu
1				5					10					15	
Thr	Gln	Gln	Pro	Phe	Pro	Gly	Ala	Ser	Asp	His	Glu	Val	Leu	Ser	Ser
			20					25					30		
Asn	Ser	Thr	Pro	Pro	Ser	Pro	Thr	Leu	Ile	Pro	Arg	Asp	Cys	Ser	Glu
		35					40					45			
Ala	Glu	Val	Gly	Asp	Cys	Arg	Gly	Thr	Ser	Arg	Lys	Leu	Arg	Ala	Arg
	50					55					60				
Arg	Gly	Gly	Arg	Asn	Arg	Pro	Lys	Ser	Glu	Leu	Ala	Leu	Ser	Lys	Gln
65					70				75						80
Arg	Arg	Ser	Arg	Arg	Lys	Lys	Ala	Asn	Asp	Arg	Glu	Arg	Asn	Arg	Met
				85					90					95	
His	Asn	Leu	Asn	Ser	Ala	Leu	Asp	Ala	Leu	Arg	Gly	Val	Leu	Pro	Thr
			100					105					110		
Phe	Pro	Asp	Asp	Ala	Lys	Leu	Thr	Lys	Ile	Glu	Thr	Leu	Arg	Phe	Ala
		115					120					125			
His	Asn	Tyr	Ile	Trp	Ala	Leu	Thr	Gln	Thr	Leu	Arg	Ile	Ala	Asp	His
		130				135					140				
Ser	Phe	Tyr	Gly	Pro	Glu	Pro	Pro	Val	Pro	Cys	Gly	Glu	Leu	Gly	Ser
145					150					155					160
Pro	Gly	Gly	Gly	Ser	Asn	Gly	Asp	Trp	Gly	Ser	Ile	Tyr	Ser	Pro	Val
				165				170						175	
Ser	Gln	Ala	Gly	Asn	Leu	Ser	Pro	Thr	Ala	Ser	Leu	Glu	Glu	Phe	Pro
			180					185					190		
Gly	Leu	Gln	Val	Pro	Ser	Ser	Pro	Ser	Tyr	Leu	Leu	Pro	Gly	Ala	Leu
		195					200						205		

20900018000000



<212> PRT  
<213> MOUSE

<400> 7

Met Phe Val Lys Ser Glu Thr Leu Glu Leu Lys Glu Glu Glu Glu Val  
1 5 10 15  
Leu Met Leu Leu Gly Ser Ala Ser Pro Ala Ser Ala Thr Leu Thr Pro  
20 25 30  
Met Ser Ser Ser Ala Asp Glu Glu Glu Asp Glu Glu Leu Arg Arg Pro  
35 40 45  
Gly Ser Ala Arg Gly Gln Arg Gly Ala Glu Ala Gly Gln Gly Val Gln  
50 55 60  
Gly Ser Pro Ala Ser Gly Ala Gly Gly Cys Arg Pro Gly Arg Leu Leu  
65 70 75 80  
Gly Leu Met His Glu Cys Lys Arg Arg Pro Ser Arg Ser Arg Ala Val  
85 90 95  
Ser Arg Gly Ala Lys Thr Ala Glu Thr Val Gln Arg Ile Lys Lys Thr  
100 105 110  
Arg Arg Leu Lys Ala Asn Asn Arg Glu Arg Asn Arg Met His Asn Leu  
115 120 125  
Asn Ala Ala Leu Asp Ala Leu Arg Glu Val Leu Pro Thr Phe Pro Glu  
130 135 140  
Asp Ala Lys Leu Thr Lys Ile Glu Thr Leu Arg Phe Ala His Asn Tyr  
145 150 155 160  
Ile Trp Ala Leu Thr Glu Thr Leu Arg Leu Ala Asp His Cys Ala Gly  
165 170 175  
Ala Gly Gly Leu Gln Gly Ala Leu Phe Thr Glu Ala Val Leu Leu Ser  
180 185 190  
Pro Gly Ala Ala Leu Gly Ala Ser Gly Asp Ser Pro Ser Pro Pro Ser  
195 200 205  
Ser Trp Ser Cys Thr Asn Ser Pro Ala Ser Ser Ser Asn Ser Thr Ser  
210 215 220  
Pro Tyr Ser Cys Thr Leu Ser Pro Ala Ser Pro Gly Ser Asp Val Asp  
225 230 235 240  
Tyr Trp Gln Pro Pro Pro Pro Glu Lys His Arg Tyr Ala Pro His Leu  
245 250 255  
Pro Leu Ala Arg Asp Cys Ile  
260

<210> 8  
<211> 1957  
<212> DNA  
<213> MOUSE

09900381.030602

<400> 8  
gatacacaca gatctagagg ctccaggaga cgatgcgaca ctccagcctga aaagatttgg 60  
aagatccaaa atgaaaactg attattgaat gaaattaaaa cctaaggtaa attaaggtta 120  
aagaaccatg ttaacactac cgtttgacga gtctgtcgta atgcccgaat cccagatgtg 180  
cagaaagttt gctagacaat gtgaggacca gaaacaaatt aagaaaccag agagctttcc 240  
aaaacaagtt gtccctcgag gaaagagcat taaaagggcc cctggagaag aaaccgagaa 300  
agaagaggag gaagaagaca gagaggaga agatgagaat ggcttgtcca gaaggagggg 360  
gtcaggaaa aaaaagacca ccaaactacg actggaaagg gtcaagttca ggagacagga 420  
agctaattgcg cgcgagagga accggatgca cggcctcaat gatgctctgg acaatttgcg 480  
aaaagtggtc cctgttact ctaaaacca aaaactgtcc aaaatagaaa ctttacgact 540  
ggccaaaaat tacatctggg cactttctga aattctgagg attggcaaga gaccggatct 600  
gtcacggttc gtccaaaact tatgcaaagg tctttcccag ccaactacaa acttggtggc 660  
aggtgctta cagctcaacg ccagaagttt cctgatgggt cagggtgggg aggtgcccc 720  
ccacacaagg tcaccctact ccacattcta cccaccctac cacagccctg agctggccac 780  
tccccaggg catgggactc ttgataattc caagtccatg aaaccctaca attactgcag 840  
tgcatatgaa tccctctatg aaagtacctc cctgagtggt gccagccctc agtttgaagg 900  
tcccttaagt cctcccccaa ttaactataa tgggatattt tccctgaagc aagaagaaac 960  
cttgactat ggcaaaaatt acaattatgg catgcattac tgtgcagtgc caccagggg 1020  
tccccttggg cagggtgcc agttcagggt gccaccgac agccacttcc cttacgactt 1080  
acatctgcgc agccaatctc tcactatgca agatgaatta aatgcagttt ttcataatta 1140  
atgaggaaaa tgaaaataaa cagtgggtcat tcacctcca ctctaattaa ggcaaagcag 1200  
atgcttgtgg gctgcgtaat tggcacaact ctatctaagg tgtttactag tttctgaagt 1260  
gtgtctcaaa gattgtgacc attttctatg tcataataaa tcccttttcg tatgagaact 1320  
tcctttcctt cctcttgtc tgtatcacac tgtgattctc tctctctctc tctctctctc 1380  
tctctctctc tctctctctt actggcagaa tatttcttct ttgttttagt ttctttcaaa 1440  
ttcacttaat ttgtttgaac aagggtgtcta agatggttgct gaataaagac atgcacacag 1500  
catacttcaa tgtctatttc agttgtacag ttatgatgaa aatgcagtt ataaaaatca 1560  
gatgagtaaa atgtgtttat aattactagg attcatatat gtatctctga aattttagtt 1620  
tttaaaatat taagagctaa ccatgaaatt aaaaggtgca tttggggatg cacaacggta 1680  
tcaaaagcta tgcaattttc tgtttattag ggacaaaaat aagtgtattc agttggtaac 1740  
aactattcct cttcaagcat tttcagagga ggaaacacgg tatttggggg aggttatcag 1800

tgtcataatt tggggacaat taattcaatc atgaagaaaa aaaatattag cacttgtttt 1860  
 gtattgttca ggatttttct gtacaggttt gttacagtgt ataattgtgt tttccatcct 1920  
 acagtttaaa agcaattaa catagatatt tccactt 1957

<210> 9  
 <211> 337  
 <212> PRT  
 <213> MOUSE

<400> 9

Met	Leu	Thr	Leu	Pro	Phe	Asp	Glu	Ser	Val	Val	Met	Pro	Glu	Ser	Gln	1	5	10	15
Met	Cys	Arg	Lys	Phe	Ala	Arg	Gln	Cys	Glu	Asp	Gln	Lys	Gln	Ile	Lys	20	25	30	
Lys	Pro	Glu	Ser	Phe	Pro	Lys	Gln	Val	Val	Leu	Arg	Gly	Lys	Ser	Ile	35	40	45	
Lys	Arg	Ala	Pro	Gly	Glu	Glu	Thr	Glu	Lys	Glu	Glu	Glu	Glu	Glu	Asp	50	55	60	
Arg	Glu	Glu	Glu	Asp	Glu	Asn	Gly	Leu	Ser	Arg	Arg	Arg	Gly	Leu	Arg	65	70	75	80
Lys	Lys	Lys	Thr	Thr	Lys	Leu	Arg	Leu	Glu	Arg	Val	Lys	Phe	Arg	Arg	85	90	95	
Gln	Glu	Ala	Asn	Ala	Arg	Glu	Arg	Asn	Arg	Met	His	Gly	Leu	Asn	Asp	100	105	110	
Ala	Leu	Asp	Asn	Leu	Arg	Lys	Val	Val	Pro	Cys	Tyr	Ser	Lys	Thr	Gln	115	120	125	
Lys	Leu	Ser	Lys	Ile	Glu	Thr	Leu	Arg	Leu	Ala	Lys	Asn	Tyr	Ile	Trp	130	135	140	
Ala	Leu	Ser	Glu	Ile	Leu	Arg	Ile	Gly	Lys	Arg	Pro	Asp	Leu	Leu	Thr	145	150	155	160
Phe	Val	Gln	Asn	Leu	Cys	Lys	Gly	Leu	Ser	Gln	Pro	Thr	Thr	Asn	Leu	165	170	175	
Val	Ala	Gly	Cys	Leu	Gln	Leu	Asn	Ala	Arg	Ser	Phe	Leu	Met	Gly	Gln	180	185	190	
Gly	Gly	Glu	Ala	Ala	His	His	Thr	Arg	Ser	Pro	Tyr	Ser	Thr	Phe	Tyr	195	200	205	
Pro	Pro	Tyr	His	Ser	Pro	Glu	Leu	Ala	Thr	Pro	Pro	Gly	His	Gly	Thr	210	215	220	
Leu	Asp	Asn	Ser	Lys	Ser	Met	Lys	Pro	Tyr	Asn	Tyr	Cys	Ser	Ala	Tyr	225	230	235	240
Glu	Ser	Phe	Tyr	Glu	Ser	Thr	Ser	Pro	Glu	Cys	Ala	Ser	Pro	Gln	Phe	245	250	255	

0990034.0990034

[illegible][illegible][illegible][illegible][illegible][illegible]

**06987**

[illegible]



Overall		Non-Black		Black	
Mean	SD	Mean	SD	Mean	SD
1.0	0.0	1.0	0.0	1.0	0.0
2.0	0.0	2.0	0.0	2.0	0.0
3.0	0.0	3.0	0.0	3.0	0.0
4.0	0.0	4.0	0.0	4.0	0.0
5.0	0.0	5.0	0.0	5.0	0.0
6.0	0.0	6.0	0.0	6.0	0.0
7.0	0.0	7.0	0.0	7.0	0.0
8.0	0.0	8.0	0.0	8.0	0.0
9.0	0.0	9.0	0.0	9.0	0.0
10.0	0.0	10.0	0.0	10.0	0.0
11.0	0.0	11.0	0.0	11.0	0.0
12.0	0.0	12.0	0.0	12.0	0.0
13.0	0.0	13.0	0.0	13.0	0.0
14.0	0.0	14.0	0.0	14.0	0.0
15.0	0.0	15.0	0.0	15.0	0.0
16.0	0.0	16.0	0.0	16.0	0.0
17.0	0.0	17.0	0.0	17.0	0.0
18.0	0.0	18.0	0.0	18.0	0.0
19.0	0.0	19.0	0.0	19.0	0.0
20.0	0.0	20.0	0.0	20.0	0.0
21.0	0.0	21.0	0.0	21.0	0.0
22.0	0.0	22.0	0.0	22.0	0.0
23.0	0.0	23.0	0.0	23.0	0.0
24.0	0.0	24.0	0.0	24.0	0.0
25.0	0.0	25.0	0.0	25.0	0.0
26.0	0.0	26.0	0.0	26.0	0.0
27.0	0.0	27.0	0.0	27.0	0.0
28.0	0.0	28.0	0.0	28.0	0.0
29.0	0.0	29.0	0.0	29.0	0.0
30.0	0.0	30.0	0.0	30.0	0.0
31.0	0.0	31.0	0.0	31.0	0.0
32.0	0.0	32.0	0.0	32.0	0.0
33.0	0.0	33.0	0.0	33.0	0.0
34.0	0.0	34.0	0.0	34.0	0.0
35.0	0.0	35.0	0.0	35.0	0.0
36.0	0.0	36.0	0.0	36.0	0.0
37.0	0.0	37.0	0.0	37.0	0.0
38.0	0.0	38.0	0.0	38.0	0.0
39.0	0.0	39.0	0.0	39.0	0.0
40.0	0.0	40.0	0.0	40.0	0.0
41.0	0.0	41.0	0.0	41.0	0.0
42.0	0.0	42.0	0.0	42.0	0.0
43.0	0.0	43.0	0.0	43.0	0.0
44.0	0.0	44.0	0.0	44.0	0.0
45.0	0.0	45.0	0.0	45.0	0.0
46.0	0.0	46.0	0.0	46.0	0.0
47.0	0.0	47.0	0.0	47.0	0.0
48.0	0.0	48.0	0.0	48.0	0.0
49.0	0.0	49.0	0.0	49.0	0.0
50.0	0.0	50.0	0.0	50.0	0.0
51.0	0.0	51.0	0.0	51.0	0.0
52.0	0.0	52.0	0.0	52.0	0.0
53.0	0.0	53.0	0.0	53.0	0.0
54.0	0.0	54.0	0.0	54.0	0.0
55.0	0.0	55.0	0.0	55.0	0.0
56.0	0.0	56.0	0.0	56.0	0.0
57.0	0.0	57.0	0.0	57.0	0.0
58.0	0.0	58.0	0.0	58.0	0.0
59.0	0.0	59.0	0.0	59.0	0.0
60.0	0.0	60.0	0.0	60.0	0.0
61.0	0.0	61.0	0.0	61.0	0.0
62.0	0.0	62.0	0.0	62.0	0.0
63.0	0.0	63.0	0.0	63.0	

Met Ser Arg Leu Leu His Ala Glu Glu Trp Ala Glu Val Lys Glu Leu  
1 5 10 15

Pro Gln Pro Pro Ala Thr Leu Gln Ala Arg Asp Leu Pro Val Tyr Pro  
35 40 45

Pro Thr Leu Gln Gly Leu Cys Thr Ala Arg Ala Ala Gln Tyr Leu Leu  
65 70 75 80

Ala Asp Ser Gln Gly Glu Leu Val Arg Arg Ser Gly Cys Gly Gly Leu  
100 105 110

Lys Gly Gly Val Val Val Asp Glu Leu Gly Cys Ser Arg Gln Arg Ala  
130 135 140

Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn His Ala Phe  
165 170 175

Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile Asn Ala Leu  
195 200 205

Thr Ala Ser Cys Lys Asn Asp His His His Leu Arg Thr Ala Ser Ser  
225 230 235 240

Pro Gly Gly Gly Pro Arg Pro Thr Pro Pro Gly Pro Cys Arg Thr Arg  
260 265 270

Phe Ser Gly Pro Ala Ser Ser Gly Gly Tyr Ser Val Gln Leu Asp Ala  
275 280 285

Leu His Phe Pro Ala Phe Glu Asp Arg Ala Leu Thr Ala Met Met Ala  
290 295 300

Gln Lys Asp Leu Ser Pro Ser Leu Pro Gly Gly Ile Leu Gln Pro Val  
305 310 315 320

Gln Glu Asp Asn Ser Lys Thr Ser Pro Arg Ser His Arg Ser Asp Gly  
325 330 335

Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu Ala Ser  
340 345 350

<210> 12  
<211> 3261  
<212> DNA  
<213> MOUSE

<400> 12  
aatctatata tggcaaaaat gtatatgaaa tccaaggaca tggaggagct ggtcaacaca 60  
caatcctgga tggacaaagg tctgagctct caaaatgaga tgaaggagca agagagaaga 120  
ccgggctctt atggaatgct cggaacctta actgaagagc atgacagtat tgaggaggat 180  
gaagaagagg aagaagatgg agataaacct aaaagaagag gtccaagaa aaagaagatg 240  
actaaagctc gccttgaaag attcagggtc cgaagagtca aggccaatgc tagagaacgg 300  
accgggatgc atggcctgaa tgatgccttg gataatctta ggagagtcac gccatgttac 360  
tctaaaactc aaaagcttct caagatagag actcttcgac tggcaaggaa ctacatctgg 420  
gccttgtctg aagtccctgga gactgggtcag acacttgaag ggaagggatt tgtagagatg 480  
ctatgtaaag gtctctctca accacaagc aacctgggtg ctggatgcct ccaactgggg 540  
cctcaatcta cctcctgga gaagcatgag gaaaaatctt caatttgtga ctctactatc 600  
tctgtccaca gcttcaacta tcagtctcca gggctcccca gccctcctta tggccatatg 660  
gaaacacatt ctctccatct caagcctcaa ccatttaaga gtttggtga ctcttttggg 720  
agccatccac ctgactgcag taccctccct tatgagggtc cactcacacc acccctgagc 780  
attagtggca acttctcctt aaagcaagac ggctccctg atttggaata atcctacaat 840  
ttcatgccac attatacctc tgcaagtcta agttcagggc atgtgcattc aactcccttt 900  
cagactggca ctccccgcta tgatgttcct gtagacctga gctatgattc ctactccac 960  
catagcattg gaactcagct caatacgatc ttctctgatt agagcaataa gataagcacc 1020  
aatatttcag agaatgaagt ggagattttt ttcacatttc tagtggctga gctaaactct 1080  
cagaaaattt aaaagaacct ttggatatgc atcaaacata atagtcctag tttgttcaga 1140  
acttcctgta cctgctaact ttcttcccat taactttctc cattggacca gtcctacatt 1200  
tggtaaactt aagtgaatat atttgatggg ttgaggccac atggtaatat aacagaaaga 1260

203030 FEB 08 60

aagcccaggc cctgttccaa tgggtgccaaa gattaattga atgctctgcc aattaacttt	1320
ccatttccag tgtttttatt gctttctgat aaacatgaag caactgttcc aaatcaacat	1380
atacctttca cctcccacac attttttaaat ttaaaagcaa tcaaagcaaa tagcaaaaat	1440
ggaatgatta tacagaactg gaaggagcat caagtacatg tctgttggct tatagaatac	1500
aaaatttgtg tgaatttgac aaatcatctt tgtgtctatt taaatataac ttccagagcc	1560
taaaataata acttggatgt taccataaat aaccagtatg ttctttaaga gatcagctct	1620
acttattact gtgctgaaag gtatacacac cttttttagt gattggagaa ccatgataga	1680
agcctcacac aaactttatt ctttatacta tttaaaaaac aactgtctta gtactaggag	1740
acaagcaaga aagacattga aatttctctt ctggcacaca gaaatatcac ctagctcatt	1800
tcttagctcc cgtgactata gggctgtaga attttgcagg tattcagggtg cttcagttag	1860
aatcagaact cagccagggt catactgtag agcaataaaa tgggtggttg ctgctatccc	1920
aactaacaca gttaaagaac tctgcctcac acatagccac tggaaaaatg tggatattct	1980
ccagcaagat gaatttcaact gtttaaagca atgcaattaa agccatagag tttcgtccac	2040
tccagtatca tatattccag aactgttgta atcaatcttg aattcttaca acataaatgc	2100
aactccttac ttcccaccta acactgattg ttatatgtc ttcaattcca agatattatg	2160
caattatatg caaaattttg attagaatca aaattaagag tcaatgaatc tgtctgtatc	2220
ttcaggacgg gttttgatca gttttaagaa agtttatttt cttttatgtg gcatctcttt	2280
tctttgtaac cacactgggt cageccaagtt tctcttctcc agagaaatta gctctgagaa	2340
attttactat catgatccat ctccacagc aattatttag gttcaactca agagtataca	2400
tagtttattt atagtgggtg aggatacacc tccaagaata aattttaaca acattaatga	2460
catatgaata tgccatttta tctaccaaac tatatatgta tctcttttct ttattgcctt	2520
tattttattt ttccactga gagttatttt gtgtocatct tattgcagca ctactctgc	2580
tctactttgc acctttggat tataaatatg tttaaaagtc tgtaaagacg tcttaacaa	2640
ctcgtgacag taattcacca cccctaagac cttgaatcac cctagtggaa ataggcaagg	2700
agaattattt atagaatcat cctatgtaat tttttttgag aatttgctct acctagcatt	2760
tatgtttata gataattgct atctgcatta tttattaggt tctatttatt taatttatct	2820
ttctttcttt ttatgtaaac atttgtgcc catagatata gcctcaaagc ttcactggga	2880
aactagctta tatgtttgga gtgagagaaa aggagaaaat cagttcttga ttgcttgcaa	2940
tggttttata aaacagagca ataattgaa tagatatgca acttaatggg tttagaattt	3000
ttcctttaag gtgcaacaga gttacattat ttttatgac tttggagaat gtagtacatg	3060
tgaaccagga ctgtaggctt gtgaagagag attttataat taaatacaaa tttagtactg	3120





```

gggagggaaa catatctaac ccntaagtca ccccagntcc tcggggagat cctttggccg      240
ggccatggta atagctgcga ggatcctggg gccaggggtc atttgcgggc catttacaca      300
aacttgggtca gaacgggggt gaaaatattt gtagaatgca tctcgcgggg gttgaccgta      360
gtcaagtctg gatccgatcg gatcgtttca gttgcaacga aactttcaag ccgcgcggat      420
ctgcaatgag ctactactac tcgtctgcct ccgaggagga tggcagttcc cagtatctgg      480
gcagtcccaa ctacaacttg acccagttgc cgccagtttc tggccaggat tacggacagg      540
gggctttctt atcgccggaa tggcaattct tggatgccgc aggcggaaact caaacggaac      600
taggacccat aatggagggt caaggacagc acaccagcc gcagaccaa cggcggagta      660
acagctccac aggatcggac ggtaggaaga gcagtcaga gcagaccaat ctcagtccca      720
cggtcagaa gagaagacga caggctgcc aatgcgcggga aaggaagcgg atgaatggat      780
taaatgcggc ttctgagcgc ctaagggaag tggatgccgc tccgtccatt gaccagaaat      840
tgtccaagtt cgagactctc cagatggccc agtcctacat cctggcgtg tgogatctcc      900
tcaacaacgg ggacgtggaa gtggatgccg ctgcatacac catcttcggc gacagcgata      960
gtggatttgg attgagcgga ggatccttgt catagatgga tgatactaga ctaaagttat     1020
gtgattttct tottactgta gattaagtta aatatgtaat gaaataaatt gaaatgttta     1080
attgaatgct aaaaataatt tcaatttcaa aggcattatt catggaacgc atogcttgat     1140
tgtgaaccaa gtgttcaatc caaatgagc tactcatcta accctttcta ccaattataa     1200
ccagcccact actatacaca gatccccaga ttcaattggc catcagatcg tttggctgcg     1260
cctcaatgat ttcgaaaacg atcataaatt aattactcaa cagttcattg atagggctac     1320
ttcaagtttt grtctaacc cgaacgattc cgaaactgcg aagccaccac agtgggcggt     1380
gtagcgtgac acccctgaac tcctggccag aactcctctc attgaataaa aaaggcagct     1440
gagtccttcg gcttcgggtg ggtgctgttt tttttt                                1476

```

```

<210> 17
<211> 189
<212> PRT
<213> DROSOPHILA

```

<400> 17

```

Met Ser Tyr Tyr Tyr Ser Ser Ala Ser Glu Glu Asp Gly Ser Ser Gln
1          5          10          15

Tyr Leu Gly Ser Pro Asn Tyr Asn Leu Thr Gln Leu Pro Pro Val Ser
20          25          30

Gly Gln Asp Tyr Gly Gln Gly Ala Phe Leu Ser Pro Glu Trp Gln Phe
35          40          45

```

Leu Asp Ala Ala Gly Gly Thr Gln Thr Glu Leu Gly Pro Ile Met Glu  
50 55 60

Val Gln Gly Gln His Thr Gln Pro Gln Thr Lys Arg Arg Ser Asn Ser  
65 70 75 80

Ser Thr Gly Ser Asp Gly Arg Lys Ser Ser Pro Glu Gln Thr Asn Leu  
85 90 95

Ser Pro Thr Val Gln Lys Arg Arg Arg Gln Ala Ala Asn Ala Arg Glu  
100 105 110

Arg Lys Arg Met Asn Gly Leu Asn Ala Ala Phe Glu Arg Leu Arg Glu  
115 120 125

Val Val Pro Ala Pro Ser Ile Asp Gln Lys Leu Ser Lys Phe Glu Thr  
130 135 140

Leu Gln Met Ala Gln Ser Tyr Ile Leu Ala Leu Cys Asp Leu Leu Asn  
145 150 155 160

Asn Gly Asp Val Glu Val Asp Ala Ala Ala Tyr Thr Ile Phe Gly Asp  
165 170 175

Ser Asp Ser Gly Phe Gly Leu Ser Gly Gly Ser Leu Ser  
180 185

<210> 18  
<211> 1074  
<212> DNA  
<213> CHICKEN

<400> 18  
tttttccctt cccttttccct cgcggagccg cggccgcttt gccttcccct acagcgagga 60  
gctccgcttt ctctctatt tatttctaaa cgtttattgc ttaaccgcag ccccgaggat 120  
gcctttccat gtgagtacgg gggacacagg cacctgcgat gcggtgcggc cgtgccaaagc 180  
actcccaccc tccctccgtc cctccttggg gttactttgg gatatttttt ccttcccttt 240  
ccccctcccc tcagcacctt cccccgctc cccctgccgc ccaactgacgg ctccggcttc 300  
tctcccgag gatgcccgcg gaggcggcga gcagcggcg cgtttcggag ccgcccggag 360  
ctccgcggga gcggcggagg agacgcggcc gtgcgcgggc gcggaccgag gctttgctgc 420  
acaccctcaa acggagccgc cgggtgaaag ccaacgaccg ggagcggaac cgcattgcacc 480  
acctcaacgc cgcgtggat gagctccgca gcgtcctgcc gaccttcccc gacgacacca 540  
aactcaccaa aatcgaaacc ctgcgcttcg cttaacaacta catctgggac ctctccgaga 600  
cccttcgttt ggccgagcag tgctccctc ctcccccgcc cttccgcggg cccccgcgc 660  
ccccagccc cggcagcgac gccggttcgt ggctgtccag cggttccccg gccgccccct 720  
cgctctgcgc ctccgcctcc ggccccagca gcccgccac ctccgaggac tgcggtacg 780  
tcccctcgga cgcctgcgg gccttcgcg ggctgcccc cgcgccccg ggcgtccct 840

gccgctagcc ctgcccgtgc gtgtctccgt cccccccac cttctccgta tcccgttgca 900  
 cttttcagcc cctcccggcc ccagcccct ctctccgggg tgccctttcc cttcggcccc 960  
 ccgcctcggt ttccatacga cttggaaaac ccggcaaaga aaagcgacag atttgctgcc 1020  
 gcagacgagg tgaaaagtca attttacaat ttgtagctct ccggtgaaga aaaa 1074

<210> 19  
 <211> 178  
 <212> PRT  
 <213> CHICKEN

<400> 19

Met Pro Ala Glu Ala Ala Ser Ser Gly Gly Val Ser Glu Pro Pro Gly  
 1 5 10 15  
 Ala Pro Arg Glu Arg Arg Arg Arg Arg Gly Arg Ala Arg Ala Arg Thr  
 20 25 30  
 Glu Ala Leu Leu His Thr Leu Lys Arg Ser Arg Arg Val Lys Ala Asn  
 35 40 45  
 Asp Arg Glu Arg Asn Arg Met His His Leu Asn Ala Ala Leu Asp Glu  
 50 55 60  
 Leu Arg Ser Val Leu Pro Thr Phe Pro Asp Asp Thr Lys Leu Thr Lys  
 65 70 75 80  
 Ile Glu Thr Leu Arg Phe Ala Tyr Asn Tyr Ile Trp Ala Leu Ser Glu  
 85 90 95  
 Thr Leu Arg Leu Ala Glu Gln Cys Leu Pro Pro Pro Pro Ala Phe Arg  
 100 105 110  
 Gly Pro Pro Ala Pro Pro Ser Pro Gly Ser Asp Ala Gly Ser Trp Leu  
 115 120 125  
 Ser Ser Gly Ser Pro Ala Ala Pro Ser Leu Cys Ala Ser Ala Ser Gly  
 130 135 140  
 Pro Ser Ser Pro Ala Thr Ser Glu Asp Cys Gly Tyr Val Pro Ser Asp  
 145 150 155 160  
 Ala Leu Arg Ala Phe Arg Gly Leu Pro Pro Ala Ala Pro Gly Ala Pro  
 165 170 175

Cys Arg

<210> 20  
 <211> 790  
 <212> DNA  
 <213> CHICKEN

<400> 20  
 gcagccgccc ggccccgggg ccgctccgac gccgcccggg cgcgtgccag cgcccccga 60

0990334.0050



ccgcccgaac gccgtcgacc agcggcccg ccccccctct ccccgcccc gcaggatgcc 120  
 ggtgaaggcg gagagcccgg cgcgcgcggc ggaggacgaa ctgtgtctgc tgcgcctcgc 180  
 ctgccccgcc cctcggcct cgctgccgtc cagcgccggc gaggaggacg aggacgagga 240  
 ggacggggcg cgcgggcggc tgcaggagg cgctcggcg gcggggcggc agcgaggggc 300  
 cccgcgggcg gcgcgcacgg cggagacggc gcagcgcatc aagcggagcc ggcggtgaa 360  
 agccaacaac cgcgagcgca accgcatgca caacctgaac gcggcgctgg acgcgtgcg 420  
 cgacgtgctg cccaccttcc ccgaggacgc caagctcacc aagatcgaga cgctgcgctt 480  
 cgcccacaac tacatctggg cgctcaccga gacgtgctgc ctggccgggg ccgcccgcct 540  
 gggggggcgcc gccgacgcgg cgcgcggggc ggccgcccag ggcagcccct cgcgcgcctc 600  
 gtcgtggagc ggcggcgcca gcccgcgcc ctccgcctcg cctacgcct gcactttatc 660  
 gcccggcagc cccgcgggt cgcctcggga cgcgagcac tggccgcccc cgcggggcg 720  
 cttcgccccg ccgcccgcgc cccaccgctg cctctaacgc ggcccggcg gccctcgctc 780  
 ctccgacgtg 790

<210> 21  
 <211> 213  
 <212> PRT  
 <213> CHICKEN

<400> 21

Met	Pro	Val	Lys	Ala	Glu	Ser	Pro	Ala	Pro	Ala	Ala	Glu	Asp	Glu	Leu
1				5					10					15	
Leu	Leu	Leu	Arg	Leu	Ala	Ser	Pro	Ala	Pro	Ser	Ala	Ser	Leu	Pro	Ser
			20					25					30		
Ser	Ala	Gly	Glu	Glu	Asp	Glu	Asp	Glu	Glu	Asp	Gly	Arg	Pro	Arg	Arg
		35					40					45			
Leu	Gln	Glu	Gly	Ala	Arg	Arg	Ala	Gly	Arg	Gln	Arg	Gly	Pro	Pro	Arg
	50					55					60				
Ala	Ala	Arg	Thr	Ala	Glu	Thr	Ala	Gln	Arg	Ile	Lys	Arg	Ser	Arg	Arg
65					70					75				80	
Leu	Lys	Ala	Asn	Asn	Arg	Glu	Arg	Asn	Arg	Met	His	Asn	Leu	Asn	Ala
			85						90					95	
Ala	Leu	Asp	Ala	Leu	Arg	Asp	Val	Leu	Pro	Thr	Phe	Pro	Glu	Asp	Ala
			100					105					110		
Lys	Leu	Thr	Lys	Ile	Glu	Thr	Leu	Arg	Phe	Ala	His	Asn	Tyr	Ile	Trp
	115						120					125			
Ala	Leu	Thr	Glu	Thr	Leu	Arg	Leu	Ala	Gly	Ala	Ala	Arg	Leu	Gly	Gly
	130					135					140				

Ala Ala Asp Ala Ala Pro Gly Ala Ala Ala Glu Gly Ser Pro Ser Pro  
 145 150 155 160

Ala Ser Ser Trp Ser Gly Gly Ala Ser Pro Ala Pro Ser Ala Ser Pro  
 165 170 175

Tyr Ala Cys Thr Leu Ser Pro Gly Ser Pro Ala Gly Ser Ala Ser Asp  
 180 185 190

Ala Glu His Trp Pro Pro Pro Arg Gly Arg Phe Ala Pro Pro Pro Pro  
 195 200 205

Pro His Arg Cys Leu  
 210

<210> 22  
 <211> 450  
 <212> DNA  
 <213> MOUSE

<400> 22  
 atgaagtcgg cctgcaaacc ccacggccct cggcggggag ctgcgggcgc gccccgtgc 60  
 gcgggcgag cagagcgcg ggtctcgtgc ggggggcccg ggcggctgga gagcgcggcg 120  
 cgcaggcgtc tggcggccaa cgcgcgcgag cggcgccgca tgcaggggct gaacacggcg 180  
 ttcgaccggc tgcgcagggt ggtgccgcag tggggccagg acaagaagct gtccaagtac 240  
 gagacactgc agatggcgct cagctacatc atcgcgctca cccgcaccc agccgaagcc 300  
 gagcgggact gggtcgggct gcgctgcgag cagcggggcc gcgatcacc ctacctccct 360  
 ttcccggtg ctaggctcca ggtagaccct gagccctatg ggcagaggct cttcggcttc 420  
 cagccggagc ccttccccat ggccagctaa 450

<210> 23  
 <211> 149  
 <212> PRT  
 <213> MOUSE

<400> 23

Met Lys Ser Ala Cys Lys Pro His Gly Pro Pro Ala Gly Ala Arg Gly  
 1 5 10 15

Ala Pro Pro Cys Ala Gly Ala Ala Glu Arg Ala Val Ser Cys Ala Gly  
 20 25 30

Pro Gly Arg Leu Glu Ser Ala Ala Arg Arg Arg Leu Ala Ala Asn Ala  
 35 40 45

Arg Glu Arg Arg Arg Met Gln Gly Leu Asn Thr Ala Phe Asp Arg Leu  
 50 55 60

Arg Arg Val Val Pro Gln Trp Gly Gln Asp Lys Lys Leu Ser Lys Tyr  
 65 70 75 80

Glu Thr Leu Gln Met Ala Leu Ser Tyr Ile Ile Ala Leu Thr Arg Ile

09980381.030602



Thr Gln Gln Pro Phe Pro Gly Ala Ser Asp His Glu Val Leu Ser Ser  
 20 25 30

Asn Ser Thr Pro Pro Ser Pro Thr Leu Ile Pro Arg Asp Cys Ser Glu  
 35 40 45

Ala Glu Val Gly Asp Cys Arg Gly Thr Ser Arg Lys Leu Arg Ala Arg  
 50 55 60

Arg Gly Gly Arg Asn Arg Pro Lys Ser Glu Leu Ala Leu Ser Lys Gln  
 65 70 75 80

Arg Arg Ser Arg Arg Lys Lys Ala Asn Asp Arg Glu Arg Asn Arg Met  
 85 90 95

His Asn Leu Asn Ser Ala Leu Asp Ala Leu Arg Gly Val Leu Pro Thr  
 100 105 110

Phe Pro Asp Asp Ala Lys Leu Thr Lys Ile Glu Thr Leu Arg Phe Ala  
 115 120 125

His Asn Tyr Ile Trp Ala Leu Thr Gln Thr Leu Arg Ile Ala Asp His  
 130 135 140

Ser Phe Tyr Gly Pro Glu Pro Pro Val Pro Cys Gly Glu Leu Gly Ser  
 145 150 155 160

Pro Gly Gly Gly Ser Asn Gly Asp Trp Gly Ser Ile Tyr Ser Pro Val  
 165 170 175

Ser Gln Ala Gly Asn Leu Ser Pro Thr Ala Ser Leu Glu Glu Phe Pro  
 180 185 190

Gly Leu Gln Val Pro Ser Ser Pro Ser Tyr Leu Leu Pro Gly Ala Leu  
 195 200 205

Val Phe Ser Asp Phe Leu  
 210

<210> 26  
 <211> 72  
 <212> DNA  
 <213> MOUSE

<400> 26  
 atgcacgggc tgaatgcggc gctggacaac ccgagaaagg tggtaccttg ctactctaag 60  
 acacagaagc tc 72

<210> 27  
 <211> 24  
 <212> PRT  
 <213> MOUSE

<400> 27

Met His Gly Leu Asn Ala Ala Leu Asp Asn Pro Arg Lys Val Val Pro  
 1 5 10 15

Cys Tyr Ser Lys Thr Gln Lys Leu

<400>	30						
cttaggaagc	gccaaagcccg	cggagcggag	gacaccgtgc	tcggttcggg	gtgggggaca		60
ttcccgga	cacaccggag	cagcagctgc	gccggaacat	tggagccggg	taggtaagt		120
tgcattgccg	ggctttccat	tcgcaggcag	tgtccccacg	caggctcacg	ccgcccacgc		180
taactocac	gtttagacgc	agtgaattct	gtgaccggca	gaagggtggc	cgagcccggg		240
gcgtccctc	ccagctctgt	cctcgccatc	ttcgogaatg	cacattgagg	gagatggagg		300
ggggggggcg	gggcgcggcg	ccagcgcac	tttaccctgt	ccattctggg	aataaatttc		360
atctgcctct	tctttctcag	gatgttcgtc	aaatctgaga	ctctggagtt	gaaggaggaa		420
gaggaggtag	tgatgctgct	gggctcggct	ttcccggcct	cggcgaccct	gaccccgatg		480
tcctccagcg	cggacgagga	ggaggacgag	gagctgcgcc	ggccgggctc	cgcgctggg		540
cagcgtggag	cggaagccga	gcaggggggtg	cagggcagtc	cggcgtcggg	tgccgggggt		600
tgccggccag	ggcggctgct	gggcctgatg	cacgagtgc	agcgtcgccc	gtcgcgctca		660
cgggcctgt	ccgagggtgc	caagacggcg	gagacgggtc	agcgcaccaa	gaagacccgc		720
aggctcaagg	ccaacaaccg	cgagcgcaac	cgcattgcac	acctaaacgc	cgcgctggac		780
gcgtgcgcg	aggtgctgcc	caccttcccc	gaggatgcc	agctcacgaa	gatcgagacg		840
ctgcgcttcg	cccacaatta	catctgggcg	ctcaccgaga	ctctgcgcct	ggcggaccac		900

tgcgcggcg cgggtggcct ccagggggcg ctcttcacgg aggcgggtgct cctgagcccg 960  
 ggagctgcmc tcggcgccag cggggacagc ccttctccac ctctctcctg gagctgcacc 1020  
 aacagcccg cgtcatcctc caactccacg tccccataca gctgcacttt atcgcccgct 1080  
 agccccgggt cagacgtgga ctactggcag cccccacctc cggagaagca tcgttatgcm 1140  
 cctcacctgc cctcgcag ggactgtatc tagagctgcm ggtctccctc tctcgtctcc 1200  
 taccggggcc ctcttccca tcttctccc gccccccacc ctccacgccc cggaatccac 1260  
 ttcacagaac agaagttgcm cctttgcaat cccctccgcm gctggtgctt cgggggttgm 1320  
 aaaacaactc tggtttattg aaattaagat tttggtcaaa aagaatatgc tttttggaat 1380  
 tgggg 1385

<210> 31  
 <211> 263  
 <212> PRT  
 <213> MOUSE

<400> 31

Met Phe Val Lys Ser Glu Thr Leu Glu Leu Lys Glu Glu Glu Glu Val  
 1 5 10 15  
 Leu Met Leu Leu Gly Ser Ala Ser Pro Ala Ser Ala Thr Leu Thr Pro  
 20 25 30  
 Met Ser Ser Ser Ala Asp Glu Glu Glu Asp Glu Glu Leu Arg Arg Pro  
 35 40 45  
 Gly Ser Ala Arg Gly Gln Arg Gly Ala Glu Ala Glu Gln Gly Val Gln  
 50 55 60  
 Gly Ser Pro Ala Ser Gly Ala Gly Gly Cys Arg Pro Gly Arg Leu Leu  
 65 70 75 80  
 Gly Leu Met His Glu Cys Lys Arg Arg Pro Ser Arg Ser Arg Ala Val  
 85 90 95  
 Ser Arg Gly Ala Lys Thr Ala Glu Thr Val Gln Arg Ile Lys Lys Thr  
 100 105 110  
 Arg Arg Leu Lys Ala Asn Asn Arg Glu Arg Asn Arg Met His Asn Leu  
 115 120 125  
 Asn Ala Ala Leu Asp Ala Leu Arg Glu Val Leu Pro Thr Phe Pro Glu  
 130 135 140  
 Asp Ala Lys Leu Thr Lys Ile Glu Thr Leu Arg Phe Ala His Asn Tyr  
 145 150 155 160  
 Ile Trp Ala Leu Thr Glu Thr Leu Arg Leu Ala Asp His Cys Ala Gly  
 165 170 175  
 Ala Gly Gly Leu Gln Gly Ala Leu Phe Thr Glu Ala Val Leu Leu Ser



tgcaagtcta	agttcagggc	atgtgcattc	aactcccttt	cagactggca	ctccccgcta	1200
tgatgttcct	gtagacctga	gctatgattc	ctactcccac	catagcattg	gaactcagct	1260
caatacgate	ttctctgatt	agagcaataa	gataagcacc	aatatttcag	agaatgaagt	1320
ggagattttt	ttcacatttc	tagtggctga	gctaaactct	cagaaaattt	aaaagaacct	1380
ttggatatgc	atcaaacata	atagtccctag	tttgttcaga	acttcctgta	cctgctaact	1440
ttcttcccat	taacttctca	cattggacca	gtcctacatt	tggtaaactt	aagtgaatat	1500
atttgatggg	ttgaggccac	atggtaatat	aacagaaaaga	aagcccaggc	cctgtttccaa	1560
tggtgccaaa	gattaattga	atgctctgcc	aattaacttt	ccatttccag	tgtttttatt	1620
gctttctgat	aaacatgaag	caactgttcc	aatcaacat	atacctttca	cctcccacac	1680
atttttaaat	ttaaaagcaa	tcaaagcaaa	tagcaaaaat	ggaatgatta	tacagaactg	1740
gaaggagcat	caagtacatg	tctgttggct	tatagaatac	aaaatttgtg	tgaatttgac	1800
aatcatctt	tgtgtctatt	taaatataac	ttccagagcc	taaaataata	acttgatgt	1860
taccataaat	aaccagtatg	ttctttaaga	gatcagctct	acttattact	gtgctgaaag	1920
gtatacacac	cttttttagt	gattggagaa	ccatgataga	agcctcacac	aaactttatt	1980
ctttatacta	tttaaaaaac	aactgtctta	gtactaggag	acaagcaaga	aagacattga	2040
aatttctctt	ctggcacaca	gaaatatcac	ctagctcatt	tcttagctcc	cgtgactata	2100
gggctgtaga	attttgcagg	tattcagggtg	cttcagttag	aatcagaact	cagccagggt	2160
catactgtag	agcaataaaa	tggtgggttg	ctgctatccc	aactaacaca	gttaaagaac	2220
tctgcctcac	acatagccac	tggaaaaatg	tggatattct	ccagcaagat	gaatttcact	2280
gtttaaagca	atgcaattaa	agccatagag	tttcgtccac	tcagtatca	tatattccag	2340
aactgttgta	atcaatcttg	aattcttaca	acataaatgc	aactccttac	ttcccaccta	2400
acactgattg	ttatattgtc	ttcaattcca	agatattatg	caattatatg	caaaattttg	2460
attagaatca	aaattaagag	tcaatgaatc	tgtctgtatc	ttcaggacgg	gttttgatca	2520
gttttaagaa	agtttatttt	cctttatgtg	gcatctcttt	tctttgtaac	cacactgggt	2580
cagccaagtt	tctcttctcc	agagaaatta	gctctgagaa	attttactat	catgatccat	2640
cttccacagc	aattatttag	gttcaactca	agagtataca	tagtttattt	atagtgggtg	2700
aggatacacc	tccaagaata	aatttttaaca	acattaatga	catatgaata	tgccatttta	2760
tctaccaaac	tatatatgta	tctcttttct	ttattgccct	tattttattc	ttcacactga	2820
gagttatttt	gtgtccatct	tattgcagca	cttactctgc	tctactttgc	acctttggat	2880
tataaatatg	tttaaaagtc	tgtaaagacg	tcttaaacaa	ctcgtgacag	taattcacca	2940
cccctaagac	cttgaatcac	cctagtggaa	ataggcaagg	agaattattt	atagaatcat	3000





Gly Pro Gln Ser Thr Leu Leu Glu Lys His Glu Glu Lys Ser Ser Ile  
180 185 190

Cys Asp Ser Thr Ile Ser Val His Ser Phe Asn Tyr Gln Ser Pro Gly  
195 200 205

Leu Pro Ser Pro Pro Tyr Gly His Met Glu Thr His Ser Leu His Leu  
210 215 220

Lys Pro Gln Pro Phe Lys Ser Leu Gly Asp Ser Phe Gly Ser His Pro  
225 230 235 240

Pro Asp Cys Ser Thr Pro Pro Tyr Glu Gly Pro Leu Thr Pro Pro Leu  
245 250 255

Ser Ile Ser Gly Asn Phe Ser Leu Lys Gln Asp Gly Ser Pro Asp Leu  
260 265 270

Glu Lys Ser Tyr Asn Phe Met Pro His Tyr Thr Ser Ala Ser Leu Ser  
275 280 285

Ser Gly His Val His Ser Thr Pro Phe Gln Thr Gly Thr Pro Arg Tyr  
290 295 300

Asp Val Pro Val Asp Leu Ser Tyr Asp Ser Tyr Ser His His Ser Ile  
305 310 315 320

Gly Thr Gln Leu Asn Thr Ile Phe Ser Asp  
325 330

<210> 34  
<211> 800  
<212> DNA  
<213> MOUSE

<400> 34  
agggtagtag agtcactaat actacgtcct tgctgtgtag ttttctcagg ttttgattca 60

ttttaagcat gggccaccaa tctcatgtac ctttttagct ttctttccaa gtgtgtctcc 120

agttttctga cccctcct gttttgctg ctctaccctg ccttgtaact ttctaatac 180

aagtcttttc agttccctta gttttcaccc atcaacttca gcagcccaca ccctctagtt 240

ccttcctggt ttaaacaata acaaacacgc agtggcaaag ctggacctgg tcagagaagc 300

cttggtgaagg aggtgtgtct ttaggctagg aaggggaggg gctaccctgt gggcaacatc 360

tcccgccctg gtcagcagcc aaaaccagca aaacggcggc aagtcagaag ctccagtcag 420

atcacaggag ctgccagag actgtggtac tgaaagaact actcgcggga gctgaccccg 480

ggaaagaggt actgaaaaga catagaaaac cagctgtggt ggaggcactg acatgaaggc 540

atcctggtag tgcatcagaa ctccaggaaa aagtagaata agtaacagcc aaggtactca 600

gaccaggaac agtcactaga aggtagctac cagtttaaca tggacgactg aaagggctct 660

ctgtttccca cgatctgcct ggctcaggtca gggtagaact gactgctctg atagttcttc 720



[illegible]

<210>	37
<211>	1412
<212>	DNA
<213>	MOUSE

<400>	37						
cgtgctcggg	tccgggctgc	ggggacattc	ccggacacac	accggagcag	cagctgcgcc		60
gcgacacatc	tggagccgcg	taggatgttc	gtcaaattctg	agactctgga	gttgaaggag		120
gaagaggagg	tactgatgct	gctgggctcg	gttcccccg	cctcggcgac	cctgaccccc		180
atgtcctcca	gcgcggacga	ggaggaggac	gaggagctgc	gccggccggg	ctccgcgcgt		240
gggcagcgtg	gagcgggaagc	cgggcagggg	gtgcaggggca	gtccggcgtc	gggtgcgggg		300
ggttgccggc	cagggcggt	gctgggcctg	atgcacgagt	gcaagcgtcg	cccgctcgcg		360
tcacggggccg	tctcccgagg	tgccaagacg	gcggagacgg	tgcagcgcac	caagaagacc		420
cgcaggctca	aggccaacaa	ccgcgagcgc	aaccgcacgc	acaacctaaa	cgccgcgcctg		480
gacgcgcctg	gcgaggtgct	gccaccttc	cccgaggatg	ccaagctcac	gaagatcgag		540
acgctgcgct	tgcgccacaa	ttacatctgg	gcgctcaccg	agactctgcg	cctggcggac		600
cactgcgcgc	gcgcgggtgg	cctccagggg	gcgctcttca	cggaggcggt	gtcctgagc		660
ccgggagctg	cgctcggcgc	cagcggggac	agcccttctc	caccttcctc	ctggagctgc		720
accaacagcc	cggcgtcatc	ctccaactcc	acgtcccat	acagctgcac	tttatcgccc		780
gctagccccg	ggtcagacgt	ggactactgg	cagcccccac	ctccggagaa	gcacgtttat		840
gcgcctcacc	tgcacctcgc	cagggactgt	atctagagct	gcgggtctcc	ctctctcgtc		900
ctctacccgg	ccctcttccc	atccttctcc	cgccctcac	cctccacgcc	ccggactcca		960
cttcacagag	cagaggtggc	ccttgcaatc	ccctcggcgg	ctggtgcatt	cgggggtgga		1020
gaccagctct	ggtttattga	agatgtgagg	atttatggtc	aaagaggact	atggcgtgtg		1080
ggagtggggg	ctggcgtggg	gaacctcgta	agactgtaaa	agacactgag	aaaaagtacc		1140
ataactaacg	agtgtgcaga	gcagactgac	gtcctcccc	tctctcagag	ctgctggagg		1200
agaactccgg	gcaggcagtt	cgtgtgaatc	tctcagaggg	aatgcaactg	gtccctgtga		1260
tcttttcacc	ttcgtttcta	catagagatg	ttaatgtcag	tcgaaagaaa	tgtatttttag		1320
catctgaatg	aatttactgg	taataatatt	atccacacat	ttgcaatggc	tggcatctgc		1380
tctattccca	ttgctgtctg	caggctgtgg	ga				1412

<210> 38  
 <211> 263  
 <212> PRT  
 <213> MOUSE

<400> 38

```

Met Phe Val Lys Ser Glu Thr Leu Glu Leu Lys Glu Glu Glu Glu Val
1          5          10          15

Leu Met Leu Leu Gly Ser Ala Ser Pro Ala Ser Ala Thr Leu Thr Pro
20          25          30

Met Ser Ser Ser Ala Asp Glu Glu Glu Asp Glu Glu Leu Arg Arg Pro
35          40          45

Gly Ser Ala Arg Gly Gln Arg Gly Ala Glu Ala Gly Gln Gly Val Gln
50          55          60

Gly Ser Pro Ala Ser Gly Ala Gly Gly Cys Arg Pro Gly Arg Leu Leu
65          70          75          80

Gly Leu Met His Glu Cys Lys Arg Arg Pro Ser Arg Ser Arg Ala Val
85          90          95

Ser Arg Gly Ala Lys Thr Ala Glu Thr Val Gln Arg Ile Lys Lys Thr
100         105         110

Arg Arg Leu Lys Ala Asn Asn Arg Glu Arg Asn Arg Met His Asn Leu
115         120         125

Asn Ala Ala Leu Asp Ala Leu Arg Glu Val Leu Pro Thr Phe Pro Glu
130         135         140

Asp Ala Lys Leu Thr Lys Ile Glu Thr Leu Arg Phe Ala His Asn Tyr
145         150         155         160

Ile Trp Ala Leu Thr Glu Thr Leu Arg Leu Ala Asp His Cys Ala Gly
165         170         175

Ala Gly Gly Leu Gln Gly Ala Leu Phe Thr Glu Ala Val Leu Leu Ser
180         185         190

Pro Gly Ala Ala Leu Gly Ala Ser Gly Asp Ser Pro Ser Pro Pro Ser
195         200         205

Ser Trp Ser Cys Thr Asn Ser Pro Ala Ser Ser Ser Asn Ser Thr Ser
210         215         220

Pro Tyr Ser Cys Thr Leu Ser Pro Ala Ser Pro Gly Ser Asp Val Asp
225         230         235         240

Tyr Trp Gln Pro Pro Pro Pro Glu Lys His Arg Tyr Ala Pro His Leu
245         250         255

Pro Leu Ala Arg Asp Cys Ile
260

```

<210> 39  
 <211> 938  
 <212> DNA

20250307 13:00:00

<213> ZEBRA FISH

<400> 39

```

cttatagggc tcgagcggcc gcccgggcag gtcaggtgta agaagagaaa tcttcccagg      60
caaaatatcc gtccctgtat ccatagccac aaactttcct cccaaaagca caaaccaaca      120
gaatggatgg aatgagcacg gatacaagag aggtggttga actcgacgtc cagcattcga      180
gcttggggcg gggggagcag agcaagtacc caccagcctt ggcaatcatg gccagcagtg      240
accacgcgc ctggctggct cccgtgcagg ctggcacctg cgcggcacac gccgaatacc      300
tgctgcactc gcccggtcgc agcgcggaag gcgtgtcctc tgccccaac ttcaggaaga      360
gcagcaagag tctgtcaaaa gtacgcgagc tctgccggct taaaggagct gtgggggcag      420
atgagggcag acagcgggcc ccatccagca aatccaccaa cgtcgtgcag aaacagagggc      480
gaatggctgc caatgcccgc gagaggcgaa gaatgcacgg attgaaccac gcgttcgacg      540
agctgcgcag tgtcatccca gcctttgaca acgacaagaa actctccaag tacgaaaccc      600
tgcagatggc ccagatctac atcaacgccc tgtccgactt actacagggc cccggtgcta      660
aagccgaccg gccaaactgc gacctgtgtc atgccaacgt gttagaaacg gaccgatctc      720
ccagaggatc accgggcgtc tgcgggagag gcacgggcgt gggttaccgc taccagtacg      780
aggacggaac attcaactct ttcattggagc aagacctcca gtcgccctct ggaacgagca      840
agtctggttc ggaggccagt aaagactcgc ctcggtcgaa ccggagtgat ggagaagttc      900
tcgcctcact gaagtgcgag tgagacctgc cggggcgcg                               938

```

<210> 40

<211> 266

<212> PRT

<213> ZEBRA FISH

<400> 40

```

Met Asp Gly Met Ser Thr Asp Thr Arg Glu Val Val Glu Leu Asp Val
1          5          10          15

Gln His Ser Ser Leu Gly Arg Gly Glu Gln Ser Lys Tyr Pro Pro Ala
          20          25          30

Leu Ala Leu Met Ala Ser Ser Asp Pro Arg Ala Trp Leu Ala Pro Val
          35          40          45

Gln Ala Gly Thr Cys Ala Ala His Ala Glu Tyr Leu Leu His Ser Pro
          50          55          60

Gly Ser Ser Ala Glu Gly Val Ser Ser Ala Ser Asn Phe Arg Lys Ser
65          70          75          80

Ser Lys Ser Pro Val Lys Val Arg Glu Leu Cys Arg Leu Lys Gly Ala
          85          90          95

```

Val Gly Ala Asp Glu Gly Arg Gln Arg Ala Pro Ser Ser Lys Ser Thr  
100 105 110

Asn Val Val Gln Lys Gln Arg Arg Met Ala Ala Asn Ala Arg Glu Arg  
115 120 125

Arg Arg Met His Gly Leu Asn His Ala Phe Asp Glu Leu Arg Ser Val  
130 135 140

Ile Pro Ala Phe Asp Asn Asp Lys Lys Leu Ser Lys Tyr Glu Thr Leu  
145 150 155 160

Gln Met Ala Gln Ile Tyr Ile Asn Ala Leu Ser Asp Leu Leu Gln Gly  
165 170 175

Pro Gly Ala Lys Ala Asp Pro Pro Asn Cys Asp Leu Leu His Ala Asn  
180 185 190

Val Leu Glu Thr Asp Arg Ser Pro Arg Gly Ser Pro Gly Val Cys Arg  
195 200 205

Arg Gly Thr Gly Val Gly Tyr Pro Tyr Gln Tyr Glu Asp Gly Thr Phe  
210 215 220

Asn Ser Phe Met Glu Gln Asp Leu Gln Ser Pro Ser Gly Thr Ser Lys  
225 230 235 240

Ser Gly Ser Glu Ala Ser Lys Asp Ser Pro Arg Ser Asn Arg Ser Asp  
245 250 255

Gly Glu Val Leu Ala Ser Leu Lys Cys Glu  
260 265

<210> 41  
<211> 948  
<212> DNA  
<213> FROG

<400> 41  
atgtcagaga tgggtcaatgt gcatgggtgg atggaggaag cccttagttc ccaggatgag 60

atgaaggaga ggaatcagtc tgcctatgat atcatttcag gtctatgcca tgaggaaagg 120

ggcagcattg atggagaaga ggatgatgaa gaagaagagg atggagagaa accaaaaaag 180

aggggaccca aaaaaaagaa gatgaccaag gctagagtgg agaggttccg tgtccgtaga 240

gtaaaagcca atgccaggga gcgttcaaga atgcatggac ttaatgatgc cctggaaaat 300

ttgagaaggg ttatgccttg ctattccaaa acacaaaagt tgtctaaaat tgagactctt 360

agactggcca gaaactatat atgggcatta totgatattc tagaacaagg tcaaaatgca 420

gagggaaagg gctttctgga aatactctgc aaaggtcttt ctacagccaac aagcaactta 480

gtagctggct gcttgcaact tggacctcag gccatgttct tggataaaca cgaagaaaag 540

tctcatatat gtgattcctc tcttactggc catacttata attaccagtc cccaggacta 600

cccagtcctc cttatggtaa cattgatgtt caccacttgc acttgaaacc ctcttctttc 660

2090301.030606





225				230					235					240	
Glu	Gly	Ala	Leu	Thr 245	Pro	Pro	Leu	Ser	Ile 250	Gly	Gly	Asn	Phe	Ser 255	Leu
Lys	Gln	Asp	Ser 260	Ser	Pro	Asp	Met	Asp 265	Lys	Ser	Tyr	Ala	Phe 270	Arg	Ser
Pro	Tyr	Pro 275	Ala	Leu	Gly	Leu	Gly 280	Gly	Ser	His	Gly	His 285	Ala	Ser	His
Phe	His 290	Thr	Ser	Val	Pro	Arg 295	Tyr	Glu	Leu	Pro	Ile 300	Asp	Met	Ala	Tyr
Glu 305	Pro	Tyr	Pro	His	His 310	Ala	Ile	Phe	Thr	Glu 315					

<210>	43
<211>	1550
<212>	DNA
<213>	MOUSE

<400>	43						
tttaaatact	gtgctggcat	tttttttcag	gtaaattaag	gttaaagaac	catgttaaca	60	
ctaccgtttg	acgagtctgt	cgtaatgccc	gaatcccaga	tgtgcagaaa	gtttgctaga	120	
caatgtgagg	accagaaaca	aattaagaaa	ccagagagct	ttccaaaaca	agttgtcctt	180	
cgaggaaaga	gcattaaaag	ggcccctgga	gaagaaaccg	agaaagaaga	ggaggaagaa	240	
gacagagagg	aagaagatga	gaatggcttg	tccagaagga	gggggctcag	gaaaaaaaaag	300	
accaccaaac	tacgactgga	aaggggtcaag	ttcaggagac	aggaagctaa	tgcgcgcgag	360	
aggaaccgga	tgcacggcct	caatgatgct	ctggacaatt	tgcgaaaagt	gttcccctgt	420	
tactctaaaa	cccaaaaact	gtccaaaata	gaaactttac	gactggccaa	aaattacatc	480	
tgggcacttt	ctgaaattct	gaggattggc	aagagaccgg	atctgctcac	gttcgtccaa	540	
aacttatgca	aaggtctttc	ccagccaact	acaaacttgg	tggcaggctg	cttacagctc	600	
aacgccagaa	gtttcctgat	gggtcagggt	ggggaggctg	cccaccacac	aaggtcaccc	660	
tactccacat	tctaccacc	ctaccacagc	cctgagctgg	ccactcccc	agggcatggg	720	
actcttgata	attccaagtc	catgaaacct	tacaattact	gcagtgcata	tgaatccttc	780	
tatgaaagta	cctccccctga	gtgtgccagc	cctcagtttg	aaggtccctt	aagtcctccc	840	
ccaattaact	ataatgggat	attttccctg	aagcaagaag	aaaccttgga	ctatggcaaa	900	
aattacaatt	atggcatgca	ttactgtgca	gtgccacca	gggggtccct	tgggcaggggt	960	
gccatgttca	ggttgcccac	cgacagccac	ttcccttacg	acttacatct	gcgcagccaa	1020	
tctctcacta	tgcaagatga	attaaatgca	gtttttcata	attaatgagg	aaaattaaaa	1080	
taaacagtgg	tcattcacct	cccactctaa	ttaaggcaaa	gcagatgctt	gtgggctgag	1140	

[illegible]

<400> 44

Gly Gly Glu Ala Ala His His Thr Arg Ser Pro Tyr Ser Thr Phe Tyr  
195 200 205

Pro Pro Tyr His Ser Pro Glu Leu Ala Thr Pro Pro Gly His Gly Thr  
 210 215 220  
 Leu Asp Asn Ser Lys Ser Met Lys Pro Tyr Asn Tyr Cys Ser Ala Tyr  
 225 230 235 240  
 Glu Ser Phe Tyr Glu Ser Thr Ser Pro Glu Cys Ala Ser Pro Gln Phe  
 245 250 255  
 Glu Gly Pro Leu Ser Pro Pro Pro Ile Asn Tyr Asn Gly Ile Phe Ser  
 260 265 270  
 Leu Lys Gln Glu Glu Thr Leu Asp Tyr Gly Lys Asn Tyr Asn Tyr Gly  
 275 280 285  
 Met His Tyr Cys Ala Val Pro Pro Arg Gly Pro Leu Gly Gln Gly Ala  
 290 295 300  
 Met Phe Arg Leu Pro Thr Asp Ser His Phe Pro Tyr Asp Leu His Leu  
 305 310 315 320  
 Arg Ser Gln Ser Leu Thr Met Gln Asp Glu Leu Asn Ala Val Phe His  
 325 330 335

Asn

<210> 45  
 <211> 1393  
 <212> DNA  
 <213> MOUSE

<400> 45  
 aagcttcggt gcacgcgacc tgggtgtgcga tctccgagtg agaggggggag ggtcagagga 60  
 ggaaggaaaa aaaatcagac cttgcagaag agactaggaa ggtttttggt gttgttggtc 120  
 ggggcttatt cccttcggtg aactgggttg ccagcacctc ctctaacacg gcacctccga 180  
 gccattgcag tgcgatgtcc cgcctgctgc atgcagaaga gtgggctgag gtaaaagagt 240  
 tgggggacca ccatcgccat cccagccgc accacgtccc gccgctgacg ccacagccac 300  
 ctgctaccct gcaggcgaga gaccttcccg tctaccggc agaactgtcc ctctggata 360  
 gcaccgaccc acgcgcctgg ctgactccca ctttgaggg cctctgcacg gcacgcgccg 420  
 cccagtatct gctgcattct cccgagctgg gtgcctccga ggccgcggcg ccccgggacg 480  
 aggctgacag ccagggtgag ctggtaagga gaagcggctg tggcggcctc agcaagagcc 540  
 ccgggcccgt caaagtacgg gaacagctgt gcaagctgaa ggggtggggt gtagtggacg 600  
 agcttggtg cagccgccag cgagcccctt ccagcaaaca ggtgaatggg gtacagaagc 660  
 aaaggaggct ggcagcaaac gcaagggaac ggcgcaggat gcacgggctg aaccacgcct 720  
 tcgaccagct gcgcaacgtt atcccgtcct tcaacaacga caagaagctg tccaaatatg 780  
 agaccctaca gatggcccag atctacatca acgctctgtc ggagttgctg cagactccca 840

20090601 13:00:00



Asp Gln Leu Arg Asn Val Ile Pro Ser Phe Asn Asn Asp Lys Lys Leu  
180 185 190

Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile Asn Ala Leu  
195 200 205

Ser Glu Leu Leu Gln Thr Pro Asn Val Gly Glu Gln Pro Pro Pro Pro  
210 215 220

Thr Ala Ser Cys Lys Asn Asp His His His Leu Arg Thr Ala Ser Ser  
225 230 235 240

Tyr Glu Gly Gly Ala Gly Ala Ser Ala Val Ala Gly Ala Gln Pro Ala  
245 250 255

Pro Gly Gly Gly Pro Arg Pro Thr Pro Pro Gly Pro Cys Arg Thr Arg  
260 265 270

Phe Ser Gly Pro Ala Ser Ser Gly Gly Tyr Ser Val Gln Leu Asp Ala  
275 280 285

Leu His Phe Pro Ala Phe Glu Asp Arg Ala Leu Thr Ala Met Met Ala  
290 295 300

Gln Lys Asp Leu Ser Pro Ser Leu Pro Gly Gly Ile Leu Gln Pro Val  
305 310 315 320

Gln Glu Asp Asn Ser Lys Thr Ser Pro Arg Ser His Arg Ser Asp Gly  
325 330 335

Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu Ala Ser  
340 345 350

<210> 47  
<211> 993  
<212> DNA  
<213> MOUSE

<400> 47  
atggcaaaaa tgtatatgaa atccaaggac atggtggagc tgggtcaacac acaatcctgg 60  
atggacaaaag gtctgagctc tcaaaatgag atgaaggagc aagagagaag accgggctct 120  
tatggaatgc tcggaacott aactgaagag catgacagta ttgaggagga tgaagaagag 180  
gaagaagatg gagataaacc taaaagaaga ggtcccaaga aaaagaagat gactaaagct 240  
cgccttgaaa gattcagggc togaagagtc aaggccaatg ctagagaacg gaccgggatg 300  
catggcctga atgatgcctt ggataatcctt aggagagtca tgccatgtta ctctaaaact 360  
caaaagcttt ccaagataga gactcttcga ctggcaagga actacatctg ggcttgtct 420  
gaagtcctgg agactgggtca gacacttgaa gggaagggat ttgtagagat gctatgtaaa 480  
ggtctctctc aaccacaaag caacctgggt gctggatgcc tccaactggg gctcaatct 540  
accctcctgg agaagcatga ggaaaaatct tcaatttgtg actctactat ctctgtccac 600  
agcttcaact atcagtctcc agggctcccc agcctcctt atggccatat ggaaacacat 660



Lys Pro Gln Pro Phe Lys Ser Leu Gly Asp Ser Phe Gly Ser His Pro  
 225 230 235 240  
 Pro Asp Cys Ser Thr Pro Pro Tyr Glu Gly Pro Leu Thr Pro Pro Leu  
 245 250 255  
 Ser Ile Ser Gly Asn Phe Ser Leu Lys Gln Asp Gly Ser Pro Asp Leu  
 260 265 270  
 Glu Lys Ser Tyr Asn Phe Met Pro His Tyr Thr Ser Ala Ser Leu Ser  
 275 280 285  
 Ser Gly His Val His Ser Thr Pro Phe Gln Thr Gly Thr Pro Arg Tyr  
 290 295 300  
 Asp Val Pro Val Asp Leu Ser Tyr Asp Ser Tyr Ser His His Ser Ile  
 305 310 315 320  
 Gly Thr Gln Leu Asn Thr Ile Phe Ser Asp  
 325 330

<210> 49  
 <211> 2264  
 <212> DNA  
 <213> FROG

<400> 49  
 gacagtcagt agatgctcct ttcccaaagt gtatcttgca gtagccttac actaatactg 60  
 cctgtcttgt agctggagag ctttgtatcg atgctaagag cactgggtat ctacaaagag 120  
 gatcactgca tatgaatgga ataaggagtg ctgctgctac ccaggtggg gtttgttccg 180  
 agcccttcaa aaccttttgg ccatagaatc actgtgttga catgaagtca gattcaccag 240  
 tgcattggga gtccatact gaatgccagt caccatgcc actaagttgc atgccagcca 300  
 ggctggaagg ctctaccaag agacgtctgg ctgccaatgc cagggaaaga aggagaatgc 360  
 aaggactgaa taccgccttc gatagtctga ggaaagttgt accgcaatgg ggtgaggaca 420  
 aaaaactttc caagtatgag actctacaga tggcactgag ctacatcatg gcactaagca 480  
 ggatcctcac ggaagcagaa agatacagca gaactgatcc aggggaatgg actaaaatgc 540  
 actttgatca cattcaggaa gaacagtgcc tcagttatat gggagtgaga tgcccaagag 600  
 actgtgatcg ctacctgcc cagacttttt ctactagga taggagatgt gagcaacagt 660  
 cagcaggcaa ggtactatag acctgaagat agcagtgtat tcctacacac agcagccaat 720  
 aatacaggga catttgcatc atgggttatt tgtcatgtca ttctgccc aa tgcactgctt 780  
 atttcattaa gcacccaaag tcccaggact gggaatatat gtagggcacc ccacgtgatg 840  
 cagcccaaag tatgtgctgc tgcaactgat agtgagctgt gggacactgg aaaagcaaag 900  
 tgcgctggta ttttgtaaat gaaaatgtca ttatgggtgg catataataa ttacttacac 960  
 acagcacagt tatataatct cattgtgtgt agaaagcccc tttgtctctt acccccatc 1020

209060-18E08660





50 55 60  
 Glu Asp Lys Lys Leu Ser Lys Tyr Glu Thr Leu Gln Met Ala Leu Ser  
 65 70 75 80  
 Tyr Ile Met Ala Leu Ser Arg Ile Leu Thr Glu Ala Glu Arg Tyr Ser  
 85 90 95  
 Arg Thr Asp Pro Gly Glu Trp Thr Lys Met His Phe Asp His Ile Gln  
 100 105 110  
 Glu Glu Gln Cys Leu Ser Tyr Met Gly Val Arg Cys Pro Arg Asp Cys  
 115 120 125  
 Asp Arg Tyr Leu Pro Gln Thr Phe Ser His  
 130 135

<210> 51  
 <211> 2123  
 <212> DNA  
 <213> FROG

<400> 51  
 gacagtcagt agatgctcct tgccctgaagt gtatcttgca gtagccttac actgccttgt 60  
 agctggagag ccttgatatca ctgctaacaa cactgggtat caacaaagaa gacaactgca 120  
 taaaaatgaa ataaggagat actaccagg ctgggggttta ttttgagtct ttcagaactt 180  
 tctagggata gaatatctct gctgacatga agtcagattc accagtgcac agggagtccc 240  
 atactggatg ccagtcacca tgcccactaa ggtgcttgcc agccaggctg gaaggctcta 300  
 ccaagagacg tctggctgcc aatgccagag aaaggaggag aatgcaagga ctaaataccg 360  
 ccttcgatag tctgaggaaa gttgtaccac aatgggggtga agacaaacaa ctttccaaat 420  
 atgagactct gcagatggcg ctgagctaca tcatggcact gagcaggatc ctctcggaag 480  
 cagagaggta cagcaggact gatccagagg aatggactaa tattcaatat gatcacattg 540  
 aggaggagca gtgcctcagt tatatggagg tgagatgcc aagagactgt gatcgttacc 600  
 tgccccagac tttttctcac taggataaga gcaggcaagg tactactgac ctgaagacag 660  
 cactgtttta atataatggg tcggttatac agcacccaat gatacaggga catttgcac 720  
 atgggctatt tgtcatgttg tttttoccaa tgcaatgctt atttccttaa gcaccctacg 780  
 ttcaggactg ggtacatatg tagggaaccc caagtgatgc agcccagagg atgcggtgct 840  
 gcaacggatg gcagtttagt agctgtggaa cactggaaaa gccaaagtga ctggtatattt 900  
 gtgaaaggac atgcaagtta ttatgggtgg catataatat ttacctccat acagcacagt 960  
 gatataactt cattgcctcc atcatacctg tgtgattata tataaaatgg tagttcctga 1020  
 gtcactactt tccatgttac ttatgcactg ttatcagata acatagagaa agtagtattt 1080  
 atacattaga aaaagtacta tatgtgcata taaattggcg tttaaagcag tctggataaa 1140

tcattttctg tggactcttt tottaccocca aggagccatt tatagtttaa gtgctgctat 1200  
aggcactgct cataagggaa aggaaacatt tttgtcactt gctgataata caaattgcat 1260  
tctacaccag aattcttaat taactatact gtctagttaa cagaaaggtc taaattaaaa 1320  
tcaacaagag gtataattta cataattttac cattttctgg cttctgtctg ctttttgaga 1380  
gtggcaaatt acaacgtata taaaattcct acaggctctca atctacttgt tgctgtaaag 1440  
acaaaccttg gtgtattttt aaggaaacct taagtaattc ttttggttag tatacatttc 1500  
ttaaataattt ttatttgtaa tgggogtcaa ttgtttattt gtaaacgcag ctccaaaaat 1560  
agcagatatg cttgtatttt tcagggtatgc aaatggattt tcagcctata ttgggaaagc 1620  
agtaagcaaa tctttgtaat tgaaattgta gtaaaactga acatatgggtg aattgcttgg 1680  
caatgtactg tatacatgct gacctataag ggctatgtag caaagttggg aaaaagtttt 1740  
ccctatcaaa atcactgcag gtttattggg ttgttgcaga tagaataata aaatctgaca 1800  
ttgctgatgt gggttaaggta ttttattccc catttaatat cttaatcttt cttcttacac 1860  
tgaaaacatt actagccctt tgccaatgta ttcttatctg tcaaattcag gagttcatga 1920  
gacttacctg tacataatcc ctatgaaacc aagacaatgt gtggggaata agaggatttg 1980  
ctgcacaaat tagggcagag atacatgggtc tgactgtgac aaatctcctc ttcttcggag 2040  
cgtttaatct ccccaaactg cttttccagg cactttgttc tccgaagtcg cccgaagttg 2100  
cctaacgagg caacttcagc acg 2123

<210> 52  
<211> 138  
<212> PRT  
<213> FROG

<400> 52

Met Lys Ser Asp Ser Pro Val His Arg Glu Ser His Thr Gly Cys Gln  
1 5 10 15

Ser Pro Cys Pro Leu Arg Cys Leu Pro Ala Arg Leu Glu Gly Ser Thr  
20 25 30

Lys Arg Arg Leu Ala Ala Asn Ala Arg Glu Arg Arg Arg Met Gln Gly  
35 40 45

Leu Asn Thr Ala Phe Asp Ser Leu Arg Lys Val Val Pro Gln Trp Gly  
50 55 60

Glu Asp Lys Gln Leu Ser Lys Tyr Glu Thr Leu Gln Met Ala Leu Ser  
65 70 75 80

Tyr Ile Met Ala Leu Ser Arg Ile Leu Ser Glu Ala Glu Arg Tyr Ser  
85 90 95

Arg Thr Asp Pro Glu Glu Trp Thr Asn Ile Gln Tyr Asp His Ile Glu

100	105	110	
Glu Glu Gln Cys Leu Ser Tyr Met Glu Val Arg Cys Pro Arg Asp Cys			
115	120	125	
Asp Arg Tyr Leu Pro Gln Thr Phe Ser His			
130	135		
<210> 53			
<211> 136			
<212> DNA			
<213> BEETLE			
<400> 53			
gcggcgaatg cgcgcgagcg gcggcggatg aacggcctga atgaagcttt cgatcggcta			60
agacaagtta taccaagcctt ggacgctgac cacaaattga gcaagtttga gactctgcag			120
atggcccaga cctaca			136
<210> 54			
<211> 45			
<212> PRT			
<213> BEETLE			
<400> 54			
Ala Ala Asn Ala Arg Glu Arg Arg Arg Met Asn Gly Leu Asn Glu Ala			
1	5	10	15
Phe Asp Arg Leu Arg Gln Val Ile Pro Ser Leu Asp Ala Asp His Lys			
	20	25	30
Leu Ser Lys Phe Glu Thr Leu Gln Met Ala Gln Thr Tyr			
	35	40	45
<210> 55			
<211> 137			
<212> DNA			
<213> BEETLE			
<400> 55			
gcggcgaatg cgagggagag gcggaggatg aacagtttga atgacgcctt cgacaggctg			60
cgggacgtgg tgccgtccct tgggaacgat cggaagctgt ccaagtttga gacacttcag			120
atggcccaga cctacat			137
<210> 56			
<211> 45			
<212> PRT			
<213> BEETLE			
<400> 56			
Ala Ala Asn Ala Arg Glu Arg Arg Arg Met Asn Ser Leu Asn Asp Ala			
1	5	10	15
Phe Asp Arg Leu Arg Asp Val Val Pro Ser Leu Gly Asn Asp Arg Lys			

20

25

30

Leu Ser Lys Phe Glu Thr Leu Gln Met Ala Gln Thr Tyr  
 35 40 45

&lt;210&gt; 57

&lt;211&gt; 1572

&lt;212&gt; DNA

&lt;213&gt; HUMAN

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1497)..(1497)

&lt;223&gt; "n" can be any nucleotide

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1504)..(1504)

&lt;223&gt; "n" can be any nucleotide

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1526)..(1526)

&lt;223&gt; "n" can be any nucleotide

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1564)..(1564)

&lt;223&gt; "n" can be any nucleotide

&lt;400&gt; 57

gtcctctgca cacaagaact ttctctgggg tgtaaaaact ctttgattgg ctgctcgcac 60

gcgcttgcgc gcgcccctcca ttggctgaga agacacgcga ccggcgcgag gaggggggttg 120

ggagaggagc ggggggagac tgagtggcgc gtgcgccttt ttaaaggggc gcagcgcctt 180

cagcaaccgg agaagcatag ttgcacgcga cctggtgtgt gatctccgag tgggtggggg 240

agggctcagg agggaaaaaa aaataagacg ttgcagaaga gacccggaaa gggccttttt 300

tttggttgag ctggtgtccc agtgtgcct ccgatactga gcgtccgagc ctttgagtg 360

caatgtcccg cctgctgcat gcagaagagt gggctgaagt gaaggagttg ggagaccacc 420

atgccagcc ccagccgcat catctccgc aaccgccgcc gccgccgag ccacctgcaa 480

ctttgcaggc gagagagcat ccggtctacc cgctgagct gtccctcctg gacagcacccg 540

acccacgcgc ctggctggct ccacttttg agggcatctg cacggcacgc gccgccagt 600

atttgctaca ttccccggag ctgggtgcct cagaggccgc tgcgcccgg gacgaggtgg 660

acggccgggg ggagctggta aggaggagca gcggcggtgc cagcagcagc aagagccccg 720

ggccggtgaa agtgcgggaa cagctgtgca agctgaaagg cgggggtggtg gtagacgagc 780

0990391.030600

Descriptive Statistics	
Mean	1.00
Standard Deviation	1.00
Minimum	0.00
Maximum	2.00
Frequency	
0	100
1	100
2	100
Total	
300	300
Descriptive Statistics	
Mean	1.00
Standard Deviation	1.00
Minimum	0.00
Maximum	2.00
Frequency	
0	100
1	100
2	100
Total	
300	300
Descriptive Statistics	
Mean	1.00
Standard Deviation	1.00
Minimum	0.00
Maximum	2.00
Frequency	
0	100
1	100
2	100
Total	
300	300
Descriptive Statistics	
Mean	1.00
Standard Deviation	1.00
Minimum	0.00
Maximum	2.00
Frequency	
0	100
1	100
2	100
Total	
300	300

<400> 58

Cys Lys Leu Lys Gly Gly Val Val Val Asp Glu Leu Gly Cys Ser Arg

130		135		140
Gln Arg Ala Pro Ser Ser Lys Gln Val Asn Gly Val Gln Lys Gln Arg				
145		150	155	160
Arg Leu Ala Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn				
	165	170		175
His Ala Phe Asp Gln Leu Arg Asn Val Ile Pro Ser Phe Asn Asn Asp				
	180	185		190
Lys Lys Leu Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile				
	195	200		205
Asn Ala Leu Ser Glu Leu Leu Gln Thr Pro Ser Gly Gly Glu Gln Pro				
	210	215		220
Pro Pro Pro Pro Ala Ser Cys Lys Ser Asp His His His Leu Arg Thr				
	225	230	235	240
Ala Ala Ser Tyr Glu Gly Gly Ala Gly Asn Ala Thr Ala Ala Gly Ala				
	245	250		255
Gln Gln Ala Ser Gly Gly Ser Gln Arg Pro Thr Pro Pro Gly Ser Cys				
	260	265		270
Arg Thr Arg Phe Ser Ala Pro Ala Ser Ala Gly Gly Tyr Ser Val Gln				
	275	280		285
Leu Asp Ala Leu His Phe Ser Thr Phe Glu Asp Ser Ala Leu Thr Ala				
	290	295		300
Met Met Ala Gln Lys Asn Leu Ser Pro Ser Leu Pro Gly Ser Ile Leu				
	305	310	315	320
Gln Pro Val Gln Glu Glu Asn Ser Lys Thr Ser Pro Arg Ser His Arg				
	325	330		335
Ser Asp Gly Glu Phe Ser Pro His Ser His Tyr Ser Asp Ser Asp Glu				
	340	345		350

Ala Ser

<210> 59  
 <211> 485  
 <212> DNA  
 <213> CHICKEN

<220>  
 <221> misc\_feature  
 <222> (147)..(147)  
 <223> "n" can be any nucleotide

<400> 59	
ccgctgctgg ggcgggacgg ggcggctgcg gcttcgcccc cggctggctg ggcgtgtgct	60
gcgccgcacg cgtgcccgcc gcgtogccgc gctacctgct gcccgccgac gaggaggacg	120
aggcggcccc tggcgggggg cgcggcncgc gttccggcgg gagcagcccc gggggagcgc	180

ggggcggcgg cgggcgcgcg gggcggcggc ggcggggccg ggccgcgggc gcaggtgagc 240  
 ggcgtgcaga agcagcgggc gctggcggcc aacgcgcggg agcggcgggc gatgcacggg 300  
 ctgaaccacg ccttcgacca gctgcgtaat gtcatcccct ccttcaacaa cgacaagaag 360  
 ctctccaagt acgagacgct gcagatggcg caaatctaca tcagcgccct cgccgagctg 420  
 ctgcacgggc cgcccgcgcc ccccgagccg cccgcgaagg ccgagctccg cggggccccc 480  
 ttoga 485

<210> 60  
 <211> 161  
 <212> PRT  
 <213> CHICKEN

<400> 60

Pro Leu Leu Gly Pro Asp Gly Ala Ala Ala Ala Ser Pro Pro Ala Gly  
 1 5 10 15  
 Trp Ala Cys Ala Ala Pro His Ala Cys Pro Pro Arg Arg Arg Ala Thr  
 20 25 30  
 Cys Cys Pro Pro Thr Arg Arg Thr Arg Arg Pro Val Ala Gly Gly Ala  
 35 40 45  
 Ala Arg Val Pro Ala Gly Ala Ala Pro Gly Glu Arg Gly Ala Ala Ala  
 50 55 60  
 Gly Ala Arg Gly Gly Gly Gly Gly Ala Gly Pro Arg Ala Gln Val Ser  
 65 70 75 80  
 Gly Val Gln Lys Gln Arg Arg Leu Ala Ala Asn Ala Arg Glu Arg Arg  
 85 90 95  
 Arg Met His Gly Leu Asn His Ala Phe Asp Gln Leu Arg Asn Val Ile  
 100 105 110  
 Pro Ser Phe Asn Asn Asp Lys Lys Leu Ser Lys Tyr Glu Thr Leu Gln  
 115 120 125  
 Met Ala Gln Ile Tyr Ile Ser Ala Leu Ala Glu Leu Leu His Gly Pro  
 130 135 140  
 Pro Ala Pro Pro Glu Pro Pro Ala Lys Ala Glu Leu Arg Gly Ala Pro  
 145 150 155 160

Phe

<210> 61  
 <211> 138  
 <212> DNA  
 <213> PUFFER FISH

<400> 61  
 gcggcgaacg cgagggagag gaggagaatg cacggcctga ataaagcgtt tgacgaactg 60

20250301 090600

aggagcgtca ttccttcctt ggaaaatgag agaaagctct ccaagtatga cactctccag 120  
atggcccaaa cctacatc 138

<210> 62  
<211> 46  
<212> PRT  
<213> PUFFER FISH

<400> 62

Ala Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn Lys Ala  
1 5 10 15

Phe Asp Glu Leu Arg Ser Val Ile Pro Ser Leu Glu Asn Glu Arg Lys  
20 25 30

Leu Ser Lys Tyr Asp Thr Leu Gln Met Ala Gln Thr Tyr Ile  
35 40 45

<210> 63  
<211> 1477  
<212> DNA  
<213> DROSOPHILA

<400> 63

atcatcttgt tagcggcttt agagccgaat cgttttctag cgccatttta agctcgcaac 60  
gaactgaggt ataaccgggc tctctgagac cgctgcaact caccaccaac tgccattggt 120  
cgtgccactc gggcggcacg tctctgcttc tgtggcaact cgtttacctg cccccctacc 180  
tgcccttcag gcccttctga ccgtcgtggt ggatttgtga gtataaatag ggccgaaagg 240  
acgagagacc agtcagaaac ccgccagcac tcgcagcggt cgatatggtt catccagcaa 300  
cataacacca ccatacagca gcagcaacat gtcgtccagt gagatctatc gctactacta 360  
caagacctcc gaggacttgc agggcttcaa gacagccgcc gccgagccgt acttcaatcc 420  
catggcagcc tacaatcccg gcgtgacca ctaccagttc aatggcaaca ccttgccag 480  
cagcagcaac tacttgtcgg ccaatggctt catcagcttc gagcaggcca gttccgatgg 540  
ctggatctcc tctcgcggg ctagccaccg atctgagagt cccgagtatg tggatctcaa 600  
taccatgtac aatggaggct gcaacaacat ggcccagaac caacaatacg gaatgattat 660  
ggagcagtct gttgtttcca cagcgcctgc aattccagtg gcctctctc cggcagtgga 720  
ggtcatgggc tctccaacg tgggcacttg caaaacgatt ccagcctcag cagctccgaa 780  
accgaagcgt agctatacca agaagaacca gccaaagcacc accgccacct ccacaccgac 840  
tgcagctgcg gactcatctg cctcagtga tctctacacg gaggagttcc agaactttga 900  
ctttgacaac tccgccttgt tcgatgacag cgtcgaggat gacgaggacc tcatgctctt 960  
cagtggcggt gaggacttgc atggcaatga tggatcctt gacttggccg atggtgagaa 1020

209050 "TBE00000"



ccaagatgcc gctgccggag gctctggaaa gaagaggcgt ggcaagcaga tcacacccgt 1080  
 cgtgaagagg aagcgtcgcc tggccgccaa tgcacgtgag cgtcgtcgga tgcagaacct 1140  
 caaccaggcc ttcgatcgtc tccgccagta ccttccctgt ctgggaaacg atcgccagct 1200  
 gtccaaacac gagaccctcc aaatggccca gacctacata tccgctctcg gggatctgct 1260  
 gcgctgaatt cccggatccc gatcccagtc ccaagtacta ttctcagtta ttgttgagc 1320  
 ttgccaaatg ttgtagctac tttgtatata ttgcctggag cccagtagtg aattaccgct 1380  
 taagtattat gctgtttatt gtttagttaa ttagcctaaa tggaagacaa tgattaagac 1440  
 taaggaagac aaaataaaaag caccattaat aatttaa 1477

<210> 64  
 <211> 312  
 <212> PRT  
 <213> DROSOPHILA

<400> 64

Met	Ser	Ser	Ser	Glu	Ile	Tyr	Arg	Tyr	Tyr	Tyr	Lys	Thr	Ser	Glu	Asp	1	5	10	15
Leu	Gln	Gly	Phe	Lys	Thr	Ala	Ala	Ala	Glu	Pro	Tyr	Phe	Asn	Pro	Met	20	25	30	
Ala	Ala	Tyr	Asn	Pro	Gly	Val	Thr	His	Tyr	Gln	Phe	Asn	Gly	Asn	Thr	35	40	45	
Leu	Ala	Ser	Ser	Ser	Asn	Tyr	Leu	Ser	Ala	Asn	Gly	Phe	Ile	Ser	Phe	50	55	60	
Glu	Gln	Ala	Ser	Ser	Asp	Gly	Trp	Ile	Ser	Ser	Ser	Pro	Ala	Ser	His	65	70	75	80
Arg	Ser	Glu	Ser	Pro	Glu	Tyr	Val	Asp	Leu	Asn	Thr	Met	Tyr	Asn	Gly	85	90	95	
Gly	Cys	Asn	Asn	Met	Ala	Gln	Asn	Gln	Gln	Tyr	Gly	Met	Ile	Met	Glu	100	105	110	
Gln	Ser	Val	Val	Ser	Thr	Ala	Pro	Ala	Ile	Pro	Val	Ala	Ser	Pro	Pro	115	120	125	
Ala	Val	Glu	Val	Met	Gly	Ser	Ser	Asn	Val	Gly	Thr	Cys	Lys	Thr	Ile	130	135	140	
Pro	Ala	Ser	Ala	Ala	Pro	Lys	Pro	Lys	Arg	Ser	Tyr	Thr	Lys	Lys	Asn	145	150	155	160
Gln	Pro	Ser	Thr	Thr	Ala	Thr	Ser	Thr	Pro	Thr	Ala	Ala	Ala	Glu	Ser	165	170	175	
Ser	Ala	Ser	Val	Asn	Leu	Tyr	Thr	Glu	Glu	Phe	Gln	Asn	Phe	Asp	Phe	180	185	190	

009031-03060

Asp Asn Ser Ala Leu Phe Asp Asp Ser Val Glu Asp Asp Glu Asp Leu  
 195 200 205  
 Met Leu Phe Ser Gly Gly Glu Asp Phe Asp Gly Asn Asp Gly Ser Phe  
 210 215 220  
 Asp Leu Ala Asp Gly Glu Asn Gln Asp Ala Ala Ala Gly Gly Ser Gly  
 225 230 235 240  
 Lys Lys Arg Arg Gly Lys Gln Ile Thr Pro Val Val Lys Arg Lys Arg  
 245 250 255  
 Arg Leu Ala Ala Asn Ala Arg Glu Arg Arg Arg Met Gln Asn Leu Asn  
 260 265 270  
 Gln Ala Phe Asp Arg Leu Arg Gln Tyr Leu Pro Cys Leu Gly Asn Asp  
 275 280 285  
 Arg Gln Leu Ser Lys His Glu Thr Leu Gln Met Ala Gln Thr Tyr Ile  
 290 295 300  
 Ser Ala Leu Gly Asp Leu Leu Arg  
 305 310

<210> 65  
 <211> 907  
 <212> DNA  
 <213> FROG

<400> 65  
 gccccggggc cactctgcgc acttgctggg acttattcgc acttacctgt catggcccg 60  
 ctgctacacg gcgctgctac tgccgctgac tgggtgcgagc tgaaggagct tccatccgag 120  
 gccgggctct tggccagaga ttacctacta gacagcagcg acccccgcgc ctggctctcc 180  
 gccacttccc tgcaaagtgc ccttgagtac gtgctgcacc ccccgggccg ggccggggcg 240  
 acaaggtgcg ggaactgtgc aaactgaagg ggctgcggga tgatgatgat gatgaggagg 300  
 atgatgagga ggaggaagag agatccgagg ggctgtgcag acacaggggt cccctggca 360  
 agggccctgg tggggttcag aagcagagga gactggcagc caatgccagg gagaggagga 420  
 ggatgcacgg gctcaatcat gccttcgata agctccgtaa tgtcatccct tcttcaata 480  
 acgacaagaa actctccaaa tacgagaccc tgcagatggc tcagatctac atcaacgccc 540  
 tgtccgacct gctgcaggcg cccccgact ccagagatcc cccctgcccg cccacctacc 600  
 aactgcattc ggggccagag ccaggttag tccagtctgg cagcatgaga ttctcggaga 660  
 cttccccccg acagtcccc ctcagccaat tccaggaggg agctgctccc agaagggaat 720  
 aggatctggg ccatcttca tcttctcggg aagacatcgc ccatcttcat cttcggggag 780  
 aagacagcaa gacatcgcaa gatctcatcg gagtgcggc gaattccggt ctccctatag 840  
 tgagtcgtat taatttcgat aagccagctg cattaatgaa tcggccaaac gcgcggggag 900  
 aggcggt 907

<210> 66  
<211> 259  
<212> PRT  
<213> FROG

<400> 66

Met Ala Arg Leu Leu His Gly Ala Ala Thr Ala Ala Asp Trp Cys Glu  
1 5 10 15  
Leu Lys Glu Leu Pro Ser Glu Ala Gly Leu Leu Ala Arg Asp Tyr Leu  
20 25 30  
Leu Asp Ser Ser Asp Pro Arg Ala Trp Leu Ser Ala Thr Ser Leu Gln  
35 40 45  
Ser Arg Pro Glu Tyr Val Leu His Pro Pro Gly Arg Ala His Lys Val  
50 55 60  
Arg Glu Leu Cys Lys Leu Lys Gly Leu Arg Asp Asp Asp Asp Asp Glu  
65 70 75 80  
Glu Glu Asp Asp Glu Glu Glu Glu Glu Arg Ser Glu Gly Leu Cys Arg  
85 90 95  
His Arg Gly Pro Pro Gly Lys Gly Pro Gly Gly Val Gln Lys Gln Arg  
100 105 110  
Arg Leu Ala Ala Asn Ala Arg Glu Arg Arg Arg Met His Gly Leu Asn  
115 120 125  
His Ala Phe Asp Gln Leu Arg Asn Val Ile Pro Ser Phe Asn Asn Asp  
130 135 140  
Lys Lys Leu Ser Lys Tyr Glu Thr Leu Gln Met Ala Gln Ile Tyr Ile  
145 150 155 160  
Asn Ala Leu Ser Asp Leu Leu Gln Ala Pro Pro Asp Ser Arg Asp Pro  
165 170 175  
Pro Cys Pro Pro Thr Tyr Gln Leu His Ser Gly Pro Glu Pro Arg Leu  
180 185 190  
Val Gln Ser Gly Ser Cys Met Arg Phe Ser Gly Asp Phe Pro Gly Gln  
195 200 205  
Ser Pro Leu Ser Phe Gln Phe Gln Glu Gly Ala Ala Leu Ser Gly Lys  
210 215 220  
Gly Ile Gly Ser Ala Pro Ser Ser Ser Ser Gly Glu Asp Ser Lys Thr  
225 230 235 240  
Ser Pro Arg Ser His Arg Ser Asp Gly Glu Phe Arg Ser Pro Tyr Ser  
245 250 255  
Glu Ser Tyr

<210> 67

20250701 10:00:00

